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ABSTRACT 
Interleukin-13 (IL-13) is a Th2 cytokine proposed to mediate aspects of asthma 
pathogenesis such as airway inflammation, hyperreactivity (AHR), remodelling and 
mucus hypersecretion.  These features of asthma have been reproduced in mice 
chronically exposed to house dust mite extract (HDM) in which IL-13 was 
demonstrated to be up-regulated.  The aim of this thesis was to investigate the role of 
IL-13 in HDM induced allergic airways disease (AAD).  This was accomplished 
using high affinity neutralising anti-mouse IL-13 monoclonal antibodies (mAb).  
Prophylactic anti-IL-13 mAb administration during HDM exposure inhibited airway 
eosinophilia, AHR, goblet cell up-regulation and airway remodelling.  Furthermore, 
therapeutic neutralisation of IL-13 after the induction of AAD reduced airway 
inflammation, AHR, goblet cell frequency and remodelling; thus implicating IL-13 in 
both the initiation and maintenance of AAD. 
To investigate the mechanisms of IL-13 inhibition in AAD the expression and 
distribution of IL-13 receptors, IL-13Rα1 and IL-13Rα2, were investigated in lungs 
from sham and HDM exposed mice.  IL-13Rα2 but not IL-13Rα1 mRNA was up-
regulated following induction of AAD.  Immunofluorescence staining for IL-13Rα2 
protein revealed expression in the airway epithelium of sham mice and abundance 
throughout the lung tissue in mice with AAD.  The key signalling receptor IL-13Rα1 
was detected in alveolar macrophages (AM) in both sham and HDM exposed mice, 
however surface expression of IL-13Rα1 was lost during AAD. 
The function of IL-13Rα1+ AM in vivo was explored by depletion of AM using 
clodronate liposomes.  The absence of AM during IL-13 or HDM induced 
inflammation resulted in exacerbated airway pathophysiology suggesting AM may 
regulate allergic airways inflammation. 
In summary, HDM induced pathophysiology in mice is largely dependent on IL-13.  
Based on receptor expression, AM were identified as IL-13 responsive cells, however 
AM depletion exacerbated AAD indicating AM, or a subset of, are not driving IL-13 
pathology and may in fact be protective. 
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1.1 Asthma 
Asthma is a chronic inflammatory disease of the conducting airways characterised by 
airflow obstruction that is reversible spontaneously or with treatment, although a 
degree of fixed airflow obstruction is often associated with severe disease (Backman 
et al., 1997).  This airflow obstruction is due in part to excessive bronchoconstriction 
in response to inhaled stimuli such as allergens, pollutants or cold air; i.e. airway 
hyperreactivity (AHR), and results in symptoms of episodic wheezing, breathlessness, 
coughing and chest tightness (O'Byrne & Inman, 2003;GINA, 2006).  In addition, 
patients with asthma exhibit reduced basal lung function and the age related rate of 
decline in lung function is accelerated (James et al., 2005). 
Asthma is a heterogeneous disease of unknown aetiology however the majority of 
cases are coupled with atopy (Wenzel, 2006); the predisposition to mount an 
excessive IgE response to otherwise innocuous allergens.  Non-atopic asthma is more 
common in patients with late-onset disease and is not associated with reactivity to 
known allergens (Wenzel, 2006).  Despite these apparent differences much of the 
underlying pathology is common to both atopic and non-atoptic asthma.  The 
development of asthma is likely to result from a complex interaction between genetic 
and environmental factors such as susceptibility to atopy, viral infections and 
exposure to pollutants and allergens.  
The underlying pathology of lung tissue from asthmatic patients exhibits 
peribronchial inflammation and persistent structural changes to the airway walls; 
termed airway remodelling.  Airway remodelling encompasses changes in the 
epithelium, basement membrane and airway smooth muscle (ASM) which leads to 
significant thickening of the airway walls.  This in turn may contribute to airflow 
restriction and decline in lung function.  The airway epithelium is thickened; 
increased epithelial turnover and epithelial shedding have also been reported, thus 
potentially compromising barrier function (James & Wenzel, 2007;Bergeron et al., 
2009).  Hyperplasia of goblet cells and submucosal glands is characteristic of asthma 
and together with the associated hypersecretion of mucus can lead to the formation of 
mucus plugs and thus contribute to airflow limitation (Ordonez et al., 2001).  
Thickening of the basement membrane occurs as a result of subepithelial fibrosis and 
specifically the deposition of extracellular matrix proteins such as collagens.  In 
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addition, asthmatic airways exhibit increased smooth muscle mass as a result of ASM 
hypertrophy and hyperplasia (James & Wenzel, 2007).  Whilst airway wall thickness 
is closely associated with disease severity; whether remodelling is deleterious to 
disease or protective remains contentious (Niimi et al., 2000;Little et al., 2002).  
Structurally, airway remodelling results in stiffening of the airway wall which may 
limit bronchoconstriction however increased ASM mass may heighten 
bronchoconstriction (James & Wenzel, 2007).  In addition, cells implicated in the 
remodelling process such as epithelial cells, ASM cells and fibroblasts may perpetuate 
the inflammatory process by releasing proinflammatory mediators (Holgate et al., 
2000;Bergeron et al., 2009).  Increasing evidence implicates the airway epithelium in 
the pathogenesis of asthma and has lead to the proposal that epithelial damage 
followed by impaired repair is responsible for initiation and propagation of the 
disease.  Thus the damaged epithelium not only permits allergen sensitisation but 
drives fibrosis in a bid to maintain barrier function (Holgate et al., 2000).  
Furthermore, it has recently been demonstrated that repeated bronchoconstriction 
induces epithelial stress, which stimulates airway remodelling even in the absence of 
allergen induced inflammation (Grainge et al., 2011).  However, it is unknown 
whether structural changes in the airway wall precede airway inflammation or arise 
from an aberrant tissue repair response driven by persistent inflammation (James & 
Wenzel, 2007;Holgate et al., 2000).  It is likely inflammation, AHR and remodelling 
are interdependent and self-perpetuating in the pathogenesis of asthma. 
The inflammatory response underpinning asthma is orchestrated by a T helper 2 (Th2) 
response.  In allergic asthmatics this response is frequently directed against innocuous 
inhaled peptides, such as those found in house dust mites (HDM) and grass pollens, 
however strikingly similar immunopathology is also present in non-atopic asthmatics 
(Kay, 2006).  Evidence for Th2 involvement in asthma primarily comes from the 
presence of Th2 cells in the airways and the associated elevation of the Th2 cytokines 
interleukin (IL)-4, IL-5 and IL-13 (Robinson et al., 1992;Brightling et al., 2002).  In 
turn, these mediators drive some of the fundamental characteristics of asthma such as 
IgE production, eosinophilia, AHR and airway remodelling.  IL-4 is increased in 
broncho-alveolar lavage (BAL) from asthma patients and is a requisite for Th2 
differentiation and B cell isotype switching to IgE (Steinke, 2004).  IL-5 is also up-
regulated in asthma and, together with eotaxin, is primarily involved in the 
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development, recruitment, activation and survival of eosinophils (Robinson et al., 
1992;Rothenberg & Hogan, 2006). 
Several recent findings have shed light on the mechanisms involved in priming Th2 
responses.  The central role of airway dendritic cells (DC) in sampling allergen and 
subsequently migrating to draining lymph nodes to present allergen and prime Th2 
responses has been well demonstrated by Lambrecht et al. (Lambrecht & Hammad, 
2009;van Rijt et al., 2005).  In addition, basophils may play a role in priming the 
allergic response.  Although it is debated whether basophils are capable of presenting 
antigen themselves, they are able to migrate to the draining lymph node where they 
may provide an early source of IL-4 to direct the immune response towards Th2 
differentiation (Hammad et al., 2010;Sokol et al., 2009;Yoshimoto et al., 
2009;Perrigoue et al., 2009).  In addition, the recent discovery of innate helper cells in 
mice may provide a novel mechanism by which Th2 responses are initiated and 
amplified at mucosal surfaces.  Several subpopulations of innate lymphoid cells have 
been described that respond to epithelial derived cytokines such as IL-25, IL-33 and 
thymic stromal lymphopoietin (TSLP) by producing Th2 cytokines (IL-4, IL-5 and 
IL-13) (Price et al., 2010;Neill et al., 2010;Saenz et al., 2010b;Moro et al., 2010).  
Furthermore, innate lymphoid cells have recently been demonstrated to be potent 
inducers of AHR, via IL-13 production, under certain circumstances (Chang 2011).  
Although these cells have yet to be identified in man, and their function in allergic 
lung inflammation unreported to date, their purpose may be to provide immediate, 
“substitute help” following epithelial damage, prior to the development of an antigen 
specific T cell response (Saenz et al., 2010a;Eberl, 2010). 
Despite the Th2 dominance in asthma, other T helper cell phenotypes have been 
demonstrated to be present in the lungs which may play a role in pathogenesis of the 
disease.  Th1 cells are elevated in BAL from asthmatics and further increased in 
sputum after exacerbation in patients with severe disease (Krug et al., 
1996;Mamessier et al., 2008).  However, the role of Th1 cells and their primary 
cytokine interferon-γ (IFNγ) is unclear.  While Th1 cells can suppress Th2 responses, 
some studies have implicated IFNγ in AHR (Vock et al., 2010).  Th17 cells have been 
isolated from biopsies from severe asthmatic patients (Pene et al., 2008).  
Furthermore, IL-17A is up-regulated in asthma and correlates with sputum 
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neutrophilia and disease severity, thus implicating Th17 cells in the pathogenesis of 
severe rather than mild-moderate asthma (Molet et al., 2001;Bullens et al., 2006;Al-
Ramli et al., 2009). 
Airway eosinophilia is one of the principal characteristics of asthma.  Eosinophils are 
increased in BAL and blood from asthmatic patients and correlate with disease 
severity (Bousquet et al., 1990).  In addition, sputum eosinophilia has been linked to 
increased basement membrane thickening and sensitivity to corticosteroid treatment 
(Berry et al., 2007).  The role of eosinophils in the pathogenesis of asthma however is 
disputed (Fattouh & Jordana, 2008;Kariyawasam & Robinson, 2007;Jacobsen et al., 
2007).  Eosinophils represent a significant source of cytokines, mediators and 
cytotoxic proteins (Kariyawasam & Robinson, 2006).  Production of pro-fibrotic 
factors such as transforming growth factor-β (TGFβ) is likely to play a direct role in 
airway remodelling while release of cytotoxins from degranulation may indirectly 
contributing disease pathogenesis by causing tissue damage (Kariyawasam & 
Robinson, 2007). 
Mast cells are fundamental in eliciting pulmonary responses to allergen.  Upon 
exposure to allergen IgE, bound to the surface of mast cells via FcεRI, cross-links 
thus inducing degranulation.  Release of intracellular stores of pro-inflammatory 
mediators by degranulation elicits the early phase asthmatic response (EAR) and the 
recruitment of cells which subsequently drive the late phase response (LAR).  
Importantly, mast cells are located within the ASM of asthmatic patients and stain 
positively for IL-4 and IL-13 (Brightling et al., 2003).  Hence, they are also proposed 
to play a role in airway remodelling and AHR by directly modulating ASM in 
addition to perpetuating inflammation. 
There is increasing evidence neutrophils are involved in asthma pathogenesis, 
specifically severe asthma.  The number of BAL neutrophils is elevated in severe but 
not mild-moderate asthma, unless the patient is experiencing an acute exacerbation.  
Moreover, sputum neutrophilia has been correlated to fixed airflow obstruction, but 
not AHR (Fahy, 2009). 
Current therapy for asthma consists of reliever and controller medication (GINA, 
2006).  Reliever medications are commonly fast acting inhaled β2 agonists used to 
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relax the ASM during bronchospasm.  In addition, many patients require controller 
medications; anti-inflammatories such as corticosteroids (CS), often taken daily to 
control asthma symptoms.  Depending on the severity of disease, CS therapy can be 
inhaled or oral.  Long-acting β2 agonists may also be used as controller therapy in 
conjunction with CS to improve lung function.  In persistent asthma add on therapies 
such as leukotriene modifiers, theophylline or anti-IgE may be employed.  However, 
disease symptoms remain poorly controlled in approximately 10% of asthma patients 
with severe disease (Wenzel, 2005).  Furthermore, current therapies fail to modify the 
course on the disease, but merely control symptoms hence there is an unmet clinical 
need for therapies that can halt or even reverse the pathogenesis of asthma.  In order 
to address this, a great deal of research has focused on targeting the underlying Th2 
response by neutralising key Th2 cytokines such as IL-4, IL-5 and IL-13. 
1.2 IL-13 
IL-13 was originally identified as an IL-4 related cytokine produced in activated 
human T cells that was capable of inducing monocyte differentiation and B cell 
differentiation and proliferation (Minty et al., 1993;McKenzie et al., 1993).  IL-13 
was subsequently demonstrated to be both sufficient and necessary for the induction 
of asthma-like pathology in mice (Wills-Karp et al., 1998;Grunig et al., 1998).  Since 
its discovery, a plethora of functions have been ascribed to IL-13 and the cytokine has 
consequently been proposed to be a central mediator in the pathogenesis of asthma 
(Wynn, 2003;Wills-Karp, 2004;Kasaian & Miller, 2008;Brightling et al., 2010). 
1.2.1 IL-13 in asthma 
In patients with atopic asthma BAL IL-13 mRNA and protein is elevated following 
allergen challenge, compared to non-asthmatic controls (Huang et al., 1995;Batra et 
al., 2004).  Furthermore, post-challenge BAL IL-13 concentration positively 
correlates with BAL eosinophilia (Kroegel et al., 1996).  Expression of IL-13 mRNA 
in bronchial biopsies has been demonstrated to be greater in asthmatic patients 
compared to non-asthmatic controls; moreover IL-13 mRNA expression is equivalent 
in atopic and non-atopic asthmatics and positively correlates with lung eosinophilia 
(Humbert et al., 1997).  Berry et al. and Saha et al. have also detected IL-13 in 
sputum and an increase in the number of IL-13 positive cells in the submucosa and 
ASM bundles in biopsies from asthmatic patients (Berry et al., 2004;Saha et al., 
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2008).  These IL-13 expressing cells have been identified predominantly as 
submucosal eosinophils and mast cells in the ASM (Berry et al., 2004;Brightling et 
al., 2003).  Furthermore, peripheral blood eosinophils from asthmatic but not control 
patients express IL-13 (Schmid-Grendelmeier et al., 2002).  However in BAL, up-
regulation of IL-13 mRNA post-allergen challenge is significant in cells enriched for 
alveolar macrophages (AM) (Prieto et al., 2000).  In addition to T cells, eosinophils, 
mast cells and AM multiple other cell types are reported to be capable of producing 
IL-13 including basophils, DC, invariant natural killer T cells (iNKT), innate 
lymphoid cells and stromal cells such as ASM and epithelium (Ochensberger et al., 
1996;Gibbs et al., 1996;Schroeder et al., 2010;de Saint-Vis et al., 1998;Kim et al., 
2008;Price et al., 2010;Moro et al., 2010;Saenz et al., 2010b;Neill et al., 
2010;Grunstein et al., 2002;Semlali et al., 2010). 
1.2.2 IL-13 activities 
IL-13 is capable of mediating many aspects of asthma pathology through its actions 
on both haematopoietic and stromal cells in the lung (Figure 1.1).  In mice 
administration of exogenous IL-13 into the airways is sufficient to provoke symptoms 
of allergic airways disease (AAD) such as BAL eosinophilia, neutrophilia, goblet cell 
metaplasia and AHR (Grunig et al., 1998;Wills-Karp et al., 1998).  In longer term 
studies, transgenic over-expression of IL-13 or adenoviral expression of IL-13 in the 
lungs induced additional pathologies; accumulation of BAL T cells, epithelial cell 
hypertrophy, subepithelial fibrosis, increased baseline airways resistance and up-
regulation of eotaxin, keratinocyte chemoattractant (KC), IL-10 and IL-12 (Zhu et al., 
1999;Kuperman et al., 2002;Therien et al., 2008).  See Table 1.1 for a summary of 
genes affected by IL-13 in cell types relevant to the pathogenesis of asthma. 
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Figure 1.1 IL-13 activities.  Summary of mechanisms by which IL-13 may contribute to the 
pathogenesis of asthma. 
IL-13 propagates Th2 immunity without directly activating, polarising or inducing 
proliferation of T cells themselves but can perpetuate inflammation via a multitude of 
activities (Zurawski & de Vries, 1994;de Vries, 1998).  Despite initial reports 
suggesting T cells to be unresponsive to IL-13, more recently Th17 cells have been 
reported to respond to IL-13 by down-regulating Th17 transcription factors and up-
regulating Th2 transcription factors (Newcomb et al., 2009;Newcomb et al., 2011).  
IL-13 can further enhance Th2 responses by augmenting DC maturation and 
activation.  Specifically IL-13 up-regulates expression of MHC II, activation markers 
such as CD205 and co-stimulatory molecules CD40 and CD86 (Padilla et al., 2005).  
Furthermore, IL-13 enhances DC mediated suppression of IFNγ expression by 
memory T cells (Webb et al., 2007).  In human B cells IL-13 induces activation, 
enhances proliferation, up-regulates CD23 and MHC II and induces IL-4 independent 
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class switching to IgG4 and IgE however, mouse B cells do not respond to IL-13 
(Punnonen et al., 1993;Zurawski & de Vries, 1994).  In addition, IL-13 primes mast 
cells by up-regulating FcεRI which consequently increases histamine release and 
proliferation upon FcεRI cross-linking (Kaur et al., 2006).  IL-13 also contributes to 
recruitment of inflammatory cells, in particular eosinophils, by inducing vascular cell 
adhesion molecule-1 (VCAM-1) and P-selectin expression on endothelial cells 
(Bochner et al., 1995;Woltmann et al., 2000). 
IL-13 induces eosinophilia via the release of chemoattractants such as eotaxin.  This 
has been demonstrated by attenuation of IL-13 stimulated airway eosinophilia in mice 
deficient in IL-5 and/or eotaxin (Yang et al., 2001;Pope et al., 2005).  Furthermore, 
allergen induced up-regulation of eotaxin is IL-13 dependent (Pope et al., 2005).  In 
addition, IL-13 itself can act as a chemoattractant for eosinophils, prolong their 
survival and induce activation, as indicated by up-regulation of CD69 (Horie et al., 
1997;Luttmann et al., 1996).  Interestingly, production of IL-13 by T cells from IL-5 
and eotaxin deficient mice with AAD is impaired indicating eosinophils may play a 
role in Th2 cell development (Mattes et al., 2002).  In addition, eosinophil derived IL-
13 has been implicated in the development of AAD although as a sole source of IL-
13, this is insufficient to sustain AAD (Walsh et al., 2011).  This illustrates a complex 
interdependency between eosinophils and T cells involving IL-13 in AAD. 
Much like IL-4, IL-13 can induce alternative activation of monocytes and 
macrophages, however, IL-13 is not essential for macrophage polarisation due to 
redundancy with IL-4 (Ramalingam et al., 2008).  (See Figure 1.2 for a diagram 
illustrating the key differences between classical and alternative activation of 
macrophages.)  Upon stimulation with IL-13, monocytes up-regulate various adhesion 
molecules (CD11b, CD11c, VLA-5, CD18 and CD29), MHC II, and FcεRII (CD23) 
and down-regulate CD14, FcγRI, FcγRII and FcγRIII expression (de Waal et al., 
1993).  In addition, IL-13 reduces antibody dependent cell cytotoxicity (ADCC) and 
lipopolysaccharide (LPS) induced production of pro-inflammatory cytokines (IL-1α, 
IL-1β, IL-6, IL-10, granulocyte colony-stimulating factor (G-CSF; CSF-3) and 
tumour necrosis factor (TNF)-α).  Furthermore, in vitro incubation of human 
monocytes with IL-13 can promote fibrocyte differentiation (Shao et al., 2008).  
Alternative activation of macrophages is characterised by the up-regulation of 
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mannose receptor, Dectin-1, MHC II, CD23, resistin-like molecule (RELM)-α, YM-
1/2 and arginase-1 and induction of 15-lipooxygenase (15-LO) in mice (Gordon, 
2003;Gordon & Martinez, 2010).  In turn, arginase expression results in production of 
proline and polyamines thus contributing to collagen synthesis and cell proliferation, 
respectively.  IL-13 inhibits the production of IL-12, IL-1, IL-6 and TNFα and 
reduces nitric oxide (NO) release in response to LPS stimulation (Doherty et al., 
1993).  In addition, alternatively activated macrophages (AAM) antagonise the effects 
of IL-1 by via expression of IL-1 decoy receptor and IL-1ra.  Furthermore, AAM 
produce CCL22 (macrophage derived chemokine; MDC), CCL17 (thymus and 
activation regulated chemokine; TARC), eotaxin, TGFβ, IL-10 and IL-13 itself 
(Gordon, 2003;Pope et al., 2005;Holtzman et al., 2009).  Overall, IL-13 counteracts 
the effect of Th1 stimuli such as LPS and IFNγ on monocytes and macrophages, 
down-regulating their cytotoxic and pro-inflammatory properties.  Instead, AAM are 
associated with trophic functions, clearance of apoptotic bodies, wound healing and 
tolerance.  However, by the same mechanisms, AAM can perpetuate Th2 immunity 
by promoting recruitment of Th2 cells, eosinophils, mast cells, basophils and 
neutrophils and driving excessive fibrosis. 
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Figure 1.2 Macrophage activation.  Summary of key differences between classical and alternative 
macrophage activation pathways.  Exposure to IFNγ (interferon-γ) in the presence of LPS 
(lipopolysaccharide) stimulates classical activation leading to up-regulation of MHC II, CD86, NOS 
(nitric oxide synthase) and the subsequent production of NO (nitric oxide) and ROS (reactive oxygen 
species).  Exposure to IL-4 or IL-13 stimulates alternative activation leading to the up-regulation of 
Dectin-1, mannose receptor, MHC II, YM-1/2, RELM-α, arginase-1 and the subsequent production of 
polyamines and proline. 
IL-13 can act directly on airway epithelium.  Various studies have demonstrated ex 
vivo stimulation of human epithelial cells with IL-13 up-regulates mucins and induces 
goblet cell metaplasia (Malavia et al., 2008).  IL-13 alters mucociliary differentiation 
by increasing the proportion of secretory cells, reduces ciliary beat frequency of 
epithelial cells and decreases epithelial barrier function (Laoukili et al., 2001;Ahdieh 
et al., 2001).  In addition, IL-13 stimulation of epithelial cells can induce the release 
of eotaxin, IL-8, TGFα, TGFβ and TSLP; each of which has the potential to provoke 
inflammation and fibrosis of the airways (Matsukura et al., 2001;Lordan et al., 
2002;Malavia et al., 2008;Miyata et al., 2009).  Furthermore, IL-13 can induce 
apoptosis of epithelial cells which in turn also increases susceptibility to the 
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development of fibrosis (Borowski et al., 2008).  Contrary to the effects on 
macrophages, IL-13 has been reported to elevate inducible nitric oxide synthase 
(iNOS) expression and activity and reduce arginase-1 levels leading to increased 
nitrite production in primary bronchial epithelial cells (Chibana et al., 2008).  By 
using transgenic mice, Kuperman et al. demonstrated IL-13 signalling exclusively in 
airway epithelial cells was sufficient to induce AHR, goblet cell metaplasia and mucin 
expression without the induction of inflammation or fibrosis (Kuperman et al., 2002). 
In fibroblasts IL-13 is reported to promote differentiation to myofibroblasts, which are 
implicated in airway remodelling.  IL-13 has been demonstrated to induce up-
regulation of α-smooth muscle actin (αSMA) and collagen III mRNA however, some 
studies report no effects of IL-13 on αSMA and collagen production (Saito et al., 
2003;Borowski et al., 2008;Batra et al., 2004).  IL-13 is capable of provoking 
fibroblast proliferation by at least two distinct mechanisms.  Stimulation of fibroblasts 
with IL-13 induces release of platelet-derived growth factors (PDGF) which 
subsequently stimulate fibroblast and myofibroblast proliferation in an autocrine 
manner (Ingram et al., 2006;Ingram et al., 2004;Ingram et al., 2003).  In addition, IL-
13 down regulates cyclooxygenase (COX)-1 and COX-2 expression in fibroblasts 
leading to reduced prostaglandin E2 (PGE2) production which permits the 
proliferation of fibroblasts (Saito et al., 2003).  IL-13 may also promote fibroblast 
activation by up-regulating the expression of CD40L and various adhesion molecules 
(Kaufman et al., 2004;Doucet et al., 1998a).  IL-13 directly induces eotaxin 
production from fibroblasts however there are multiple mechanisms by which this 
response may be augmented (Wenzel et al., 2002;Chibana et al., 2003;Fritz et al., 
2009).  IL-13 can synergise with TGFβ (and to a lesser extent TNFα) to up-regulate 
eotaxin expression in fibroblasts (Wenzel et al., 2002).  Similarly, oncostatin M 
(OSM), IL-6 and IL-11 augment IL-13 induced eotaxin production by up-regulating 
the expression of IL-13 receptor subunits (Fritz et al., 2009).  IL-13 also synergises 
with Leukotriene C4 (LTC4) to enhance eotaxin production by up-regulating cysteinyl 
leukotriene receptor CysLT1R expression on fibroblasts (Chibana et al., 2003).  
Taken together these mechanisms demonstrate multiple pathways by which the 
actions of IL-13 on fibroblasts may contribute to asthma pathology. 
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Up-regulated Down-regulated Cells 
Genes Reference Genes Reference 
T cells GATA-3 Newcomb 2009 ROR-γT Newcomb 2009 
B cells Germline ε Punnonen 1993 
Eosinophils CD69 Luttmann 1996 
  
IFNγMonocytes   
IL-12 
Zurowski 1994 
YM-1 
Arginase-1 
Ramalingam 2008 Macrophages 
Eotaxin-2/CCL24 Pope 2005 
  
Endothelia P-selectin Woltmann 2000   
Eotaxin/CCL11 Matsukura 2001 Arginase-1 Chibana 2008 
Muc5ac 
RELMα 
CLCA3 
Kuperman 2002 Epithelia 
iNOS Chibana 2008 
  
YM-1 COX-1 
RELMα COX-2 
Saito 2003 
IL-13Rα2 
Ramalingam 2008 
Collagens I & III 
αSMA
Borowska 2008 
PDGF-A 
PDGF-C 
Erg-1 
Ingram 2006 
Eotaxin/CCL11 Wenzel 2002 
Fibroblasts 
CysLT1R Chibana 2003 
  
PDGF-C Bosse 2008 KLF5 Risse 2011 
CD38 Deshpande 2004 
IL-5 Grunstein 2002 
Calponin 
Vinculin 
Risse 2011 
VCAM-1 
P-selectin 
MCP-1/CCL2 
Eotaxin/CCL11 
CTACK/CCL27 
IL-13Rα2 
IL-1R 
Tenascins C & R 
Collagens I, III & VI 
CD44 
IFNβ1
Vimentin 
Tropomyosin 1 & 2 
Actin 
Phospholipase D 
Calreticulin 
TRPC 4 & 6 
Sphingosine kinase 1 
Rho GDP dissociation inhibitor 
FKBP1A 
ASM 
Hisatmine H1 receptor 
Syed 2005 
  
Table 1.1 Summary of genes affected by IL-13.  Table summarises genes up-regulated and down-
regulated following IL-13 stimulation of cell types relevant to the pathogenesis of asthma.  
Abbreviations: ROR (retinoic acid receptor-related orphan receptor); IFN (interferon); IL (interleukin); 
RELM (resistin-like molecule); CLCA3 (calcium-activated chloride channel); iNOS (inducible nitric 
oxide synthase); COX (cyclooxygenase); SMA (smooth muscle actin); PDGF (platelet-derived growth 
factor); Erg (early growth response); CysLT1R (cysteinyl leukotriene 1 receptor); KLF (kruppel-like 
factor); VCAM (vascular cell adhesion molecule); MCP (monocyte chemotactic protein); CTACK 
(cutaneous T-cell-attracting chemokine); TRPC (transient receptor potential cation channels); GDP 
(guanosine diphosphate); FKBP (FK506 binding protein) 
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IL-13 stimulation of ASM cells up-regulates the expression of multiple genes 
including adhesion molecules, chemokines, extracellular matrix (ECM), cytoskeletal 
constituents and calcium regulators, thus potentially contributing to airway 
inflammation, remodelling and AHR (Syed et al., 2005).  IL-13 does not directly 
induce ASM proliferation and can inhibit proliferation of ASM under certain 
circumstances (Bosse et al., 2008;Risse et al., 2011).  However, IL-13 does induce 
PDGF which can induce proliferation of ASM cells primed with fibroblast growth 
factor 2 (FGF2) to increase expression of PDGF receptor on ASM and hence 
sensitivity to PDGF (Bosse et al., 2008).  Importantly, IL-13 has been reported to 
reduce ASM responsiveness to β agonists, thus impairing relaxation and enhancing 
contractility induced by agonists such as carbachol, cysteinyl leukotrienes (cys-LT) 
and histamine (Laporte et al., 2001;Tliba et al., 2003;Eum et al., 2005;Risse et al., 
2011).  This enhanced contractility is due to elevated calcium signalling; perhaps via 
IL-13 induced up-regulation of CD38 expression and activity on ASM (Tliba et al., 
2003;Deshpande et al., 2004).  Alone, IL-13 induces transient intracellular calcium 
mobilisation and though this is insufficient for contraction, augmented calcium 
mobilisation and hence contraction is observed upon stimulation (Eum et al., 2005).  
Interestingly, although IL-13 elevates ASM contractility it does not alter ASM 
phenotype by modifying the expression of contractile proteins (Risse et al., 2011).  In 
addition, IL-13 induces IL-5 and eotaxin production from ASM; which may or may 
not play a role in augmented contractility but are likely to contribute to airway 
inflammation (Grunstein et al., 2002;Hirst et al., 2002;Eum et al., 2005).  Thus, the 
effects of IL-13 on ASM are not only implicated in AHR but also potentially in 
airway inflammation and remodelling in asthma. 
In summary, although IL-13 does not play a direct role in initiating Th2 polarisation, 
it can perpetuate an allergic response in the lungs and the associated tissue 
remodelling and AHR by exerting a multitude of effects on numerous distinct cell 
types.  Hence the proposal that IL-13 is a central mediator of asthma. 
1.2.3 IL-13 receptors 
IL-13 has two known binding proteins; IL-13Rα1 and IL-13Rα2.  The effects of IL-
13 are predominantly mediated via the type II IL-4 receptor, a heterodimer 
comprising of IL-4Rα and IL-13Rα1 which binds both IL-13 and IL-4 (Miloux et al., 
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1997).  This shared receptor usage explains some of the overlapping functions of IL-
13 and IL-4.  IL-13 initially binds IL-13Rα1 with relatively low affinity and 
subsequently binds IL-4Rα with high affinity to form a stable complex which signals 
by phosphorylating signal transducer and activator of transcription 6 (STAT6) via 
Janus activating kinase 1 (JAK1) and protein tyrosine kinase 2 (TYK2) activation 
(Figure 1.3 A) (Andrews et al., 2002;LaPorte et al., 2008).  IL-4 however, initially 
binds the IL-4Rα subunit which subsequently binds IL-13Rα1 to activate STAT6 
(Figure 1.3 B i) (LaPorte et al., 2008).  Phospho-STAT6 subsequently dimerises and 
translocates to the nucleus where it binds DNA to induce gene transcription.  In 
addition to STAT6 phosphorylation, there is also evidence that type II IL-4 receptor 
signalling activates STAT3, p38 mitogen-activated protein kinase (MAPK), 
extracellular signal-related kinase (ERK) and phosphatidylinositol 3-kinase δ (PI3Kδ) 
pathways, although activation of these pathways may be cell specific (LaPorte et al., 
2008;Moynihan et al., 2008;Laporte et al., 2001;Atherton et al., 2003;Farghaly et al., 
2008). 
In contrast to the interaction between IL-13 and IL-13Rα1, IL-13 binds IL-13Rα2 
with high affinity and does not activate STAT6 (Andrews et al., 2002).  The role of 
IL-13Rα2 is complex.  IL-13Rα2 has been detected in two forms; membrane bound 
and soluble (Figure 1.3 C).  In mice soluble IL-13Rα2 (sIL-13Rα2) originates from 
cleavage of membrane bound IL-13Rα2 or may be synthesised directly from a splice 
variant and secreted as sIL-13Rα2 (Tabata et al., 2006).  However, this splice variant 
is not produced in man and hence sIL-13Rα2 is produced exclusively by cleavage of 
membrane bound IL-13Rα2 (O'Toole et al., 2008;Chen et al., 2009).  Thus the 
functions of IL-13Rα2 are likely to differ considerably between mice and men.  Due 
to the high binding affinity, short cytoplasmic tail and abundance of sIL-13Rα2, IL-
13Rα2 was originally proposed to function primarily as a non-signalling decoy 
receptor, sequestering IL-13 and therefore reducing IL-13Rα1 dependent pathology 
(Tabata et al., 2006;Daines et al., 2006).  Indeed, IL-13Rα2 can down-regulate IL-13 
induced IL-13Rα1 signalling by directly competing for IL-13, furthermore membrane 
associated IL-13Rα2 internalises following IL-13 binding thus reducing the 
availability of IL-13 for binding IL-13Rα1 (Yasunaga et al., 2003;Kawakami et al., 
2001).  However, membrane bound IL-13Rα2 signalling has been demonstrated via 
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activation of an activating protein-1 (AP-1) variant which leads to TGFβ induction 
(Fichtner-Feigl et al., 2006).  Thus IL-13, via IL-13Rα2 can deliver a pro-fibrotic 
signal under certain, inflammation-dependent circumstances (Strober et al., 2009).  In 
addition, membrane bound IL-13Rα2 is proposed to modulate IL-4 signalling by 
associating with IL-4Rα where the cytoplasmic tail of IL-13Rα2 disrupts the 
activation of IL-4Rα associated signalling molecules (Rahaman et al., 2002;Andrews 
et al., 2006).  IL-13Rα2 forms a complex with IL-4Rα only in the presence of IL-4.  
Similarly, IL-13Rα2 can associate with IL-13Rα1 in the presence of IL-13 and inhibit 
STAT6 activation, providing yet another mechanism by which IL-13Rα2 can down 
regulate IL-13 activity (Rahaman et al., 2002).  Given the multiple mechanisms by 
which membrane bound IL-13Rα2 can regulate IL-4 and IL-13 signalling it is 
interesting to note that loss of surface IL-13Rα2 could therefore render cells more 
sensitive to IL-4 and IL-13 stimulation.  Surface IL-13Rα2 may be lost by several 
means, each of which is conceivably elevated in an allergic setting; i) increased 
activity of endogenous proteases e.g. matrix metalloproteinase (MMP) 8; ii) exposure 
to exogenous proteases e.g. allergens; iii) greater receptor internalisation due to the 
presence of IL-13 (Chen et al., 2009;Daines et al., 2007;Kawakami et al., 2001). 
IL-4 and IL-13 share the type II IL-4 receptor and hence many of their functions are 
overlapping, however IL-4 and IL-13 also induce various cytokine specific genes 
(Lewis et al., 2009).  Some of these discrepancies may be explained by the ability of 
IL-4 to use the type I IL-4 receptor which IL-13 cannot (Figure 1.3 B ii).  Unlike the 
type II IL-4 receptor, the type I receptor activates the insulin receptor substrate-2 
(IRS2) pathway in addition to STAT6 (Heller et al., 2008).  Aside from type I IL-4 
receptor signalling, IL-4 and IL-13 deliver distinct signals, with different potencies, 
via the type II receptor; with IL-4 signalling being more rapid and able to signal at 
lower concentrations than IL-13 (LaPorte et al., 2008).  In addition to this intrinsic 
difference, the responsiveness of a specific cell to each cytokine is also governed by a 
fine balance between the relative abundances of receptor subunits and the cytokines 
themselves (Junttila et al., 2008).  Thus, IL-4 and IL-13 induced receptor activation is 
complex and the quality of signal arising can vary in what is likely to be a cell 
specific manner. 
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Figure 1.3 IL-13 and IL-4 receptor assembly.  Figure depicts the sequential assembly of the type II 
IL-4 receptor in the presence of IL-13 (A) and IL-4 (B i); assembly of the type I IL-4 receptor (B ii) 
and IL-13 binding IL-13Rα2 (C).  Arrows numbered 1 and 2 represent sequential binding where event 
1 must precede event 2.  Abbreviations: IL (interleukin); R (receptor); TYK (protein tyrosine kinase); 
JAK (janus activating kinase); STAT (signal transducer and activator of transcription); IRS (insulin 
receptor substrate); AP (activating protein). 
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Much of the evidence pertaining to expression of IL-13 receptors is based on 
functional responses to IL-13 in vitro, however several studies have directly 
investigated the distribution of IL-13Rα1 and IL-13Rα2.  IL-13Rα1 has been 
detected on the surface of human B cells, specifically naïve and memory B cells, but 
not germinal centre B cells, and is up-regulated by stimulation with CD40L, 
consistent with the role of IL-13 in antibody class switching (Graber et al., 1998).  In 
contrast, mouse B cells do not express IL-13Rα1, in accordance with IL-13 being 
superfluous to antibody class switching in mice (Punnonen et al., 1993;Zurawski & de 
Vries, 1994).  Human monocytes have been reported to express IL-13Rα1 which is 
down regulated following IL-13 or IL-4 stimulation (Graber et al., 1998).  In addition, 
IL-13Rα1 and IL-4Rα subunits are present on mast cells within the bronchial 
submucosa; furthermore the numbers of these receptor expressing cells are higher in 
lung biopsies from asthmatic patients compared to healthy controls (Kotsimbos et al., 
1998;Kaur et al., 2006).  Although intracellular IL-13Rα1 protein is present in human 
T cells, it is not readily detected on the cell surface (Graber et al., 1998).  However 
surface expression has recently been described in mouse and human Th17 polarised 
cells but not other T cell subsets (Newcomb et al., 2009;Newcomb et al., 2011).  In 
lung specimens from asthmatic patients both IL-13Rα1 and IL-4Rα have been 
detected on bronchial smooth muscle cells, epithelial cells and fibroblasts (Kaur et al., 
2006;Heinzmann et al., 2000;Ingram et al., 2009).  Thus numerous haematopoietic 
and non-haematopoietic cells implicated in asthma pathogenesis have the potential to 
respond to IL-13. 
IL-13Rα2 has been detected intracellularly in monocytes, primary human epithelial 
cells and fibroblasts (Daines & Hershey, 2002;Yasunaga et al., 2003;Konstantinidis et 
al., 2008).  In addition, surface expression of IL-13Rα2 is evident on fibroblasts, 
albeit at very low levels, and on bronchial epithelial cells (Daines & Hershey, 
2002;Lordan et al., 2002).  IL-13Rα2 can be mobilised to the cell surface of 
monocytes, epithelial cells or fibroblasts by stimulation with IFNγ, though this does 
not up-regulate expression of IL-13Rα2 (Daines & Hershey, 2002;Andrews et al., 
2006).  IL-13Rα2 expression can be up-regulated by exposure to IL-4 or IL-13 
(Yasunaga et al., 2003;Tanabe et al., 2008).  In mice both membrane bound IL-
13Rα2 and sIL-13Rα2 have been demonstrated to be up-regulated in AAD, despite 
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differential regulation, however the effects of allergen exposure on IL-13Rα2 
expression in humans are contentious (Yasunaga et al., 2003;Tabata et al., 
2006;Daines et al., 2007;O'Toole et al., 2008). 
1.2.4 Modulation of IL-13 
The roles of IL-13 and it’s receptors in the pathogenesis of AAD in vivo have 
previously been investigated using knock-out mice and by neutralising IL-13 activity 
with IL-13Rα2 fusion protein or anti-IL-13 antibodies (Table 1.2).  However, much 
of this data is derived from experiments in which systemic sensitisation with antigen 
in the chemical adjuvant aluminium hydroxide (alum) is required to induce immunity 
to an otherwise innocuous protein such as ovalbumin (OVA).  In these model systems 
the absence of IL-13 does not prevent development of a Th2 response; demonstrated 
by airway inflammation, the presence of antigen specific IgE and the production of 
IL-4 and IL-5 from draining lymph node cells following ex vivo stimulation in Il13-/- 
mice sensitised and challenged with OVA (Walter et al., 2001).  However, Il13-/- mice 
do exhibit reduced AAD pathophysiology.  OVA induced changes in AHR, goblet 
cell frequency and collagen deposition are prevented in Il13-/- mice (Walter et al., 
2001;Leigh et al., 2004b).  In addition, allergen induced airway eosinophilia appears 
to be partially dependent upon IL-13. 
 AHR Eosinophilia Mucus Fibrosis IgE Reference 
Il13-/- ↓↓↓ ↓↓ ↓↓↓ ↓↓↓ ↓ specific 
Walter 2001 
Leigh 2004 
sIL-13Rα2-Fc 
(T.O.C) 
↓↓↓ ↓↓ ↓↓  - specific 
Grunig 1998 
Wills-Karp 1998 
Anti-IL-13 
(T.O.C) 
↓↓↓ ↓↓ ↓↓↓ ↓↓ -/↓↓ specific 
Yang 2004 
Yang 2005 
Il13rα1-/- ↓↓↓ ↓ ↓↓↓  ↓↓ total Munitz 2008 
Ramalingam 2008 
Il13rα2-/- - -/↑ -   Zheng 2008 
Wilson 2007 
stat6-/- ↓↓↓ ↓↓/↓↓↓ ↓↓↓  ↓↓↓ total 
Akimoto 1998 
Kuperman 1998 
 
Table 1.2 The effects of IL-13 signalling modulation.  Table summarises the response to 
induction of AAD in mice deficient in IL-13, IL-13 receptors or signalling molecules and in mice in 
which IL-13 has been neutralised by fusion protein or mAb treatment at time of challenge (T.O.C).  – 
No effect; ↓ <50% inhibition; ↓↓ >50% inhibition; ↓↓↓ >75% inhibition; ↑ elevation. 
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These effects have been recapitulated by IL-13 neutralisation by means of sIL-
13Rα2-Fc fusion protein or anti-IL-13 polyclonal (pAb) or monoclonal antibodies 
(mAb) administered at time of allergen challenge.  Initial studies utilised the high 
affinity of sIL-13Rα2 for IL-13 to generate fusion proteins that neutralise IL-13 in 
vivo.  This approach abrogated the development of OVA induced AHR, goblet cell 
up-regulation and BAL eosinophilia (Grunig et al., 1998;Wills-Karp et al., 1998).  
Further investigation into allergen induced changes in lung function revealed 
treatment with sIL-13Rα2-Fc inhibited the late phase but not early phase response 
(Taube et al., 2002).  Moreover, sIL-13Rα2-Fc reduced BAL IL-5 concentration but 
had no affect on the generation of antigen specific antibodies (Taube et al., 2002).  
Similarly, anti-IL-13 mAb treatment at time of allergen challenge inhibited AHR, 
goblet cell up-regulation and BAL eosinophilia in OVA sensitised and challenged 
mice (Yang et al., 2004).  Longer term studies have demonstrated that anti-IL-13 
mAb treatment inhibits airway remodelling (Yang et al., 2005) and furthermore can 
reduce eosinophilia, goblet cell hyperplasia, AHR and collagen deposition after the 
development of AAD (Kumar et al., 2004).  In an alternative model of AAD driven 
by Aspergillus fumigatus sensitisation, treatment with anti-IL-13 pAb after airway 
challenge also ameliorated AHR, collagen deposition and goblet cell hyperplasia 
(Blease et al., 2001).  In addition, anti-IL-13 treatment has been demonstrated to 
inhibit OVA induced IL-4, IL-5, TNFα, macrophage inflammatory protein (MIP)-1α, 
eotaxin, monocyte chemotactic protein (MCP)-1 and KC in lung tissue (Yang et al., 
2004;Yang et al., 2005).  However, the reduction in OVA induced IL-5 and eotaxin 
and the associated inhibition of eosinophilia has not always been reproduced (Eum et 
al., 2005).  Furthermore, there is some discrepancy in the effects of IL-13 
neutralisation on the generation of antigen specific IgE.  OVA specific IgE titres are 
partially reduced in Il13-/- mice and mice treated with anti-IL-13 mAb at time of 
allergen challenge however, no effects on OVA specific IgE were observed with sIL-
13Rα2-Fc treatment or anti-IL-13 pAb treatment at time of challenge in equivalent 
models (Walter et al., 2001;Yang et al., 2004;Wills-Karp et al., 1998;Wang & 
McCusker, 2005).  These inconsistencies are likely to result from subtle differences in 
the experimental models, the IL-13 neutralising entity used and associated dosing 
regime.  However, since murine B cells do not express IL-13Rα1, effects of IL-13 
neutralisation on allergen specific antibody generation must be indirect (Punnonen et 
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al., 1993;Zurawski & de Vries, 1994).  Thus, inhibition of antibody production in 
Il13-/- mice or by anti-IL-13 mAb treatment may be a reflection of reduced IL-4 
production in these mice.  Taken together these data demonstrate that IL-13 
neutralisation after sensitisation, at the time of allergen challenge, replicates the 
effects observed in Il13-/- mice.  Hence indicating IL-13 is not required for the 
initiation of Th2 immunity, but is a key effector cytokine in the development of 
airway responses. 
Consistent with IL-13Rα1 being a component of the principal signalling receptor for 
IL-13, Il13rα1-/- mice exhibit pathophysiology comparable to Il13-/- mice and mice 
treated with sIL-13Rα2-Fc or anti-IL-13 antibodies following induction of AAD.  
Upon OVA sensitisation and challenge AHR and goblet cell hyperplasia were 
completely abrogated in Il13rα1-/- mice (Munitz et al., 2008).  Furthermore, 
eosinophilia, MCP-1, TARC, eotaxin-1, eotaxin-2 and TGFβ were reduced in BAL 
from Il13rα1-/- mice compared to wild type.  However, the absence of IL-13Rα1 did 
not affect OVA induced IL-4 or IL-5 in BAL and IL-13 and IL-10 concentrations 
were actually elevated in BAL.  Interestingly, although OVA sensitisation elevated 
serum IgE levels in wild type and Il13rα1-/- mice, Il13rα1-/- mice displayed lower 
titres compared to wild type controls in both sensitised and non-sensitised groups.  
This has also been observed in a Schistosoma mansoni egg antigen (SEA) model of 
AAD in Il13rα1-/- mice (Ramalingam et al., 2008).  Il13rα1-/- mice were also 
protected from SEA induced AHR and mucus hypersecretion.  Furthermore, eotaxin-1 
mRNA up-regulation in the lung tissue was prevented in SEA sensitised Il13rα1-/- 
mice and the corresponding BAL eosinophilia modestly reduced.  However, SEA 
induced IL-4, IL-5 and IL-13 mRNA expression was heightened in Il13rα1-/- mice.  
Collectively, these data from Il13rα1-/- mice confirm IL-13Rα1 and therefore IL-13, 
is not required for the development of a Th2 response, but is essential for airway 
specific effector responses.  These studies also reveal a novel role for IL-13Rα1 in the 
regulation of basal, natural IgE expression.  Moreover, the observation that IL-13, 
amongst other Th2 cytokines, may be elevated in Il13rα1-/- mice with AAD indicates 
IL-13Rα1 could also play a role in negatively regulating Th2 responses.  In addition, 
these two studies suggest that while the type II IL-4 receptor may be dispensable for 
alternative activation of macrophages, alternative activation marker genes are 
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differentially regulated by the type I and II IL-4 receptors and hence full 
differentiation may require IL-13Rα1 (Ramalingam et al., 2008;Munitz et al., 2008). 
Deficiency in STAT6, the primary transcription factor for type II IL-4 receptor 
mediated signalling, also resulted in protection from allergen induced AHR and goblet 
cell up-regulation (Kuperman et al., 1998;Akimoto et al., 1998).  However, since 
stat6-/- mice are also incapable of responding to IL-4 (via the type I or II IL-4 
receptor) they cannot mount Th2 responses and therefore display a more profound 
reduction in AAD than that observed in Il13rα1-/- mice.  Specifically, OVA induced 
eosinophilia and BAL IL-4 and IL-5 concentrations were severely impaired in stat6-/- 
mice (Kuperman et al., 1998).  Furthermore, serum IgE was undetectable in stat6-/- 
mice, even after OVA sensitisation and challenge indicating the generation of both 
antigen specific IgE and basal, natural IgE is STAT6 dependent (Kuperman et al., 
1998;Akimoto et al., 1998). 
In contrast to Il13-/- and Il13rα1-/- mice, Il13rα2-/- mice exhibit an exaggerated 
response to allergen.  Total BAL cells, eosinophils and lymphocytes were 
significantly increased in Il13rα2-/- mice compared to wild type following OVA 
sensitisation and challenge (Zheng et al., 2008).  Furthermore, IL-13 (but not IL-4) 
induced airway inflammation, goblet cell up-regulation and fibrosis were elevated in 
Il13rα2-/- mice.  However, OVA induced BAL IL-13, IL-4 and IL-5 levels were 
comparable in Il13rα2-/- and wild type mice, indicating IL-13Rα2 negatively 
regulates IL-13 effector functions in the lung without altering the underlying Th2 
response.  This is consistent with the hypothesis that IL-13Rα2 acts primarily as an 
IL-13 decoy receptor in this model.  Conversely, in an SEA driven model of AAD 
airway inflammation, mucus hypersecretion and AHR were unaltered in Il13rα2-/- 
mice compared to wild type, however Il13rα2-/- mice developed a stronger IL-10 
response which may be regulating AAD in the absence of IL-13Rα2 (Wilson et al., 
2007).  Interestingly, the phenotype of naive Il13rα2-/- mice presents with reduced 
serum IL-13, increased IL-13 in the lung tissue and increased serum IgE titres, even in 
the absence of allergen exposure (Wood et al., 2003).  These observations indicate 
that IL-13Rα2 may play a homeostatic role in regulating IL-13 distribution and tissue 
clearance, perhaps by acting as a chaperone for IL-13; prolonging its plasma half-life.  
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Furthermore, they demonstrate IL-13Rα2 and therefore IL-13 regulates natural IgE 
production. 
Based on the reported functions of IL-13, its up-regulation in asthma and its role in 
the pathogenesis of AAD in mice, neutralisation of IL-13 activity is being pursued as 
a novel therapeutic for the treatment of asthma.  Further investigation into the effects 
of disrupting IL-13 signalling has been conducted in cynomolgus monkeys naturally 
sensitised to Ascaris suum. In this pre-clinical model of AAD treatment with the anti-
human IL-13 mAb IMA-638, 24 hours prior to antigen challenge reduced total BAL 
cells, eosinophils, neutrophils and monocytes (Bree et al., 2007).  In addition, anti-IL-
13 mAb treatment inhibited allergen induced eotaxin and RANTES (CCL5) 
production in BAL.  In a subsequent study the same anti-IL-13 mAb was shown to 
reduce allergen specific IgE titre and allergen induced histamine release from 
basophils 8 weeks after allergen challenge (Kasaian et al., 2008).  In addition, another 
anti-human IL-13 mAb, CAT-345, has demonstrated inhibition of A. suum induced 
AHR, BAL eosinophilia and total IgE titres in an equivalent cynomolgus monkey 
model (Walsh, 2010).  However, in A. suum sensitised macaques yet another anti-
human IL-13 mAb inhibited allergen induced eotaxin production, but had no effect on 
lung function, BAL eosinophilia or BAL IgE concentrations (Martin et al., 2008).  
Thus, variable results have been attained with IL-13 neutralising mAbs in pre-clinical, 
non-human primate models of AAD. 
At present, multiple clinical trials are ongoing to evaluate the safety and efficacy of 
anti-IL-13 mAb treatment in asthma.  An acceptable safety profile and linear 
pharmacokinetics in patients with mild to moderate asthma have been reported for the 
anti-IL-13 mAb CAT-354 (Singh et al., 2010).  A phase II study with this mAb, now 
termed “Tralokinumab”, in adults with uncontrolled, moderate to severe asthma has 
recently completed.  The primary endpoint for this study was asthma control, with 
secondary endpoints of time to asthma control; time to first exacerbation; 
exacerbation rates and severity and variable airflow obstruction, amongst others, 
however no data from this study is currently available (Walsh, 2010). 
In patients with seasonal allergic rhinitis IL-13 neutralisation has been reported to 
have limited effects on the late phase reaction following allergen challenge despite 
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significant attenuation of free IL-13 (Nicholson et al., 2011). Administration of 
QAX576, another anti-human IL-13 mAb, showed a trend towards reduced eotaxin 
production however no effects on nasal eosinophilia or symptom score were 
demonstrated. 
IMA-638, “Anrukinzumab”, demonstrated inhibition of the EAR and LAR post-
allergen challenge in mild, atopic asthmatics however anrukinzumab treatment did not 
affect allergen induced AHR to methacholine (Gauvreau et al., 2008).  A subsequent 
phase II study with anrukinzumab in patients with persistent asthma did not reach its 
clinical efficacy endpoint, leading to termination of the development of this mAb (Oh 
et al., 2010).  IMA-638 was superseded by IMA-026; another anti-IL-13 mAb binding 
a different epitope.  In a phase II trial directly comparing the two antibodies in mild 
atopic asthmatic patients the reduction in allergen induced EAR and LAR seen 
previously was reproduced in the IMA-638 arm (Gauvreau et al., 2011).  However 
IMA-026 failed to significantly affect allergen induced EAR or LAR.  No significant 
effects on AHR, sputum eosinophilia or total IgE titres were observed with either 
mAb.  Interestingly, a greater elevation in circulating IL-13 levels was observed in 
IMA-026 compared to IMA-638 treated patients.  Further investigation revealed this 
IMA-026 induced accumulation of serum IL-13 was due to impaired IL-13 clearance 
via IL-13Rα2 dependent internalisation (Kasaian et al., 2011).  Since IMA-026 
blocks the interaction between IL-13 and IL-13Rα2, but IMA-638 does not, this is 
proposed to account for the diminished efficacy of IMA-026. 
Perhaps the furthest advanced anti-IL-13 mAb in the clinic is lebrikizumab 
(MILR1444A) which has recently completed two phase II studies assessing efficacy 
in patients with asthma not taking inhaled corticosteroids (ICS) and patients with 
asthma inadequately controlled by ICS (clinicaltrials.gov).  The primary outcome for 
both studies was change in forced expiratory volume in 1s (FEV1).  Lebrikizumab 
treatment significantly improved FEV1 in patients with inadequately controlled 
asthma (Corren et al., 2011).  In addition, lebrikizumab reduced fractional expiratory 
NO (FENO), serum MCP-4 (CCL13), TARC (CCL17) and IgE levels however, 
peripheral blood eosinophil counts were elevated.  Furthermore, patients receiving 
lebrikizumab exhibited a trend towards reduced rate of exacerbations.  Patient 
stratification based on serum periostin levels (a biomarker of IL-13 activity 
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(Woodruff et al., 2007)) indicated patients with high periostin were more responsive 
to lebrikizumab treatment.  Based on these positive phase II results lebrikizumab is to 
progress into phase III studies (Roche half-year results 2011). 
An alternative approach to neutralising IL-13 activity has been investigated using 
pitrakinra, an IL-4 mutant protein (mutein) that binds IL-4Rα thus antagonising the 
effects of both IL-4 and IL-13.  Pitrakinra has been formulated for both inhaled and 
subcutaneous (s.c.) administration.  In A.suum sensitised cynomolgus monkeys both 
inhaled and s.c. formulations significantly attenuated allergen induced AHR and 
reduced airway eosinophilia (Tomkinson et al., 2010).  Both formulations were 
subsequently investigated in a phase II study of allergic asthmatic patients.  Inhaled 
and s.c. pitrakinra inhibited the decline in FEV1 associated with the LAR post-
allergen challenge (Wenzel et al., 2007).  Furthermore, inhaled pitrakinra exhibited 
superior efficacy to s.c. administration.  In addition, inhaled pitrakinra reduced basal 
FENO, but not post-challenge FENO.  However, neither formulation significantly 
affected the EAR or AHR.  Preliminary data from additional studies with inhaled 
pitrakinra in uncontrolled moderate to severe asthma indicated treatment failed to 
improve the primary endpoint, incidence of asthma exacerbation (Antoniu, 2010).  
However, incidence of exacerbation, time to exacerbation and asthma symptom scores 
were improved in a subset of patients with eosinophilic asthma.  Thus, direct delivery 
of an IL-13 antagonist into the lungs may be beneficial in the treatment of a 
subpopulation of asthma patients. 
In summary, there is evidence IL-13 plays a role in allergen induced airway responses 
and basal lung function in man.  However, the limited data available from current 
trials is insufficient to establish whether anti-IL-13 therapy could be beneficial in 
asthma.  It is likely that only a subpopulation of asthmatic patients may be responsive 
to anti-IL-13 therapy as indicated by trials with pitrakinra and lebrikizumab (Corren et 
al., 2011;Antoniu, 2010).  Therefore the key to demonstrating efficacy and 
subsequent patient treatment may be patient stratification into groups of potential 
responders.  Woodruff et al. has identified two subpopulations of asthmatic patients; 
Th2-high and Th2-low asthma (Woodruff et al., 2009).  In the Th2-high subset IL-13 
expression in bronchial biopsies, and hence potential susceptibility to IL-13 
inhibition, was significantly elevated above controls and Th2-low asthma (Woodruff 
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et al., 2009).  Furthermore, identification of serum periostin as a biomarker of IL-13 
activity facilitates patient stratification (Woodruff et al., 2007;Corren et al., 2011).  In 
addition, genetic analysis of asthma subpopulations and their subsequent division into 
clusters has been conducted however it is not yet known how these clusters relate to 
treatment susceptibility (Moore et al., 2010;Haldar et al., 2008).  These early clinical 
studies with IL-13 neutralising entities highlight some discrepancies between data 
generated in mouse models of AAD and man.  Mouse studies demonstrate IL-13 is 
instrumental in airway eosinophilia and AHR however IL-13 neutralisation in man 
had no effect on eosinophilia or AHR (Gauvreau et al., 2011;Gauvreau et al., 2008).  
This indicates that the mouse models currently used are inappropriate approximations 
of human asthma. 
1.3 HDM induced AAD 
As previously illustrated, models of AAD in mice commonly use the model antigen 
OVA.  However, airway exposure to OVA is generally well tolerated and does not, in 
itself induce inflammation.  Therefore mice are sensitised to OVA, often twice prior 
to airway exposure, by peritoneal injection of OVA adsorbed onto the adjuvant 
aluminium hydroxide (alum).  This elicits a strong, systemic Th2 response which is 
subsequently directed to the lungs by a series of airway challenges with OVA.  
Clearly the induction of this immune response is quite dissimilar to the likely routes 
of allergen sensitisation in man.  Furthermore, the period of airway challenge is often 
limited by a waning of the response and even induction of tolerance to OVA 
following prolonged periods of airway challenge (Van Hove et al., 2007).  Thus OVA 
induced models of AAD are typically of an acute nature and hence fail to replicate the 
chronic airway inflammation and associated airway remodelling that is characteristic 
of asthma.  In addition, comparisons between OVA studies can be complicated by the 
varying levels of contaminating endotoxin in OVA preparations.  A further disparity 
between asthma and OVA induced AAD is resolution after cessation of allergen 
challenge. 
In order to circumvent some of these issues, a relatively novel model of AAD, elicited 
by the environmentally relevant aeroallergen HDM, has been developed (Johnson et 
al., 2004).  HDM extract (from Dermatophagoides pteronyssinus or D.farinae) is a 
complex allergen with numerous components that promote allergic sensitisation and 
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therefore negates the need for systemic sensitisation and chemical adjuvants.  Thus, 
continuous airway exposure to HDM, via intranasal administration, evokes chronic 
airway inflammation.  Furthermore, prolonged exposure elicits structural changes in 
the airway wall akin to those present in asthma.  In addition, this remodelling and to 
an extent, AHR does not resolve following cessation of allergen challenge.  
Importantly, allergen exposure is only via the respiratory tract in this model and 
therefore the response to HDM is initiated by lung epithelial cells and pulmonary 
DCs; a mechanism likely to be relevant to aeroallergen exposure and sensitisation in 
man. 
HDM extract is a cocktail of allergens and additional components that posses multiple 
intrinsic properties that activate innate immunity and promote allergen sensitisation 
(Figure 1.4).  Detection of danger signals is paramount for the initiation of an immune 
response and relies heavily on pattern recognition receptors (PRR).  PRRs can sense 
pathogen associated molecular patterns (PAMP) via toll-like receptors (TLR), C-type 
lectin receptors (CLR), nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLR) and protease activated receptors (PAR) (Willart & Hammad, 2010).  
In addition, PRRs can recognise damage associated molecular patterns (DAMP) via 
complement receptors, purinergic receptors and heat shock protein receptors, amongst 
others.  Many of these PAMP and DAMP receptors are expressed on lung epithelial 
cells and DCs where constituents of HDM, but not OVA, activate them upon 
inhalation. 
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Figure 1.4 Allergeneic properties of HDM.  Figure depicts multiple mechanisms by which 
HDM extract may promote allergic sensitisation by inducing the release of mediators:  Toll-like 
receptor 4 (TLR4) activation on airway epithelial cells in the presence of lipopolysaccharide (LPS) and 
MD-2 mimic stimulates the release of CCL2, CCL20, thymic stromal lymphopoietin (TSLP), 
interleukin (IL)-25 and IL-33; occludin cleavage reduces epithelial barrier integrity and permits HDM 
exposure to underlying dendritic cells (DC) resulting in DC activation; activation of protease activated 
receptor (PAR)-2 on epithelial cells stimulates the production of granulocyte-macrophage colony-
stimulating factor (GM-CSF), CCL11, IL-6 and IL-8; ligation of C-type lectin receptors (CLR) on 
airway epithelial cells, DC and alveolar macrophages (AM) induced production of CCL20 and 
cysteinyl leukotrienes (Cys-LT), respectively. 
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The development of HDM induced AAD has been demonstrated to be dependent 
upon the activation of TLR4 on airway epithelial cells (Hammad et al., 2009).  TLR4 
is activated by LPS binding in conjunction with the accessory proteins MD-2 and 
CD14.  Invariably, HDM preparations contain a degree of LPS from contaminating 
Gram-negative bacteria, furthermore, the major group 2 allergens of HDM (e.g. Der p 
2) exhibit structural and functional homology to MD-2 (Trompette et al., 2009).  
Ordinarily, the low level of MD-2 expression on airway epithelial cells renders them 
relatively unresponsive to LPS stimulation; hence administration of Der p 2 heightens 
LPS sensitivity (Jia et al., 2004).  Thus, HDM administration provides the TLR4 
ligand LPS and furthermore, facilitates TLR4 signalling in epithelial cells by 
providing the MD-2 mimic, Der p 2.  TLR4 signalling in epithelial cells stimulates the 
release of DC chemo-attractants such as CCL2 (MCP-1) and CCL20 (MIP-3α) and 
the epithelial derived cytokines TSLP, IL-25 and IL-33 which promote allergen 
sensitisation and Th2 immunity (Hammad et al., 2009;Lloyd, 2009). 
In addition to TLR4 ligands, HDM extract also contains TLR2 ligands such as chitins 
and TLR9 ligands such as mite and bacterial DNA.  The roles of these TLRs in HDM 
induced AAD are currently unknown.  Administration of chitin into the lungs has 
previously been demonstrated to induce accumulation of innate effector cells 
associated with AAD, however the role of chitins in Th2 responses is ambiguous 
(Reese et al., 2007;Lee et al., 2008). 
Another characteristic property of HDM fundamental to its allergenicity is the 
protease activity of many of the main allergens.  Der p 1, 3, 6 and 9 are all cysteine 
and/or serine proteases (John et al., 2000;Wan et al., 1999).  This protease activity has 
numerous effects that are likely to contribute to allergen sensitisation; indeed 
administration of proteolytically active Der p 1 into the lungs of pre-sensitised mice 
induces a significantly greater response than that of inactive Der p 1 (Gough et al., 
2003).  Importantly, Der p 1 is capable of disrupting epithelial tight junctions by 
cleaving occludin, and disrupting ZO-1 distribution thus increasing epithelial 
permeability (Wan et al., 1999).  This in turn enables allergens (together with other 
PAMPs that may be present in the airway lumen) to cross the epithelial barrier, 
therefore increasing the accessibility to DCs.  In addition, Der p 1, 3 and 9 have been 
demonstrated to induce pro-inflammatory cytokine release from epithelial cells, in 
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part via PAR-2 activation (Asokananthan et al., 2002;Sun et al., 2001).  Furthermore, 
HDM proteases have been reported to cleave a multitude of endogenous proteins that 
may influence the pathogenesis of AAD:  Group 3 allergens (Der f 3 in this case) can 
cleave C3 and C5 to generate the anaphylatoxins C3a and C5a, respectively, (Maruo 
et al., 1997).  These active complement components have a range of actions including 
increasing vascular permeability, smooth muscle contraction and stimulating 
histamine release from mast cells.  Der p 1 activity promotes the generation of Th2 
responses and IgE production by cleaving various molecules involved in the 
development and regulation of B and T cell differentiation.  Cleavage of CD40 and 
DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) 
from DCs, CD25 from T cells and CD23 from B cells has all been reported 
(Furmonaviciene et al., 2007;Ghaemmaghami et al., 2002;Schulz et al., 1998;Schulz 
et al., 1995).  Der p 1 also degrades lung surfactant proteins A and D (SP-A and SP-
D, respectively) which have previously been shown to be protective in AAD (Deb et 
al., 2007).  In addition, HDM has been demonstrated to cleave IL-13Rα2 from the 
cell surface and subsequently degrade sIL-13Rα2; potentially rendering cells more 
sensitive to IL-13 stimulation (Daines et al., 2007). 
HDM also contains glycans that are recognised by various CLRs.  Indeed Der p 1 
itself is taken up into DCs via mannose receptor mediated endocytosis (Deslee et al., 
2002).  HDM derived β-glucan moieties interacting with an as yet unidentified dectin-
like receptor have been reported to be the stimulus driving CCL20 release from 
airway epithelial cells (Nathan et al., 2009).  CCL20 is a chemoattractant for 
immature DCs which may subsequently take up allergen and initiate sensitisation.  
Furthermore, glycans present in HDM have been demonstrated to activate Dectin-2 on 
DCs to induce cys-LT production via activation of the arachidonic acid pathway 
(Barrett et al., 2009).  In addition, the glycan chitin can alternatively activate 
pulmonary macrophages, via an as yet unknown mechanism, to produce LTB4 (Reese 
et al., 2007). 
These adjuvant properties intrinsic to HDM render this allergen capable of directly 
and indirectly (via stimulating the airway epithelium) activating DCs.  DCs have been 
demonstrated to be crucial in both the initiation and maintenance of allergic responses 
(van Rijt et al., 2005).  Collectively, these data illustrate how HDM can be such a 
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potent inducer of allergic sensitisation in mice and men, and hence demonstrate why 
HDM is a preferred allergen for studying AAD in animal models. 
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1.4 Hypothesis 
IL-13 is required for the initiation, development and maintenance of pulmonary 
inflammation, airway remodelling and AHR in mice chronically exposed to inhaled 
HDM allergen. 
1.5 Aims 
1. To establish the HDM induced model of AAD described by Johnson et al. 
with respect to expression of IL-13 (Johnson et al., 2004). 
2. To define the effects of IL-13 neutralisation in mice chronically exposed to 
inhaled HDM allergen on inflammation, lung function and airway 
remodelling. 
3. To determine the distribution of IL-13 receptors in naïve and inflamed 
airways.  The key cell types expressing IL-13Rα1 and IL-13Rα2 will be 
identified. 
4. Use the appropriate cell type identified in aim 3 to characterise the underlying 
mechanisms of IL-13 inhibition in vivo by specific cell depletion. 
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2. MATERIALS AND METHODS 
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2.1 Animals 
Male BALB/c mice (6-8 weeks old) were purchased from Harlan (Loughborough, 
UK).  All mice were housed in specific pathogen free conditions and provided with 
food and water ad libitum.  All experiments were performed in accordance with the 
UK Animals (Scientific Procedures) Act 1986. 
2.2 HDM exposure 
HDM used was whole milled Dermatophagoides pteronyssinus (Greer, Lenoir, USA; 
XPB82D3A2.5).  Mice were exposed to 25μg HDM protein in 25μl saline via intra-
nasal (i.n.) administration under light isoflurane anaesthesia for 4 consecutive days 
per week for 1-8 weeks.  Sham exposed mice received 25μl saline alone i.n., 4 times 
per week for the duration of the study.  Mice were killed by cervical dislocation 4 or 
24 hours after the final HDM exposure. 
2.3 Anti-IL-13 mAbs and treatment 
Murinised anti-mouse IL-13 mAbs, CA154_582 (582) and CA154_587 (587) were 
generated by UCB and in vitro activities were characterised as reported previously 
(Berry et al., 2009).  582 prevents the interaction between IL-13 and IL-13Rα1 and 
hence the subsequent association with IL-4Rα (KD 11pM). In addition, 582 prevents 
IL-13 binding to IL-13Rα2.  587 blocks the interaction between the IL-13-IL-13Rα1 
complex and IL-4Rα (KD 8pM), but does not prohibit IL-13 binding IL-13Rα2.  Both 
mAbs 582 and 587 disrupt assembly of the IL-13 receptor signalling complex and 
hence prevent STAT6 activation.  The isotype control mAb, 101.4, was also generated 
by UCB.   
Mice were dosed with 582, 587, 101.4 or vehicle (phosphate buffered saline (PBS)) 
s.c. weekly at 0.3, 3, 10 or 30mg/kg, as indicated, in 100μl injection volume.  Anti-IL-
13 treatment commenced prior to HDM exposure (prophylactically) or after 5 weeks 
of HDM exposure (therapeutically).  Once initiated IL-13 treatment continued for the 
course of the experiment during concomitant HDM exposure. 
2.4 Assessment of AHR 
AHR was determined by direct measurement of lung resistance (RL) and dynamic 
compliance (Cdyn) in anaesthetised, ventilated mice using FinePoint apparatus (Buxco, 
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Wilmington, USA).  Twenty-four hours post HDM exposure mice were terminally 
anaesthetised with ketamine (200mg/kg i.m., Vetalar V, Pfizer, Sandwich, UK) and 
pentobarbital (35mg/kg i.p., Sigma-Aldrich, Dorset, UK; P3761), tracheostomised and 
ventilated via a tracheal cannula at 160 breaths/min, tidal volume 200μl.  After a short 
period of acclimatisation mice were exposed to aerosolised PBS followed by 
increasing concentrations of aerosolised methacholine (3, 10, 30 and 100mg/ml MCh; 
Sigma-Aldrich, Dorset, UK; A2251) via the tracheal cannula.  MCh was aerosolised 
for 30s and mean RL and Cdyn recorded for the following 3min with a 2min recovery 
period between doses. 
In addition AHR was determined as enhanced pause (Penh) using unrestrained whole 
body plethysmography (WBP; Buxco, Wilmington, USA) during the fourth week of 
HDM sensitisation (Hamelmann et al., 1997).  Changes in Penh were measured in 
response to PBS followed by doubling concentrations of MCh (3.125-50mg/ml) 
aerosolised into the chambers for 2 minute periods.  The average Penh was taken over 
a 4 minute period from the start of aerosolisation.  Mice were allowed time to recover 
and Penh stabilise between each MCh exposure. 
2.5 Collection of samples 
Blood samples were collected via cardiac puncture under terminal anaesthesia prior to 
cervical dislocation.  Blood samples were allowed to clot for several hours at room 
temperature prior to centrifugation (10,000g, 10min). Serum was taken and stored at -
20°C for future analysis.  Where blood was required for analysis of cells by flow 
cytometry, blood was taken via cardiac puncture, into heparinised syringes.  BAL was 
performed post mortem via tracheal cannula with 3 x 0.4ml PBS (containing 0.4%w/v 
bovine serum albumin (BSA; Sigma-Aldrich, Dorset, UK; A7906) and 12mM HEPES 
(Sigma-Aldrich, Dorset, UK; H0887)).  Lungs were excised post mortem and 
processed accordingly (unless otherwise stated):  Left lobe preserved in 10% formalin 
(Surgipath, Peterborough, UK; 3800754) for histological analysis; caudal lobe 
digested for analysis by flow cytometry; medial lobe preserved in RNAlater (Ambion, 
Applied Biosystems, Warrington, UK; 7021) for RNA extraction and subsequent real-
time polymerase chain reaction (PCR); cranial lobe snap frozen in liquid nitrogen for 
future cytokine analysis. 
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2.6 Lung digest 
Lung tissue cells were liberated from the caudal lobe by digestion.  Prior to digestion 
lung lobes were finely chopped with a mechanical tissue chopper.  Tissues were 
incubated in media (RPMI 1640 (GIBCO, Invitrogen, Paisley, UK) + 10% FCS, 
100U/ml penicillin/streptomycin) containing 150μg/ml Collagenase D (Roche 
Applied Science, Burgess Hill, UK; 11088858001) and 25μg/ml DNAse (Roche 
Applied Science, Burgess Hill, UK; 10104159001) for one hour at 37ºC in a shaking 
water bath.  Single cell suspensions were generated by pushing the resultant digest 
through 70μm nylon sieves.  Cells were centrifuged at 700g for 5min, supernatants 
discarded and cells resuspended in 10ml media.  Cells were washed in media twice 
more (450g, 5min) then finally resuspended in 1-5ml media. 
2.7 Flow cytometry 
BAL, lung digest (LD) and blood cells were phenotyped and quantified by flow 
cytometry.  Prior to staining blood samples (500μl) were subjected to red cell lysis 
(Sigma-Aldrich, Dorset, UK; R7757; 3ml for 5 minutes), washed and resuspended in 
500μl FACS buffer (PBS + 0.4% BSA, 12mM HEPES, 500mM EDTA).  50-100μl 
BAL, LD or blood cells were stained with combinations of antibodies listed in Table 
2.1.  Where stimulation of cells was required for intracellular cytokine staining BAL, 
LD and blood cells were incubated with 1 in 500 BD Activation cocktail (BD 
Biosciences, Oxford, UK; 550583) containing phorbol 12-myristate 13-acetate 
(PMA), ionomycin and brefeldin A for 4 hours at 37°C.  After stimulation cells were 
washed and resuspended in FACS buffer for staining.  Prior to addition of staining 
antibody cocktails cells were incubated with 1 in 100 Fc block (BD Biosciences, 
Oxford, UK; 553142) for 5min.  Antibody cocktails were then added to the cells and 
incubated for 20 minutes at 4°C in the presence of Fc block.  Cells were washed by 
addition of 2ml FACS buffer and centrifugation (450g, 5min). Samples were fixed 
with Cytofix (BD Biosciences, Oxford, UK; 554655), Cytofix/Cytoperm (BD 
Biosciences, Oxford, UK; 554722) or FACSLyse (BD Biosciences, Oxford, UK; 
349202) for 10min, RT, then washed as above.  Samples requiring intracellular 
staining that were not fixed with Cytofix/Cytoperm were permeabilised with 1ml 
Perm/Wash buffer (BD Biosciences, Oxford, UK; 554723) for 15min, RT or with 
500μl 0.1% nonidet-P40 (Fluka, Sigma-Aldrich, Dorset, UK; 74385) for 3min for 
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FoxP3 staining.  Samples were then centrifuged and supernatants discarded.  Cells 
were resuspended in intracellular staining antibody cocktails prepared in Perm/Wash 
buffer and incubated for 20min, 4°C, then washed by addition of 2ml Perm/Wash 
buffer and centrifugation (450g, 5min). 
Prior to acquisition samples were resuspended in a know concentration of reference 
microbeads for quantification of events acquired.  Each sample was resuspended in 
300μl PKH26 reference microbeads (Sigma-Aldrich, Dorset, UK; P7458) at 22 000 
beads/ml. Samples were acquired on a FACScan or FACSCanto II (BD Biosciences, 
Oxford, UK) and analysed offline using Flowjo v8.8.4 (Tree Star, Ashland, USA).  
Where population comparisons were made, the Overton cumulative histogram 
comparison algorithm was used to determine the percentage of stained cells (Overton, 
1988). 
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Antibody specificity Conjugation Dilution used (1 in X) Supplier Catalogue no. 
CD3e APC-Cy7 100 BD Biosciences 557596 
CD3e FITC 200 BD Biosciences 553061 
CD3e PE-Cy7 100 BD Biosciences 552774 
CD4 APC 200 BD Biosciences 553051 
CD4 PE 100, 200 BD Biosciences 553048 
CD4 PerCP-Cy5.5 100, 200, 400 BD Biosciences 550954 
CD8 APC-Cy7 100 BD Biosciences 557654 
CD8 PE 200 BD Biosciences 553033 
CD8 FITC 200 BD Biosciences 553030 
CD11b APC-Cy7 100 BD Biosciences 557657 
CD11b PE 200 BD Biosciences 553311 
CD11c APC-Cy7 100 BD Biosciences 561241 
CD11c PE 200 BD Biosciences 553802 
CD11c PerCP-Cy5.5 100 BD Biosciences 560584 
CD16/CD32 
(Fc block) purified 100 BD Biosciences 553142 
CD19 FITC 100 BD Biosciences 557398 
CD25 APC-Cy7 400 BD Biosciences 557658 
CD44 FITC 1000 BD Biosciences 553133 
CD45 APC-Cy7 200 BD Biosciences 557659 
CD45 PE 1000 BD Biosciences 553081 
CD45 PE-Cy5 1000 BD Biosciences 553082 
CD45 PE-Cy7 200 BD Biosciences 552848 
CD45 PerCP-Cy5.5 200 BD Biosciences 550994 
CD62L PE-Cy7 200 BD Biosciences 560516 
CD68 RPE neat AbD Serotec MCA1957PEB 
CD205 PE-Cy7 20 eBioscience 25-2051-42 
CD206 PE neat AbD Serotec MCA2235PE 
Dectin-1 Alexa-647 neat AbD Serotec MCA2289A647 
F4/80 PE-Cy7 40 eBioscience 25-4801-82 
FoxP3 PE 200 eBioscience 12-5773-82 
Gr-1 PE 500 BD Biosciences 553128 
Gr-1 PerCP-Cy5.5 200 BD Biosciences 552093 
IFNγ PE-Cy7 100, 500 BD Biosciences 557649 
IL-10 PerCP-Cy5.5 100 eBioscience 45-7101-82 
IL-13 Alexa-647 100 eBioscience 51-7133-80 
IL-13 PE 100 eBioscience 12-7133-82 
IL-13Rα1 purified 20 Santa Cruz Biotechnology sc-27861 
IL-17 PE 100, 500 BD Biosciences 559502 
MOMA2 FITC 100 AbD Serotec MCA519F 
Siglec F PE 200 BD Biosciences 552126 
T1ST2 FITC 200, 400 MD Biosciences 101001F 
TGFβ PE neat R&D Systems IC1835P 
Secondaries 
Goat Cy5 100, 200 Jackson ImmunoResearch 705-176-147 
Goat Dy-light 649 200 Jackson ImmunoResearch 705-496-147 
Table 2.1 Antibodies used for flow cytometry.  Suppliers: BD Biosciences, Oxford, UK; AbD 
Serotec, Kidlington, UK; eBioscience, Hatfield, UK; Santa Cruz Biotechnology, Santa Cruz, USA; MD 
Biosciences, St. Paul, USA; Jackson ImmunoResearch, West Grove, USA. 
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2.8 Cytokine analysis 
BAL samples were centrifuged (450g, 5min), supernatants taken and stored at -80ºC 
until required for assay.  Cranial lobes were also stored at -80ºC prior to 
homogenisation.  Lobes were thawed, weighed and homogenised in Hank’s balanced 
salt solution (HBSS; GIBCO, Invitrogen, Paisley, UK) containing complete protease 
inhibitor (Roche Applied Science, Burgess Hill, UK; 11697498001) at 50mg tissue 
per ml HBSS.  Homogenates were centrifuged (20820g, 25min, +4 ºC), supernatants 
taken and stored at -80 ºC until required for assay. 
BAL and lung homogenate (LH) supernatants were analysed for cytokine and 
chemokine content by sandwich enzyme-linked immunosorbent assay (ELISA) or 
multiplex MSD assay.  IL-4, IL-5, IFNγ, IL-12, IL-10 and KC were quantified using 
mouse Th1/Th2 9-plex ultra-sensitive kits (Meso Scale Discovery (MSD), 
Gaithersburg, USA; K11013C-2) according to the manufacturer’s instructions.  IL-17 
(R&D Systems, Abingdon, UK; DY421), eotaxin (R&D Systems, Abingdon, UK; 
DY420), IL-25 (R&D Systems, Abingdon, UK; DY1399), IL-33 (R&D Systems, 
Abingdon, UK; DY3626) and TSLP (R&D Systems, Abingdon, UK; DY555) were 
quantified using the appropriate DuoSet kit according to the manufacturer’s 
recommendations. 
2.9 Detection of serum immunoglobulins 
Total serum IgE was assessed by sandwich ELISA.  96 well polystyrene plates 
(MaxiSorp, Nunc, Thermo Fisher Scientific, Rochester, USA) were coated with 
4μg/ml anti-mouse IgE (BD Biosciences, Oxford, UK; 553413) in PBS (100μl/well) 
at +4ºC, overnight.  Plates were washed twice with wash buffer (PBS + 0.05% 
Tween), blocked for 1 hour with 200μl assay diluent (PBS + 1% BSA) then washed 
twice.  Samples were loaded in the plates in duplicate, 100μl/well, and incubated for 2 
hours at RT.  Samples were diluted 1 in 100 or 1 in 500 in assay diluent.  Plates were 
then washed four times in wash buffer before addition of 100μl horseradish 
peroxidise (HRP) conjugated rat anti-mouse IgE (AbD Serotec, Kidlington, UK; 
MCA419P) at 1 in 1000. Plates were incubated for a further hour prior to washing 
four times.  100μl 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich, 
Dorset, UK; T8665) was added and colour allowed to develop for 5-10min.  The 
Chapter 2 
 57
reaction was stopped with 50μl 1N H2SO4 and read at 450-650nm.  Data are presented 
as mean optical density (OD) from duplicate wells, for each mouse. 
HDM specific IgE, IgG1, IgG2a and IgG2b antibodies in the serum were detected by 
ELISA.  Plates were coated with 4μg/ml HDM in PBS (100μl/well) at +4ºC, 
overnight.  The following day plates were washed twice with wash buffer, blocked for 
1 hour with 200μl assay diluent then washed twice more.  Samples were loaded in the 
plates in duplicate, 100μl/well, and incubated for 2 hours at RT.  Samples were 
diluted in assay diluent according to Table 2.2.  Plates were then washed four times in 
wash buffer before addition of 100μl of detection antibody (see Table 2.2 for details) 
and incubated for a further hour prior to washing four times.  For the detection of 
HDM specific IgE an additional step was required; addition of 100μl HRP conjugate 
for 30min followed by 4 washes.  100μl TMB was added and colour allowed to 
develop for 5-10min.  The reaction was stopped with 50μl 1N H2SO4 and read at 450-
650nm.  Data are presented as mean OD from duplicate wells, for each mouse. 
Detection Antibody Assay Sample 
Dilution 
(1 in X) 
Specificity Supplier 
(Catalogue number) 
Dilution 
(1 in X) 
Rat anti-mouse IgE BD Biosciences 
(553413) 
1 000 IgE 100, 300 
Goat anti-rat Fc-HRP Jackson ImmunoResearch 
(112-036-071) 
10 000 
IgG1 1 000, 2 000 Rat anti-mouse IgG1-HRP AbD Serotec 
(MCA336P) 
5 000 
IgG2a 100 Rat anti-mouse IgG2a-HRP AbD Serotec 
(MCA421P) 
5 000 
IgG2b 100 Goat anti-mouse IgG2b-HRP AbD Serotec 
(STAR83P) 
5 000 
Table 2.2 Antibodies used for immunoglobulin ELISAs. Suppliers: BD Biosciences, Oxford, 
UK; AbD Serotec, Kidlington, UK; Jackson ImmunoResearch, West Grove, USA. 
2.10 Histology 
2.10.1 Paraffin sections 
Left lobes (unless stated) were excised post mortem and preserved in 10% formalin 
(Surgipath, Peterborough, UK), embedded in paraffin and sectioned for staining with 
Alcian blue periodic acid Schiff’s stain (AB/PAS) for mucin or Masson’s Trichrome 
for collagen visualisation.  The frequency of goblet cells was assessed by scoring 
bronchioles according to the extent of mucin staining within the airway epithelia 
(Figure 2.1).  A score of 0 indicated no positive staining, bronchioles with few stained 
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cells (<5%) scored 1, moderate numbers of stained cells scored 2 and bronchioles 
scoring 3 exhibited high numbers of positively stained cells (>95%).  All visible 
bronchioles were scored in each section; one section was analysed per mouse and data 
represented as median score from each mouse.  Peribronchial collagen thickness was 
measured using Image-Pro Plus (v5, Media Cybernetics, Bethesda, USA) or 
AxioVision (release 4.7.2, Carl Zeiss MicroImaging, Göttingen, Germany) software.  
Three bronchioles were selected at random from each section and the mean depth of 
collagen from the basement membrane determined from five measurements around 
the bronchiole (Figure 2.2).  Peribronchial collagen associated with adjacent blood 
vessels was disregarded.  One section was analysed per mouse and data presented as 
mean collagen depth for each mouse. 
 
Figure 2.1 Goblet cell scoring.  Representative images of bronchioles scoring 0 (A), 1 (B), 2 (C) 
and 3 (D); original magnification x400. 
A B
C D
Chapter 2 
 59
 
 
 
Figure 2.2 Measurement of peribronchial collagen.  Representative of bronchioles from sham (A) 
and HDM mice (B), showing collagen depth measurements; original magnification x200. 
 
A 
B 
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2.10.2 Frozen sections 
Left lobes were inflated with 1:1 optimum cutting temperature formulation 
(OCT):PBS via a tracheal cannula, excised, mounted on a cork bed and frozen in 
isopentane over liquid nitrogen.  Blocks were stored at -80ºC until required for 
staining.  6μm sections were cut and stained according to the immunofluorescence 
staining protocol below (2.10.4). 
2.10.3 BAL cytospins 
50-100μl BAL was loaded into disposable cassettes and spun onto slides by 
cytocentrifugation (190g, 1min).  Slides were air-dried for 30min, fixed with 2-3 
drops of ICC fixative (BD Biosciences, Oxford, UK; 550010) then washed in tris-
buffered saline (TBS; 2 x 5min).  After air-drying over night slides were foil wrapped 
and stored at -80ºC until required for staining. 
2.10.4 Immunofluorescence 
Lung sections were fixed with 4% paraformaldehyde for 10min, rinsed in PBS and 
permeabilised in blocking buffer (TBS + 0.3% Triton X100 (Sigma-Aldrich, Dorset, 
UK; X100) + 10% normal donkey serum (Jackson ImmunoResearch, West Grove, 
USA; 017-000-121) + 1% BSA (Jackson ImmunoResearch, West Grove, USA; 001-
000-162) + 1% normal mouse serum) for 1 hour, RT.  After tipping off the buffer, 
primary antibodies or controls (Table 2.3) were added onto the slides and incubated 
overnight, 4 ºC.  All antibodies were diluted in blocking buffer.  Slides were washed 3 
times in wash buffer (TBS + 0.3% Triton X100) followed by 2 washes in TBS 
(3min/wash) then incubated in fluorochrome conjugated secondary antibodies (Table 
2.3) for 1 hour in the dark, RT.  Slides were washed in wash buffer and TBS as above, 
incubated in 600nM 4’,6-diamidino-2-phenylindole dilactate (DAPI; Invitrogen, 
Paisley, UK; D3571) for 5min then rinsed twice in PBS.  Slides were mounted using 
ProLong Gold antifade reagent (Invitrogen, Paisley, UK; P36930) for imaging on a 
Leica SP5 (10x oil/0.4NA). 
Chapter 2 
 61
 
Antibody 
specificity Format 
Working 
concentration 
 
Supplier Catalogue no. 
IL-13Rα1 Goat pAb 2μg/ml Santa Cruz Biotechnology sc-27861 
control Goat pAb 2μg/ml R&D Systems AB-108-C 
IL-13Rα2 Goat pAb 1 - 4μg/ml R&D Systems AF539 
control Goat pAb 1 - 4μg/ml R&D Systems AB-108-C 
MOMA-2 Rat mAb 2 - 10μg/ml AbD Serotec MCA519G 
control Rat mAb 2 - 10μg/ml R&D Systems MAB006 
CD68 Rat mAb 1 - 4μg/ml AbD Serotec MCA1957 
control Rat mAb 1 - 4μg/ml R&D Systems MAB006 
Secondaries 
Rat Cy3 F(ab’)2 1 in 250 Jackson ImmunoResearch 712-166-153 
Goat Cy5 F(ab’)2 1 in 250 Jackson ImmunoResearch 705-176-147 
Table 2.3 Antibodies used for immunofluorescence.  Suppliers: Santa Cruz Biotechnology, Santa 
Cruz, USA; R&D Systems, Abingdon, UK; AbD Serotec, Kidlington, UK; Jackson ImmunoResearch, 
West Grove, USA. 
2.11 cDNA Synthesis and real-time PCR 
Real-time PCR was used to quantify expression of muc5ac, IL-13, IL-13Rα1, IL-
13Rα2 and IL-4Rα mRNA in lung tissue.  The medial lobe, preserved in RNAlater, 
was homogenised and total RNA isolated using RNeasy Plus Mini Kits (Qiagen, 
Crawley, UK; 74104) according to the manufacturer’s instructions.  Genomic DNA 
was eliminated using gDNA eliminator columns included in the kit.  1μg of total 
RNA (quantified by spectrophotometry) was reverse transcribed using TaqMan 
Reverse Transcription Reagents (Applied Biosystems, Warrington, UK; N8080234) 
containing MultiScribe Reverse Transcriptase and random hexamers as primers.  The 
samples were incubated at 25ºC for 10 minutes to allow hexamer binding, 37ºC for 60 
minutes for the reverse transcription followed by 95ºC for enzyme inactivation.  
Specific cDNA was detected by pre-designed probes from Applied Biosystems 
(Warrington, UK; Table 2.4).  TaqMan Eukaryotic 18S rRNA Endogenous Control 
(Applied Biosystems, Warrington, UK; 4333760F) was used as an internal calibrator.  
10μl real-time PCR reactions were performed in a 7900HT Fast Real-Time PCR 
System (Applied Biosystems, Warrington, UK) using TaqMan Universal PCR Master 
Mix (Applied Biosystems, Warrington, UK; 4304437).  Relative gene expression 
levels were calculated using the Comparative CT (ΔΔCT) method (Livak & 
Schmittgen, 2001) and results expressed as fold change in expression relative to sham 
mice (2-ΔΔCT). 
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mRNA TaqMan Gene Expression Assay I.D. Number 
muc5ac Mm01276725_g1 
IL-13 Mm00434204_m1 
IL-13Rα1 Mm00446729_m1 
IL-13Rα2 Mm00515166_m1 
IL-4Rα Mm00439634_m1 
Table 2.4 Probes used for real-time PCR.  All probes were sourced from Applied Biosystems, 
Warrington, UK. 
2.12 Statistical Analysis 
3-11 mice per group were used in all experiments.  Experiments were performed once 
only, unless otherwise stated.  Data are expressed as single data points with bars 
representing group medians, unless otherwise stated.  Statistical significance was 
determined by Mann Whitney test where 2 groups are compared or non-parametric 
one-way analysis of variance (Kruskal-Wallis ANOVA) with Dunn’s post test where 
analysis of more than two groups was required.  Statistically significant differences 
are denoted by asterisks whereby * p<0.05, ** p<0.01 and *** p<0.001.  Graph 
generation and statistical analyses were performed using GraphPad Prism (version 5, 
USA). 
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3. CHARACTERISATION OF HDM INDUCED AAD 
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3.1 Introduction 
Animal models used to replicate the features of asthma have focussed on inducing a 
Th2 response and AHR in the lungs, but rarely recapitulate the frequency of allergen 
exposure and hence chronicity of airway inflammation seen in patients.  The most 
commonly used animal model of AAD uses the relatively innocuous protein OVA as 
an antigen.  Exposure of the airways to OVA alone in naïve mice does not induce 
inflammation.  Therefore to stimulate an immune response animals must first be 
sensitised to OVA by peripheral injection (usually i.p.) of OVA in the adjuvant alum 
prior to airway challenge with OVA.  Although this induces a strong Th2 response, it 
does not reflect the likely allergen sensitisation pathway in man.  Furthermore, 
continuous OVA challenge in sensitised mice can induce tolerance (Van Hove et al., 
2007).  To mimic sensitisation to aeroallergens it is important that the first exposure 
to allergen is via the respiratory tract where local pulmonary antigen presenting cells 
(APC), rather than peritoneal APCs, will process the allergen and initiate a response 
accordingly.  For this reason a relatively novel model of AAD induced by HDM was 
chosen in which to study mechanisms of allergic inflammation. 
This mouse model of experimental asthma aims to replicate the persistence and 
chronicity of pulmonary inflammation in asthma by continuous exposure to a relevant 
aeroallergen, HDM (Johnson et al., 2004).  The allergenic properties of HDM negate 
the requirement for powerful chemical adjuvants such as alum.  Chronic exposure of 
the airways to HDM elicits strong Th2 driven inflammation accompanied by airway 
remodelling, goblet cell hyperplasia and AHR.  And importantly, this allergic 
response is stimulated by activation of lung epithelial cells and pulmonary dendritic 
cells; a mechanism that may be applicable to the provocation of asthma and hence 
may share subsequent mechanisms of pathophysiology (Hammad & Lambrecht, 
2008). 
HDM extract possesses multiple properties that promote allergic sensitisation, 
primarily via activation of airway epithelial cells and DCs.  The proteolytic activity of 
Der p 1 and Der p 9 disrupts epithelial integrity by cleavage of tight junction proteins, 
thus allowing increased access between allergen and sub-epithelial DCs (Wan et al., 
1999).  In addition these proteases can directly activate DCs and epithelial cells via 
PARs which polarise DCs to induced Th2 responses and stimulate the production of 
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Th2 cytokines and chemokines (Hammad & Lambrecht, 2008).  Der p enzymes also 
cleave of various cell surface molecules such as DC-SIGN, CD40, CD25 and CD23 
which further tilts the balance in favour of Th2 sensitisation.  C-type lectins within the 
HDM cocktail attract DCs, via the production of CCL20 from epithelial cells, and 
induce production of cysteinyl leukotrienes (Nathan et al., 2009;Barrett et al., 2009).  
HDM extract also induces TLR4 signalling by containing contaminating LPS.  
Airway exposure to low level LPS promotes Th2, rather than Th1 responses 
(Eisenbarth et al., 2002).  In addition TLR4 expression may be stabilised by Der p 2, a 
functional homolog of MD-2 (Trompette et al., 2009).  Taken together, these 
observations demonstrate HDM is a potent inducer of Th2 immunity. 
3.1.1 Aim 
1. To establish the HDM induced model of AAD described by Johnson et al. 
with respect to expression of IL-13 (Johnson et al., 2004). 
The aim of this chapter was to establish the HDM induced model of AAD described 
by Johnson et al. with respect to IL-13 and draw parallels to the pathophysiology of 
clinical asthma (Johnson et al., 2004).  Furthermore, to assess the suitability of the 
model for investigating the role of IL-13 in AAD. 
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3.2 Methods 
3.2.1 HDM exposure. 
Male balb/c mice were exposed to 25μg intranasal HDM extract, 4 consecutive days 
per week for 1, 3 or 5 weeks according to Figure 3.1. 
3.2.2 IL-13 Immunofluorescence staining. 
Staining was conducted on BAL cytospins and frozen lung sections as Kim et al. with 
anti-IL-13 from R&D Systems (BAF413) and tyramide signal amplification (TSA) kit 
(Invitrogen T20933) (Kim et al., 2008).  Briefly, lung sections were fixed with 4% 
paraformaldehyde for 10min, rinsed in PBS and endogenous peroxidise activity 
quenched with peroxidise-blocking solution (Dako S2023) for 10min followed by a 
rinse in H20 then TBS (5min).  Endogenous biotin was blocked by sequential 
incubations with avidin solution (15min), TBS wash (5min) then biotin solution 
(15min; Vector, SP-2001) followed by two TBS washes (5min/wash).  Sections were 
blocked with 2% gelatin (Sigma G7765) in blocking buffer (TBS + 0.1% saponin 
(Sigma S4521) + 5% normal goat serum (Jackson ImmunoResearch 005-000-121)) 
for 1 hour, RT.  After tipping off the buffer, biotinylated goat anti-mouse IL-13 
(BAF413) or biotinylated normal goat IgG control (BAF108, R&D Systems) were 
added onto the slides at 0.5-2μg/ml in blocking solution D and incubated overnight, 
4ºC.  Slides were washed 3 times in wash buffer (PBS + 0.1% saponin; 3min/wash) 
followed by incubation with HRP conjugate at 1 in 100 in blocking solution D for 
45min in the dark, RT.  Slides were washed in wash buffer as above, and incubated in 
tyramide solution at 1 in 100 in amplification buffer for 10min.  Finally, slides were 
washed in wash buffer as above and incubated in 600nM DAPI (Invitrogen D3571) 
for 5min then rinsed twice in PBS.  Slides were mounted using Prolong Gold Antifade 
(Invitrogen P3693) for imaging. 
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Figure 3.1 Experimental protocol for exposure to HDM.  Mice were exposed to intranasal HDM 
on 4 consecutive days per week for 1, 3 or 5 weeks.  Sham treated mice received intranasal saline 
alone.  Mice were culled 4 or 24 hours after the final HDM exposure for collection of blood, BAL and 
lung samples. 
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3.3 Results 
3.3.1 Chronic exposure to HDM induces AHR 
As previously reported chronic exposure of the airways to HDM extract administered 
5 times per week induces AHR to inhaled spasmogens such as MCh (Gregory et al., 
2009;Johnson et al., 2004).  The current exposure regime of 25μg HDM i.n. for 4 
consecutive days per week did not induce AHR to MCh challenge after just one week 
of exposure (Figure 3.2 A-B).  After 3 weeks of HDM exposure the decline in Cdyn in 
response to MCh challenge was enhanced compared to sham exposed control mice; 
however no changes in RL were observed (Figure 3.2 C-D).  Five weeks of HDM 
exposure provoked an exacerbated response to MCh challenge observed as elevated 
RL and reduced Cdyn (Figure 3.2 E-F).   Moreover, baseline lung function prior to 
methacholine exposure was impaired in mice exposed to HDM for 5 weeks compared 
to sham exposed mice (Figure 3.2 G-H).  Changes in basal lung function were not 
observed after one or 3 weeks of HDM exposure (data not shown). 
3.3.2 Chronic exposure to HDM induces pulmonary inflammation 
Accumulation of eosinophils, neutrophils, CD4+ T cells and CD8+ T cells in BAL 
and lung tissue were quantified following repeated intranasal exposure to HDM.  
HDM induced eosinophilia was apparent after 3 and 5 weeks in both lung tissue and 
BAL however there was no change number of eosinophils compared to sham mice 
after just one week of exposure (Figure 3.3 A-B).  Significant infiltration of 
neutrophils was detected in BAL at week 1 and continued to increase throughout the 5 
week time-course with increased HDM exposure.  Tissue neutrophilia was not 
apparent after one week of HDM; however 3 weeks of exposure induced significant 
neutrophilia which was further elevated at 5 weeks (Figure 3.3 C-D).  HDM exposure 
induced accumulation of CD4+ and CD8+ T cells in BAL from week 1.  The number 
of BAL CD4+ and CD8+ T cells was further elevated at weeks 3 and 5.  Conversely, 
the number of tissue CD4+ and CD8+ T cells appeared slightly reduced at week 1 
compared to sham treated mice however 5 weeks of HDM exposure induced 
significant CD4+ and CD8+ T cell accumulation in the lung tissue (Figure 3.3 E-H). 
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Figure 3.2 Chronic exposure to HDM induces AHR.  AHR to MCh was determined as changes in 
lung resistance (RL) (A, C, E and G) and dynamic compliance (Cdyn) (B, D, F and H) measured 24 
hours post HDM.  AHR was assessed after 1 (A-B), 3 (C-D) or 5 (E-H) weeks of HDM exposure.  
Open symbols represent saline exposed mice and closed symbols HDM exposed mice.  (G-H) Baseline 
RL (G) and Cdyn (H) after 5 weeks of HDM exposure.  Data are shown as mean ± SEM, n = 6-8 
mice/group.  * p<0.05, ** p<0.01 and *** p<0.001 relative to saline group by Mann Whitney test. 
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Figure 3.3 Chronic exposure to HDM induced pulmonary inflammation.  BAL and lungs (caudal 
lobe) were taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  
Eosinophils (A-B), neutrophils (C-D), CD4+ T cells (E-F) and CD8+ T cells (G-H) in BAL (A, C, E 
and G) and lung tissue digest (LD) (B, D, F and H) were identified and quantified by flow cytometry.  
n = 8 mice/group, bar represents median.  * p<0.05, ** p<0.01 and *** p<0.001 relative to sham group 
by Mann Whitney test. 
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3.3.3 HDM induced pulmonary inflammation is Th2 biased 
To further characterise HDM induced inflammation T-helper subsets within the BAL 
and tissue CD4+ T cell populations were identified and quantified.  Th2 cells were 
defined by T1ST2 expression (Xu et al., 1998;Lohning et al., 1998); Th1 cells by 
intracellular IFNγ and Th17 cells by intracellular IL-17 expression.  HDM exposure 
stimulated accumulation of all three T-helper subsets in BAL from week 1 which 
increased further with continued HDM exposure (Figure 3.4).  However, the number 
of Th2 cells in BAL at weeks 3 and 5 were at least 2-fold greater than the number of 
Th1 or Th17 cells present.  In lung tissue the number of Th2 cells was elevated above 
sham after 3 weeks of HDM exposure and further increased after 5 weeks.  Contrary 
to the BAL, there were no significant changes in the number of Th1 cells in the lung 
tissue over the 5 week time-course.  Accumulation of Th17 cells in lung tissue was 
modestly increased above sham after 3 weeks of exposure and further increased at 
week 5.  In the lung tissue, as in BAL, the number of Th2 cells exceeds that of Th1 or 
Th17 cells indicating a predominant but not exclusively Th2 biased response to HDM 
exposure. 
3.3.4 HDM induced cytokine profile 
The cytokine milieu in the lung tissue was assessed to corroborate the inflammation 
observed after HDM exposure.  Cytokine and chemokine concentrations in lung 
homogenate supernatants were measured by ELISA or MSD multiplex assay.  In 
accordance with the predominant presence of Th2 cells identified above, the Th2 
cytokines IL-4 and IL-5 were elevated above sham levels after 3 and 5 weeks of 
HDM exposure (Figure 3.5 A-B).  Similarly, modest increases in IL-17 were detected 
after 3 and 5 weeks of HDM exposure which are likely to reflect the accumulation of 
Th17 cells at the same time points (Figure 3.5 C).  Low levels of IFNγ were measured 
above sham at week 5 which may be linked with the low level presence of Th1 cells 
at this time point (Figure 3.5 D).  However, high concentrations of IL-12 were 
measured in the tissue after one week of HDM exposure.  HDM induced IL-12 
concentrations diminish slightly after week 1 but remain elevated at weeks 3 and 5 
(Figure 3.5 E).  Interestingly, the regulatory cytokine IL-10 was induced by HDM, but 
not before 5 weeks of exposure (Figure 3.5 F). 
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The eosinophil chemoattractant eotaxin was elevated in LH after 3 and 5 weeks of 
HDM exposure (Figure 3.6 A), corresponding to the presence of eosinophils in the 
lungs at the same time points.  However, in BAL a significant increase in eotaxin 
above sham was only observed at 3 weeks of HDM exposure (Figure 3.6 B).  The 
neutrophil chemoattractant KC was elevated in LH at 3 and 5 weeks (Figure 3.6 C) 
indicative of the tissue neutrophilia observed after 3 and 5 weeks of HDM exposure.  
In BAL, significant increases in KC were observed at weeks 1, 3 and 5 (Figure 3.6 D). 
No changes were observed in concentrations of the epithelial derived cytokines IL-25 
or TSLP after HDM exposure; however IL-33 was significantly elevated at week one 
and further increased at each time point (Figure 3.7). 
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Figure 3.4 Chronic exposure to HDM induces a predominant Th2 response.  BAL and lungs 
(caudal lobe) were taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM 
instillation.  Th2 (A, B), Th1 (C, D) and Th17 cells (E, F) in BAL (A, C and E) and lung tissue digest 
(LD) (B, D and F) were identified and quantified by flow cytometry.  n = 8 mice/group, bar represents 
median.  * p<0.05, ** p<0.01 and *** p<0.001 relative to sham group by Mann Whitney test. 
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Figure 3.5 Induction of T cell cytokines following HDM exposure.  Lungs (cranial lobe) were 
taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  Cytokines were 
quantified in lung homogenate supernatant by MSD assay (A-B, D-F) or ELISA (C).  n = 7-8 
mice/group, bar represents median.  * p<0.05, ** p<0.01 and *** p<0.001 relative to sham group by 
Mann Whitney test. 
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Figure 3.6 HDM induced chemokine expression.  Lungs (cranial lobe) and BAL were taken after 
1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  Chemokines were 
quantified in lung homogenate and BAL supernatant by ELISA (A-B) or MSD assay (C-D).  n = 7-8 
mice/group, bar represents median.  * p<0.05, ** p<0.01 and *** p<0.001 relative to sham group by 
Mann Whitney test. 
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Figure 3.7 Expression of epithelial derived cytokines following HDM exposure.  Lungs (cranial 
lobe) were taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  
Cytokines were quantified in lung homogenate supernatant by ELISA.  n = 5-8 mice/group, bar 
represents median.  * p<0.05 and *** p<0.001 relative to sham group by Mann Whitney test. 
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3.3.5 HDM induced antibody production 
Total serum IgE was assessed by ELISA to indicate the presence of an allergic 
response.  Total serum IgE titres were elevated after 5 weeks of HDM exposure 
(Figure 3.8 A).  In addition HDM specific antibodies in the serum were measured by 
ELISA to gauge antigen specificity of the HDM induced inflammatory response.  
HDM specific IgE, IgG1, IgG2a and IgG2b were detected after 3 weeks of HDM 
exposure and titres further increased after 5 weeks of HDM exposure (Figure 3.8 B-
E).  This confirms the presence of an antigen specific, adaptive immune response after 
3 weeks of chronic exposure to HDM. 
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Figure 3.8 Generation of IgE and HDM specific antibodies following HDM exposure.  Blood 
was taken via cardiac puncture after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM 
instillation.  Total IgE (A) and HDM specific IgE (B), IgG1 (C), IgG2a (D) and IgG2b (E) were 
assessed in serum by ELISA.  n = 8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 
relative to sham group by Mann Whitney test. 
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3.3.6 HDM induced airway remodelling 
Prolonged airway inflammation is proposed to lead to structural changes in the 
airways such as goblet cell hyperplasia/metaplasia and increased collagen deposition.  
Goblet cell frequency was assessed histologically in AB/PAS stained sections and 
scored accordingly.  Increased goblet cell frequency was apparent after 3 and 5 weeks 
of HDM exposure (Figure 3.9 A-E).  In addition, muc5ac mRNA expression in lung 
tissue was determined by real time PCR.  Muc5ac expression was significantly 
elevated at weeks 3 and 5 after HDM exposure corroborating goblet cell up-regulation 
at these time points (Figure 3.9 F). 
Peribronchial collagen depth was measured in Masson’s trichrome stained sections.  
Significant collagen deposition was detected as early as one week after HDM 
exposure.  This was further elevated at week 3 and 5 following HDM exposure 
(Figure 3.10). 
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Figure 3.9 Up-regulation of mucus production following HDM exposure.  Lungs were taken after 
1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  (A-D) representative 
photomicrographs of airway sections stained with AB/PAS from mice exposed to saline (A) or HDM 
for 1 (B), 3 (C) or 5 (D) weeks; original magnification x200.  (E) Goblet cell frequency was scored in 
AB/PAS stained sections.  (F) Muc5ac mRNA in lung tissue was quantified by RT-PCR and 
normalised to sham.  n = 7-8 mice/group, bar represents median.  *** p<0.001 relative to sham group 
by Mann Whitney test. 
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Figure 3.10 Chronic exposure to HDM induces peribronchial collagen deposition.  Lungs were 
taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  (A-D) 
representative photomicrographs of airway sections stained with Masson’s trichrome from mice 
exposed to saline (A) or HDM for 1 (B), 3 (C) or 5 (D) weeks; original magnification x200.  (E) 
Peribronchial collagen depth was measured in Masson’s trichrome stained sections.  n = 8 mice/group, 
bar represents median.  * p<0.05, ** p<0.01 and *** p<0.001 relative to sham group by Mann Whitney 
test. 
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3.3.7 HDM exposure up-regulates IL-13 
Repeated exposure of the airways to HDM induced significant IL-13 mRNA up-
regulation in the lung tissue evident from week 1 of exposure.  IL-13 mRNA was 5.4 
fold greater than sham treated mice after one week of HDM exposure and further 
elevated to over 500-fold greater than sham at weeks 3 and 5 (Figure 3.11 A).  In 
addition elevated concentrations of IL-13 protein were detected in lung tissue after 3 
and 5 weeks of HDM exposure.  However no significant increases in IL-13 were 
detected in BAL supernatants from HDM exposed mice compared to sham at the time 
points assessed in this study. 
Immunofluorescence (IF) staining of the lung tissue and BAL cells was employed to 
reveal potential sources of IL-13 in the lungs.  No specific IL-13 signal could be 
detected in the tissue or BAL.  High background staining was observed in epithelial 
cells and subsets of lung parenchyma cells (Figure 3.12) and in BAL cells (Figure 
3.13).  This was observed even in the absence of primary control antibodies and hence 
is likely to result from the signal amplification kit used.  A variety of anti-IL-13 
antibodies, in the presence or absence of signal amplification, were tested however no 
specific IL-13 signal could be detected. 
Alternatively, intracellular IL-13 staining of inflammatory cells in the lung digest was 
conducted in order to identify IL-13 expressing cells after HDM exposure.  IL-13 was 
detected in CD4+ T cells following ex vivo stimulation; shown as a shift in 
fluorescence compared to isotype control (Figure 3.14 A-C).  Following one week of 
HDM exposure there was no differences in the mean fluorescence intensity (MFI) of 
IL-13 staining in CD4+ cells, or the frequency of IL-13+ cells within the CD4+ 
population.  However, the number of IL-13+ CD4+ T cells was slightly diminished in 
HDM exposed mice compared to sham.  At week 3, the intensity of IL-13 staining 
was greater in CD4+ cells from HDM exposed mice than sham mice, although the 
percentage of IL-13+ cells within the CD4+ population was higher in sham mice.  No 
differences were observed in the number of IL-13+ CD4+ T cells after 3 weeks of 
HDM exposure compared to sham.  After 5 weeks of HDM exposure, IL-13 MFI and 
the number of IL-13+ CD4+ T cells were equivalent to sham, however the frequency 
of IL-13+ cells within the CD4+ population was greater in sham mice compared to 
HDM exposed (Figure 3.14 D-F). 
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Low levels of IL-13 staining were also detected in CD8+ T cells following ex vivo 
stimulation (Figure 3.15 A).  One week of HDM exposure had no effect on the MFI of 
IL-13 staining, proportion of IL-13+ CD8+ cells or the number of IL-13+ CD8+ T 
cells.  Following 3 weeks of HDM exposure the intensity of IL-13 staining in CD8+ 
cells was elevated however, both the percentage of IL-13+ CD8+ cells and the 
number of IL-13+ CD8+ cells was diminished compared to sham.  At week 5, no 
differences in IL-13 MFI or the number of IL-13+ CD8+ T cells were observed 
between sham and HDM exposures, although the proportion of IL-13+ cells within 
the CD8+ population was greater in sham than HDM exposed mice (Figure 3.15 B-
D). 
Analysis of IL-13 expression specifically in Th2 cells revealed the intensity of IL-13 
staining was significantly higher in HDM mice than sham mice after 3 and 5 weeks of 
exposure (Figure 3.16 A-B).  Due to the very low levels of Th2 cells in LD from sham 
mice, calculation of the percentage and number of IL-13 expressing cells within this 
population was not deemed valid.  However, IL-13+ Th2 cells were present in LD 
from HDM exposed mice and increased in both proportion and number with length of 
HDM exposure (Figure 3.16 C-D). 
In addition to T cells, IL-13 was detected in neutrophils and eosinophils in the lungs.  
After 5 weeks of HDM exposure, the numbers of IL-13+ neutrophils and eosinophils 
were significantly greater in the lungs of HDM exposed mice compared to sham 
exposed mice (Figure 3.17). 
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Figure 3.11 IL-13 expression following chronic HDM exposure.  Lungs were taken after 1, 3 or 5 
weeks of HDM exposure, 4 hours after the last HDM instillation.  (A) IL-13 mRNA in lung tissue was 
quantified by real time PCR and normalised to sham.  IL-13 protein was quantified in lung homogenate 
supernatant (B) and BAL (C) by ELISA.  n = 7-8 mice/group, bar represents median.  ** p<0.01 and 
*** p<0.001 relative to sham group by Mann Whitney test. 
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Figure 3.12 Non-specific IL-13 staining in the lungs following exposure to HDM.  Lungs were 
taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  Green indicates IL-13 
staining and blue is DAPI.  Representative images of lungs stained with IL-13 (A, B), isotype control 
(C, D) or no primary antibody (E, F) from sham (A, C, E) and HDM (B, D, F) exposed mice.  Scale bar 
represents 75μm. 
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Figure 3.13 Non-specific IL-13 staining in BAL following exposure to HDM.  Cytospin slides were 
generated from BAL.  BAL was taken after 5 weeks of HDM exposure, 24 hours after the last HDM 
instillation.  Green indicates IL-13 staining and blue is DAPI.  Representative images of BAL from 
sham (A, C, E, G) and HDM (B, D, F, H) exposed mice.  BAL was stained with IL-13 (A-D) or isotype 
control (E-H).  (C), (D), (G) and (H) depict further magnified images of (A), (B), (E) and (F), 
respectively.  Scale bar represents 75μm, unless stated. 
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Figure 3.14 IL-13 expression in CD4+ cells following chronic HDM exposure.  Lungs were taken 4 
hours after the last HDM instillation.  (A-B) Representative plots of CD4+ T cells stained with anti-
CD4 and intracellular IL-13 (B) or isotype control (A) at week 5.  (C) Representative histogram of 
intracellular IL-13 staining (black line) and isotype control (blue line) in CD4+ T cells at week 5.  MFI 
(D), % (E) and number (F) of IL-13+ CD4+ T cells, identified and quantified by flow cytometry. n = 7-
8 mice/group, bar represents median. * p<0.05 and ** p<0.01 relative to sham group by Mann Whitney 
test. 
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Figure 3.15 IL-13 expression in CD8+ cells following chronic HDM exposure.  Lungs were taken 4 
hours after the last HDM instillation.  (A) Representative histogram of intracellular IL-13 staining 
(black line) and isotype control (blue line) in CD8+ T cells at week 5.  MFI (B), % (C) and number (D) 
of IL-13+ CD8+ T cells, identified and quantified by flow cytometry. n = 7-8 mice/group, bar 
represents median. ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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Figure 3.16 IL-13 expression in Th2 cells following chronic HDM exposure.  Lungs were taken 4 
hours after the last HDM instillation.  (A) Representative histogram of intracellular IL-13 staining 
(black line) and isotype control (blue line) in Th2 cells at week 5.  MFI (B), % (C) and number (D) of 
IL-13+ Th2 cells, identified and quantified by flow cytometry. n = 7-8 mice/group, bar represents 
median. * p<0.05 and *** p<0.001 relative to sham group by Mann Whitney test or ## p<0.01 and ### 
p<0.001 by Kruskal-Wallis test with Dunn’s post test. 
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Figure 3.17 IL-13 expression in neutrophils and eosinophils following chronic HDM exposure.  
Lungs were taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation and stained 
for intracellular IL-13 or isotype control.  Numbers of IL-13+ neutrophils (A) and eosinophils (B) were 
identified and quantified by flow cytometry. n = 8 mice/group, bar represents median.  ** p<0.01 and 
*** p<0.001 relative to sham group by Mann Whitney test. 
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3.4 Discussion 
The induction of airway pathophysiology by chronic intranasal exposure to HDM was 
first described by Johnson et al. (Johnson et al., 2004).  Allergic airways disease 
(AAD) with similarities to asthma was induced in the absence of prior systemic 
sensitisation and without the use of chemical adjuvants.  The primary aim of this 
chapter was to establish this model of AAD and further characterise the allergic 
response.  This will allow identification of an appropriate HDM exposure regime to 
be used in subsequent studies analysing the role of specific mediators and cell types in 
AAD pathophysiology.  In addition this chapter aimed to confirm the up-regulation of 
IL-13 previously observed in lungs from mice chronically exposed to HDM and 
identify potential sources of IL-13 in the lungs during AAD (Gregory et al., 2009). 
3.4.1 HDM exposure induces allergic airways disease 
The use of relevant animal models to study the mechanisms and molecules involved 
in the pathogenesis of allergic asthma is paramount.  HDM is a complex cocktail of 
antigens, proteases and TLR agonists, e.g. endotoxin.  This is much more akin to the 
array of substances people are regularly exposed to via their airways and hence 
provides a more relevant experimental allergen than previously used surrogate 
antigens, such as ovalbumin.  Importantly, the nature of HDM as an allergen mitigates 
the requirement for systemic sensitisation with chemical adjuvants, such as alum, 
prior to airway exposure.  Therefore the first contact with allergen is via the airways 
and hence the allergic response is initiated by airway resident APCs; providing a 
much more appropriate means of studying the pathogenesis of allergic asthma.  
Furthermore, this allergenic property of HDM allows repeated exposure of the 
airways to HDM without the induction of tolerance.  The ability to chronically expose 
the airways in this way permits the induction of persistent inflammation and hence 
investigation into the subsequent structural changes in the airways. 
As previously reported, chronic exposure to i.n. HDM induced AHR, inflammation 
and airway remodelling (Johnson et al., 2004).  AHR was assessed 24 hours post-
HDM; the optimal time point for observing changes in RL in HDM exposed mice 
(Gregory et al., 2009).  In the current study, hyper-reactivity was apparent after 3 
weeks of HDM exposure as an exaggerated decline in Cdyn in response to MCh 
challenge.  However, this was not accompanied by increased RL at the same time 
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point.  By week 5 AHR was evident as both increased RL and reduced Cdyn in 
response to MCh.  Moreover a decline in basal lung function was also observed at 
week 5 prior to MCh challenge.  These observations at week 5 are in agreement with 
those previously reported however, Gregory et al. demonstrated significant changes in 
RL from week 3 of HDM exposure (Johnson et al., 2004;Gregory et al., 2009).  This 
apparent disparity may be attributable to variation between batches of HDM or subtle 
differences in the HDM exposure regime and techniques used for assessing lung 
function. 
Analyses of cellular inflammation and inflammatory mediators were conducted 4 
hours post-HDM to capture peak cytokine production in the lungs and encompass 
significant cell infiltration (Gregory et al., 2009).  Infiltration of all the cell subsets 
investigated in this study increased throughout the 5 week time course of HDM 
exposure.  One week of HDM exposure induced an early, low level, accumulation of 
neutrophils and T cells (CD4+ and CD8+) in BAL.  In contrast to the BAL, T cells 
(CD4+ and CD8+) in the tissue appear to dip at the same time point.  This was 
unexpected but may be due to migration of cells from the circulation and/or lung 
parenchyma into the airway lumen as a result of HDM exposure.  Neutrophils 
however, did not exhibit a corresponding dip in the tissue, perhaps because they are 
more readily mobilised into the circulation from bone marrow.  On further analysis of 
BAL CD4+ T cells Th1, Th2 and Th17 cells were present at week 1 although none of 
the cytokines or chemokines investigated were detected in the tissue at this early time 
point, with the exception of IL-12 and IL-33.  This suggests the immune response at 
this early time point is not yet adaptive and is perhaps initiated by an innate response 
to HDM.  The induction of IL-12 at week 1 suggests exposure of airway APCs to LPS 
with in the HDM extract and may indicate DC activation (Eisenbarth et al., 2002).  
This LPS component of HDM can also activate the airway epithelium via pattern 
recognition receptors leading to release of epithelial derived cytokines such as IL-33 
(Hammad et al., 2009).  IL-33, in turn, acts as an alarmin and is capable of promoting 
innate and allergic inflammation by multiple mechanisms (Lloyd, 2010). IL-33 has 
been reported to recruit Th2 cells; activate mast cells, eosinophils, basophils, 
polarised Th2 cells, natural killer (NK) cells, iNKT cells and DCs; amplify the 
polarisation of alternatively activated macrophages and activate innate lymphoid cells 
(Komai-Koma et al., 2007;Allakhverdi et al., 2007;Cherry et al., 2008;Stolarski et al., 
Chapter 3 
 93
2010;Smithgall et al., 2008;Hammad & Lambrecht, 2008;Kurowska-Stolarska et al., 
2009;Neill et al., 2010;Price et al., 2010;Chang et al., 2011).  In addition, direct 
administration of IL-33 into the airways, or transgenic over-expression of IL-33, 
induces airway inflammation, goblet cell hyperplasia, up-regulation of Th2 cytokines 
and eosinophilia (Kurowska-Stolarska et al., 2009). 
After 3 weeks of HDM exposure the profound eosinophilia and accumulation of Th2 
cells in both BAL and lung tissue indicates a strong Th2 response.  This was 
supported by the presence of Th2 cytokines IL-4 and IL-5, the eosinophil chemo-
attractant eotaxin and the Th2 amplifying cytokine IL-33 in the lung tissue and 
corresponds with the development of AHR.  Gregory et al. observed a similar profile 
of AHR, eosinophilia, accumulation of Th2 cells and up-regulation of Th2 cytokines 
at this time point (Gregory et al., 2009). 
In addition to this dominant Th2 response, low levels of Th1 and Th17 cells were 
present in BAL after 3 weeks of HDM exposure.  This was accompanied by low 
levels of tissue IL-17 but not IFNγ.  Interestingly the accumulation of Th17 cells in 
BAL following HDM exposure, but not the corresponding tissue IL-17, has been 
previously reported by Gregory et al. (Gregory et al., 2009).  In addition, Gregory et 
al. also detected significant levels of IFNγ in the tissue, in contrast to the data 
presented here at this time point.  IL-12 concentrations in the tissue of HDM exposed 
mice at week 3 remain significantly greater than sham exposed, though are reduced 
compared to week 1.  The presence of IL-4 at this time point may be down-regulating 
the production of IL-12 (Koch et al., 1996).  Taken together, HDM exposure appears 
to stimulate weak Th1 and Th17 responses in conjunction with a dominant Th2 
response. 
BAL neutrophilia is further elevated at week 3 and coupled to a significant tissue 
neutrophilia.  The neutrophil chemo-attractant KC was also elevated in the tissue.  
This strong neutrophilic response may be driven directly by HDM exposure, via 
endotoxin stimulation of TLR4, although the ensuing adaptive immune response may 
also play a role in driving neutrophilia.  For example both IL-13 and IL-17 are 
capable of recruiting neutrophils via KC generation (Grunig et al., 1998;Witowski et 
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al., 2000).  HDM induced KC and neutrophilia have been previously reported 
(Gregory et al., 2009). 
After 5 weeks of HDM exposure the inflammatory profile was comparable to week 3 
but heightened.  Significant numbers of eosinophils, neutrophils, CD4+ T cells and 
CD8+ T cells were detected in both BAL and tissue.  Further analysis of CD4+ T cell 
phenotype revealed a dominant presence of Th2 cells in BAL and tissue.  Th1 cells 
were detected in the BAL but not tissue while Th17 where present in BAL and tissue.  
IL-4, IL-5, IL-17, IFNγ, IL-12, IL-10, eotaxin, KC and IL-33 were all elevated in the 
lung tissue. 
Further evidence to support the development of a HDM specific Th2 response is 
provided by the analysis of total IgE and HDM specific serum antibodies.  Total 
serum IgE was elevated after 5 weeks of HDM exposure and HDM specific IgE, 
IgG1, IgG2a and IgG2b were detected in the serum of mice exposed to HDM for 3 
weeks and further elevated after 5 weeks of exposure.  The presence of these isotypes 
indicates the coexistence of multiple T cell responses however the abundance of 
HDM specific IgG1 indicates a predominant Th2 response.  The induction of the Th2 
associated antibodies IgE and IgG1 by HDM exposure has been shown previously and 
confirms allergic sensitisation of the mice from 3 weeks of exposure to HDM 
(Johnson et al., 2004;Gregory et al., 2009). 
Chronic inflammatory insult of the airways leads to structural changes within the 
airway wall such as goblet cell hyperplasia and peribronchial collagen deposition 
(McMillan & Lloyd, 2004;Johnson et al., 2004;Southam et al., 2007).  Histological 
assessment of the lungs revealed goblet cell hyperplasia after 3 weeks of HDM 
exposure which was accompanied by a robust up-regulation of muc5ac mRNA 
expression.  Interestingly neither goblet cell frequency nor muc5ac expression 
increased with further exposure to HDM.  Significant peribronchial collagen 
deposition was evident as early as week 1 of HDM exposure, but more robust after 3 
and 5 weeks of HDM exposure.  Peribronchial collagen depth was greatest at week 5, 
which was coincident with peak AHR and deterioration of basal lung function, the 
latter of which may be in part attributable to collagen deposition (Southam et al., 
2007). 
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Chronic exposure to HDM induces allergic airways disease which shares many of the 
hallmarks of allergic asthma.  AHR, airway inflammation with eosinophilia and a 
strong Th2 component, elevated IgE titres and airway remodelling are cardinal 
features of asthma that have been demonstrated in mice after 3-5 weeks of HDM 
exposure (O'Byrne & Inman, 2003;Bousquet et al., 1990;Robinson et al., 
1992;Brightling et al., 2002;Vignola et al., 2000;Bergeron et al., 2009).  However, 
while exposure to HDM induces a dominant Th2 response, other, weaker T cell 
responses are also evident.  In light of recent observations that T cells may be more 
plastic than originally suggested and the identification of alternative T cell subsets in 
the lungs of asthmatic patients, the heterogeneous inflammation induced by HDM 
exposure may be more relevant to clinical disease (Lloyd & Hessel, 2010).  
Accumulation of both Th1 and Th17 subsets was observed in BAL after HDM 
exposure.  Th1 cells have been detected in BAL from asthmatic patients, including 
during exacerbation, however their presence is controversial, thus their role remains 
unknown (Krug et al., 1996;Mamessier et al., 2008;Brightling et al., 2002;Vock et al., 
2010).  The presence of Th17 cells and IL-17 expression in asthma have also been 
demonstrated, although the source of IL-17 is not solely Th17 cells (Pene et al., 
2008;Molet et al., 2001;Bullens et al., 2006).  Interestingly, IL-17 appears to correlate 
with disease severity (Al-Ramli et al., 2009). 
3.4.2 HDM exposure up-regulates IL-13 
IL-13 is proposed to be a central mediator of asthma (Wills-Karp, 2004).  It is 
elevated in both asthma and models of AAD (Berry et al., 2004;Gregory et al., 2009).  
It was important to confirm the up-regulation of IL-13 in HDM exposed mice and 
thus validate this mouse model as appropriate for determining the role of IL-13 in 
driving airway pathophysiology in future studies.  IL-13 mRNA expression was up-
regulated from week 1 of HDM exposure and subsequently vigorously up-regulated at 
weeks 3 and 5.  This was detected as an increase in the tissue concentration of IL-13 
protein at weeks 3 and 5, but not 1.  In contrast to the findings of Gregory et al., 
significant changes in IL-13 were not observed in the BAL (Gregory et al., 2009).  
Again, this may be due to subtle differences in the HDM exposure regime or HDM 
batch variations or different assay sensitivities for measuring IL-13.  However, HDM 
induced up-regulation of IL-13 mRNA in the lung tissue, in the absence of detectable 
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IL-13 protein in the BAL has previously been reported at week 5 in an equivalent 
mouse model (Ulrich et al., 2008). 
On establishing the up-regulation of IL-13 in lung tissue following HDM exposure, IF 
staining was conducted in order to identify potential sources of IL-13 within the 
lungs.  Initial IF stains using a series of different anti-IL-13 reagents in the protocol 
described in 2.10.4 failed to produce a positive signal, therefore a signal amplification 
system was employed as used by Kim et al. for IL-13 detection in lung tissue (Kim 
2008).  This protocol generated a positive signal in airway epithelial cells and a subset 
of parenchymal cells and BAL cells, possibly alveolar macrophages; a similar staining 
pattern to that reported by Kim et al. in mice with virally induced chronic lung 
inflammation.  However, in the present studies these cells also stained positive in 
sections incubated with control primary antibody or with no primary at all 
demonstrating this signal was not specific to IL-13.  Furthermore, this indicated that 
the amplification system employed was responsible for this non-specific staining, and 
is therefore inappropriate for the detection of IL-13 in this case. 
In the absence of an effective IF protocol, flow cytometry was used to determine 
whether any of the leukocytes assessed in these studies were responsible, in part, for 
the observed increase in IL-13 production.  Intracellular IL-13 was detected in CD4+ 
T cells, including but not exclusively Th2 cells, and in CD8+ T cells.  However, the 
number of IL-13+ CD4+ and IL-13+ CD8+ T cells was not elevated after HDM 
exposed when compared to sham exposure.  Following one week of HDM exposure 
there was little deviation from sham with respect to the intensity of IL-13 staining, 
percentage of IL-13+ cells and number of IL-13+ cells in both CD4+ and CD8+ T cell 
populations.  At week 3 the intensity of IL-13 staining in CD4+ and CD8+ cells was 
greater in HDM than sham mice.  However, the proportion of IL-13+ cells within 
these populations was reduced in the HDM group compared to sham.  The actual 
number of IL-13+ CD4+ T cells was comparable in sham and HDM mice, while the 
number of IL-13+ CD8+ T cells was slightly less in HDM compared to sham mice.  
This indicated the majority of T cells accumulating in the lungs following HDM 
exposure did not express IL-13 and were therefore having a dilution effect on the 
existing IL-13+ T cells present.  Coupled with the increase in MFI this also suggested 
that these existing IL-13+ cells express more IL-13 per cell upon exposure to HDM, 
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rather than the number of IL-13 expressing cells increasing.  After 5 weeks of HDM 
exposure the percentage of IL-13+ CD4+ and CD8+ T cells remained lower than 
sham while the numbers of IL-13+ T cells were equivalent in sham and HDM groups; 
again indicating that the majority of T cells accumulating in the lungs do not express 
IL-13.  Furthermore, no differences in IL-13 MFI were apparent between sham and 
HDM T cells at this time point.  Interestingly, the numbers of IL-13+ CD4+ and IL-
13+ CD8+ T cells in sham exposed mice appear to increase over time.  This may be 
an age related effect or might be a result of repeated anaesthetic events and i.n. 
instillations. 
Specific analysis of Th2 cells demonstrated IL-13 staining was more intense 
following 3 or 5 weeks of HDM exposure compared to sham.  This was accompanied 
by an increase in both the percentage of Th2 cells expressing IL-13 and the number of 
IL-13+ Th2 cells compare to week one of HDM exposure.  Thus, Th2 cells were 
identified as a potential source of IL-13 in the lungs during HDM exposure.  In 
addition, neutrophils and eosinophils also represented sources of IL-13 in the lungs of 
HDM exposed mice. 
Many cell types, both haematopoietic and stromal, are reported to be potential sources 
of IL-13 in the lung.  IL-13 was first discovered in activated T cells and although 
subsequently characterised as a Th2 cytokine, its production has also been 
demonstrated in Th1, CD8+ T cells, memory T cells, naïve T cells and NKT cells 
(Minty et al., 1993;de Waal et al., 1995;Jung et al., 1996;Kim et al., 2008).  Mast 
cells, eosinophils and basophils are all competent IL-13 producing cells present in 
asthmatic airways (Jaffe et al., 1996;Brightling et al., 2003;Schmid-Grendelmeier et 
al., 2002;Spencer et al., 2009;Spencer et al., 2009;Gibbs et al., 1996;Ochensberger et 
al., 1996;Schroeder et al., 2010).  Resident cells such as airway smooth muscle, 
airway epithelium, macrophages and DCs are also capable of IL-13 production under 
certain conditions (Grunstein et al., 2002;Freishtat et al., 2010;Prieto et al., 2000;de 
Saint-Vis et al., 1998).  The recent characterisation of innate lymphoid cells/nuocytes 
as key IL-13 producing cells could be of significant importance in the pathogenesis of 
allergic inflammation although, as yet these cells have not been identified in the lungs 
of mice with AAD (Saenz et al., 2010;Moro et al., 2010;Neill et al., 2010;Chang et 
al., 2011).  However, contrary to the observations in this study, there have been no 
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reports in the literature of neutrophils producing IL-13.  In fact Reglier  et al. reported 
human neutrophils from healthy volunteers unable to produce or release IL-13 
(Reglier et al., 1998).  This discrepancy may lie in species differences between mouse 
and human, or the allergic status of the subjects.  Nonetheless, this observation 
warrants further investigation to confirm or disprove neutrophils as a source of IL-13 
during allergic inflammation.  Taken together, the present study verifies T cells and 
eosinophils are sources of IL-13 in allergic lungs and that neutrophils may represent 
an addition source of IL-13.  However, a multitude of other cell types, both stromal 
and haematopoietic, are also likely to be contributing the increased production of IL-
13 in HDM induced AAD. 
In summary, a mouse model of HDM induced AAD has been reproduced from the 
literature and further characterised.  AAD with similarities to asthma was observed 
after 3-5 weeks of exposure.  In addition IL-13 was up-regulated throughout the HDM 
exposure period.  Thus this animal model was considered appropriate for the 
subsequent investigation into the role of IL-13 in AAD. 
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4. THE ROLE OF IL-13 IN HDM INDUCED AAD 
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4.1 Introduction 
Multiple pathophysiological features of AAD have been demonstrated to be IL-13 
dependent in various animal models.  Previous reports have assessed the role of IL-13 
by use of sIL-13Rα2-Fc, Il13-/- mice, Il13ra1-/- mice and anti-IL-13 monoclonal and 
polyclonal antibodies in mice, sheep or non-human primates (NHP).  However, much 
of the mouse data is derived from OVA induced models of lung inflammation, 
dependent on peripheral sensitisation prior to airways exposure and there are no 
reports of the effects of IL-13 neutralisation in HDM induced AAD.  Furthermore, 
very few studies have investigated the role of IL-13 in established AAD.  In addition, 
there are a number of discrepancies between reports of IL-13 depletion, depending 
upon the animal model employed and the method of IL-13 depletion.  Therefore, the 
present series of experiments were conducted to determine the role of IL-13, using an 
anti-IL-13 monoclonal antibody, in the HDM induced mouse model of AAD 
described in chapter 3.  Prophylactic and therapeutic dosing regimes with anti-IL-13 
mAb were employed in this mouse model to investigate the role of IL-13 in both the 
development and maintenance of AAD. 
Due to the sequential nature of type II IL-4 receptor assembly (Figure 4.1A), there are 
at least two distinct axes of intervention for IL-13 specific neutralising mAbs; 
blocking IL-13 binding IL-13Rα1 (Figure 4.1 B) or preventing the subsequent 
association of IL-13 with IL-4Rα (Figure 4.1 C).  Both of these approaches prevent 
receptor assembly and hence IL-13 induced STAT6 activation.  However blocking the 
interaction between IL-13 and IL-13Rα1 also prevents IL-13 binding IL-13Rα2.  
MAbs 582 and 587 are murinised anti-mouse IL-13 mAbs which bind these distinct 
functional epitopes; previously identified and characterised in vitro and in vivo (Berry 
et al., 2009).  These mAbs both bind IL-13 with high affinity (KD 11pM and 8pM, 
respectively) and prevent IL-13 signalling via the type II IL-4 receptor.  Upon binding 
IL-13 mAb 582 blocks the initial association between IL-13 and IL-13Rα1 and hence 
prevents recruitment of the IL-4Rα subunit.  In addition 582 blocks IL-13 binding IL-
13Rα2 (Figure 4.1 B).  Conversely, mAb 587 binds IL-13 but does not prevent 
binding to IL-13Rα1 or IL-13Rα2.  587 blocks the ensuing interaction between the 
IL-13-IL-13Rα1 complex and IL-4Rα subunit (Figure 4.1 C).  Thus one of the key 
differentiating factors between these mAbs is their ability to block IL-13 binding IL-
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13Rα2.  In mice, IL-13Rα2 may be membrane bound or soluble and has at least three 
potential functions which may play a role in the pathogenesis of AAD.  Membrane 
bound IL-13Rα2 has been reported to deliver a pro-fibrotic signal and hence may 
contribute to IL-13 dependent pathology in AAD (Fichtner-Feigl et al., 2006).  
Conversely, sIL-13Rα2 is proposed to act as a decoy receptor, sequestering IL-13 
thus potentially reducing IL-13 dependent pathology (Andrews et al., 2006;Yasunaga 
et al., 2003).  Furthermore, membrane bound IL-13Rα2 may negatively regulate type 
II IL-4 receptor dependent pathology by sequestering IL-4Rα (Andrews et al., 2006).  
Thus, the additional effects of blocking IL-13Rα2 are unpredictable and depend upon 
the relative contributions of the mechanisms described above.  Both blocking 
mechanisms elicited equivalent inhibition of OVA induced mucin gene up-regulation 
in OVA sensitised mice (Berry et al., 2009). Similarly, using different mAbs with 
corresponding binding properties, comparable inhibition of antigen induced IgE and 
pulmonary inflammation has been demonstrated in an NHP model of AAD (Kasaian 
et al., 2008).  However, neither of these studies examined the effects of both blocking 
approaches on chronic features of asthma, such as airway remodelling, in which IL-
13Rα2 may be implicated.  Therefore, prior to in depth analysis of anti-IL-13 
efficacy, a direct comparison between 582 and 587 was conducted in order to 
elucidate whether these distinct binding specificities confer any differences in 
efficacy.  The most appropriate anti-IL-13 mAb was then selected to elucidate the 
effects of IL-13 neutralisation on the development of AAD. 
The effects of IL-13 neutralisation in established AAD is of greater clinical relevance 
than neutralising IL-13 during the development of AAD.  Prophylactic treatment of 
asthma is impractical since diagnosis is made upon presentation of symptoms which 
occur after the disease is established (GINA, 2006).  Hence, current treatment of 
asthma is therapeutic.  Therefore it is important to ascertain the role of IL-13 in 
maintaining established AAD and whether features of airway pathophysiology are 
reversible.  To address this, a therapeutic protocol was devised in which anti-IL-13 
mAb treatment was not commenced until significant airway hyperreactivity, 
inflammation and remodelling had developed.  Based on the time-course of 
pathophysiology characterised in chapter 3 dosing began after 5 weeks of HDM 
exposure and proceeded for a further 3 weeks during continued HDM exposure. 
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4.1.1 Aim 
2. To define the effects of IL-13 neutralisation in mice chronically exposed to 
inhaled HDM allergen on inflammation, lung function and airway 
remodelling. 
The initial aims of this chapter were to determine a suitable dose and mAb for IL-13 
neutralisation in vivo and subsequently define the effects of IL-13 neutralisation on 
the development of HDM induced AAD.  In addition, to elucidate the effects of 
therapeutic IL-13 neutralisation on established HDM induced AAD. 
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Figure 4.1 Type II IL-4 receptor formation and mAb specificity.  
IL-13 has two receptors; the type II IL-4 receptor and IL-13Rα2.  The type II IL-4 receptor comprises 
of IL-13Rα1 and IL-4Rα subunits which activate STAT6 in the presence of IL-13.  Membrane 
associated IL-13Rα2 signals via an AP-1-like molecule in the presence of IL-13.  IL-13 also binds sIL-
13Rα2 (A).  MAb 582 binds IL-13 and prevents IL-13 binding IL-13Rα1 or IL-13Rα2 (B).  MAb 587 
binds IL-13 and permits binding of IL-13Rα1 and IL-13Rα2 but prevents binding to IL-4Rα (C). 
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4.2 Methods 
4.2.1 Mice and HDM sensitisation. 
Male balb/c mice were exposed HDM for 5 or 8 weeks.  For prophylactic anti-IL-13 
mAb treatment mice were exposed to HDM for 5 weeks and dosed with 0.3, 3, 10 or 
30mg/kg 582, 587, 101.4 mAb (isotype control) or vehicle (PBS) s.c., weekly 
throughout the exposure period from 1 hour prior to the first HDM exposure (Figure 
4.2 A).  Unrestrained WBP, where used, was conducted during the fourth week of 
HDM exposure, 24 hours post HDM.  Mice were killed after 5 weeks for collection of 
samples, 24 hours after the last HDM exposure, or 4 hours post HDM exposure for 
cytokine and chemokine readouts. 
For therapeutic anti-IL-13 mAb treatment mice were exposed to HDM for 8 weeks 
and dosed with 10mg/kg 582 or 101.4 s.c., weekly from the beginning of week 6 (day 
35) (Figure 4.2 B).  Mice were killed after 8 weeks for collection of samples 24 hours 
post HDM.  An additional group of HDM exposed mice was killed after 5 weeks, 
immediately before the start of therapeutic anti-IL-13 dosing, to assess histological 
changes in the lung prior to treatment (“pre-dose”). 
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Figure 4.2 Experimental protocols for exposure to HDM.  Mice were exposed to intranasal HDM 
on 4 consecutive days per week for 5 or 8 weeks.  Sham treated mice received intranasal saline alone.  
Mice were dosed with anti-IL-13 mAb s.c., weekly, throughout HDM exposure (A; prophylactic 
protocol) or after AAD had established from day 35 (B; therapeutic protocol).  AHR was assessed by 
WBP during week 4 or by direct measurement of RL and Cdyn (R/C) at the end of the study.  Mice were 
culled 4 or 24 hours after the final HDM exposure for collection of blood, BAL and lung samples. 
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4.3 Results 
4.3.1 Dose response to anti-IL-13 mAb 
To determine the effects of neutralising IL-13 in HDM induced AAD an initial dose 
finding study was conducted with 0.3, 3 and 30mg/kg 582.  The effects of 582 on 
BAL inflammatory infiltrate, goblet cells and collagen deposition were assessed after 
5 weeks of HDM exposure with prophylactic 582 treatment. 
Treatment with 582 had comparable effects on BAL cellularity at 0.3, 3 and 30mg/kg 
thus no dose response relationship was observed over these doses.  3mg/kg 582 
significantly reduced the total number of BAL leukocytes, with 0.3 and 30mg/kg 
exhibiting a similar, but non-significant effect (Figure 4.3 A).  All three doses of 582 
elicited robust inhibition of BAL eosinophilia, but had no significant effect on BAL 
neutrophilia (Figure 4.3 B-C).  A non-significant trend towards inhibition of T cell 
accumulation in BAL was observed with each dose of 582 (Figure 4.3 D). 
Prophylactic 582 treatment dose-dependently inhibited HDM induced goblet cell 
hyperplasia.  0.3mg/kg 582 partially reduced the frequency of goblet cells but did not 
affect the expression of muc5ac mRNA.  However 3 and 30mg/kg 582 had 
comparable effects in completely reducing goblet cell frequency and significantly 
attenuating muc5ac expression (Figure 4.4 A-B).  A non-significant trend towards 
dose related inhibition of peribronchial collagen deposition was observed with the 
three doses of 582 tested in this study (Figure 4.3 C).  Since 3mg/kg 582 induced 
equivalent efficacy to 30mg/kg, 3mg/kg was presumed to be at the top of the dose-
response curve. Therefore, 10mg/kg 582 was selected as a super-maximally 
efficacious dose for subsequent studies. 
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Figure 4.3 Effects of IL-13 neutralisation on BAL cells.  BAL was taken after 5 weeks of HDM 
exposure, 24 hours after the last HDM instillation.  Mice were dosed with 0.3, 3 or 30mg/kg 582 s.c., 
weekly, throughout the HDM exposure period.  Total leukocytes (A), eosinophils (B), neutrophils (C) 
and T cells (D) in BAL were identified and quantified by flow cytometry.  n = 10 mice/group, bar 
represents median.  * p<0.05 and ** p<0.01 relative to vehicle group by Kruskal-Wallis test with 
Dunn’s post test. 
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Figure 4.4 Effects of IL-13 neutralisation on airway remodelling.  Lungs were taken after 5 weeks 
of HDM exposure, 24 hours after the last HDM instillation.  Mice were dosed with 0.3, 3 or 30mg/kg 
582 s.c., weekly, throughout the HDM exposure period. (A) Goblet cell frequency was scored in 
AB/PAS stained sections.  (B) Muc5ac mRNA in lung tissue was quantified by real-time PCR and 
normalised to sham.  (C) Peribronchial collagen depth was measured in Masson’s trichrome stained 
sections.  n = 10 mice/group, bar represents median.  * p<0.05 and *** p<0.001 relative to vehicle 
group by Kruskal-Wallis test with Dunn’s post test. 
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4.3.2 Direct comparison of anti-IL-13 mAbs with distinct functional epitopes. 
582 and 587 are affinity matched IL-13 neutralising mAbs which recognise distinct 
functional epitopes on IL-13 and thus disrupt assembly of the type II IL-4 receptor 
signalling complex at different stages of assembly.  Importantly, 582 also prevents IL-
13 binding IL-13Rα2 whereas 587 does not (Berry et al., 2009).  In order to 
determine whether these differences in binding specificities conferred any functional 
consequence, a study was conduced in which 582 and 587 were directly compared at 
single dose levels.  Mice were dosed with 10mg/kg anti-IL-13 mAb, weekly, 
throughout the 5 week HDM exposure period, after which BAL cellularity, AHR, 
goblet cell hyperplasia and collagen deposition were assessed. 
Both anti-IL-13 mAbs elicited equivalent, reproducible effects on AAD 
pathophysiology.  582 and 587 profoundly reduced the number of BAL eosinophils 
whilst having no significant effects on neutrophil or T cell accumulation in BAL 
(Figure 4.5 A-C).  Both antibodies completely prevented the development of AHR, 
determined by WBP (Figure 4.6), and goblet cell hyperplasia, assessed histologically 
(Figure 4.7 A-E).  Similarly, both 582 and 587 inhibited peribronchial collagen 
deposition to the same degree (Figure 4.8 A-E).  No significant differences were 
observed between the effects of 582 and 587 at 10mg/kg with respect to any of the 
parameters assessed in this study, therefore 582 was selected for further investigation 
into the effects of IL-13 neutralisation in this mouse model. 
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Figure 4.5 Effects of 582 and 587 treatment on BAL cells.  BAL was taken after 5 weeks of HDM 
exposure, 24 hours after the last HDM instillation.  Mice were dosed with 10mg/kg 582 or 587 s.c., 
weekly, throughout the HDM exposure period.  Eosinophils (A), neutrophils (B) and T cells (C) in 
BAL were identified and quantified by flow cytometry.  n = 10 mice/group, bar represents median.  * 
p<0.05 relative to vehicle group by Kruskal-Wallis test with Dunn’s post test.  n.s.: no significant 
difference. 
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Figure 4.6 Effects of 582 and 587 treatment on AHR.  AHR to MCh was determined as changes 
Penh measured by WBP during the fourth week of HDM exposure, 24 hours post HDM exposure.  
Mice were dosed with 10mg/kg 582 or 587 s.c., weekly, throughout the HDM exposure period.  Data 
are shown as mean ± SEM, n = 10 mice/group. n.s.: no significant difference by Kruskal-Wallis test 
with Dunn’s post test. 
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Figure 4.7 Effects of 582 and 587 treatment on goblet cell frequency.  Lungs were taken after 5 
weeks of HDM exposure, 24 hours after the last HDM instillation.  Mice were dosed with 10mg/kg 582 
or 587 s.c., weekly, throughout the HDM exposure period.  (A-D) Representative AB/PAS stained 
sections from sham exposed (A), HDM exposed vehicle dosed (B), HDM exposed 582 dosed (C) and 
HDM exposed 587 dosed (D) mice; original magnification x200.  (E) Goblet cell frequency was scored 
in AB/PAS stained sections.  n = 10 mice/group, bar represents median.  *** p<0.001 relative to 
vehicle group by Kruskal-Wallis test with Dunn’s post test.  n.s.: no significant difference. 
A B
C D
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Figure 4.8 Effects of 582 and 587 treatment on peribronchial collagen deposition.  Lungs were 
taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  Mice were dosed with 
10mg/kg 582 or 587 s.c., weekly, throughout the HDM exposure period.  (A-D) Representative 
Masson’s trichrome stained sections from sham exposed (A), HDM exposed vehicle dosed (B), HDM 
exposed 582 dosed (C) and HDM exposed 587 dosed (D) mice; original magnification x200.  (E) 
Peribronchial collagen depth was measured in Masson’s trichrome stained sections.  n = 10 mice/group, 
bar represents median.  * p<0.05 and ** p<0.01 relative to vehicle group by Kruskal-Wallis test with 
Dunn’s post test.  n.s.: no significant difference. 
A B
C D
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4.3.3 IL-13 neutralisation inhibits AHR 
AHR is a defining feature of asthma and AAD in which IL-13 is proposed to play a 
key role.  The previous study alluded to a role for IL-13 in the development of AHR 
by assessment of Penh by WBP.  In order to confirm these observations AHR to MCh 
was assessed by direct measurement of lung resistance (RL) and dynamic compliance 
(Cdyn) in terminally anaesthetised, ventilated mice previously exposed to HDM for 5 
weeks and dosed prophylactically with 10mg/kg 582.  Prophylactic IL-13 
neutralisation inhibited MCh stimulated changes in RL and Cdyn at each MCh 
concentration (Figure 4.9 A, C), thus confirming prior results obtained by WBP.  In 
addition, anti-IL-13 mAb treatment prevented HDM induced changes in baseline RL 
and Cdyn (Figure 4.9 B, D).  
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Figure 4.9 Effects of IL-13 neutralisation on AHR.  AHR to MCh was determined as changes in 
lung resistance (RL) (A, B) and dynamic compliance (Cdyn) (B, C) measured 24 hours post HDM, after 
5 weeks of HDM exposure.  Mice were dosed with 10mg/kg 582 or isotype control (101.4) s.c., 
weekly, throughout the HDM exposure period.  Data are shown as mean ± SEM, n = 6-8 mice/group.  * 
p<0.05, ** p<0.01 and *** p<0.001 relative to HDM/101.4 group by Mann Whitney test. 
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4.3.4 Effects of IL-13 neutralisation on pulmonary inflammation 
The effects of anti-IL-13 mAb treatment on pulmonary inflammation have previously 
been alluded to by assessment of BAL cells; however it is important to establish the 
inflammatory infiltrate within the lung tissue itself since this is likely to have a greater 
impact on lung physiology.  Thus, lung digest (LD) cells were phenotyped and 
quantified by flow cytometry in addition to BAL cells.  Furthermore, a greater 
diversity of inflammatory cell types implicated in the allergic response was assessed 
in BAL and LD. 
IL-13 neutralisation reduced the total number of leukocytes in both BAL and LD, but 
not to levels seen in non-allergic mice (Figure 4.10 A-B).  As previously observed, 
anti-IL-13 mAb treatment profoundly reduced the number of BAL eosinophils; this 
effect was also evident in LD (Figure 4.10 C-D).  In addition, IL-13 neutralisation 
partially inhibited neutrophilia in BAL and LD; an effect not seen in earlier studies 
(Figure 4.10 E-F).  Interestingly, anti-IL-13 mAb treatment induced a modest increase 
in BAL and LD macrophages (Figure 4.11 A-B).  In the BAL this was attributable to 
an increase in alveolar macrophages (AM; Figure 4.11 C) whereas both alveolar and 
interstitial macrophages (IM) were elevated in the lung tissue (Figure 4.11 D and F).  
Anti-IL-13 mAb treatment had no significant effects on the number of CD4+ or CD8+ 
T cells in BAL or LD after exposure to HDM (Figure 4.12 A-D).  However, 582 did 
reduce the number of B cells present in BAL following HDM exposure, although this 
effect was not evident in LD (Figure 4.12 E-F).  When the phenotype of infiltrating 
CD4+ T cells was further investigated after anti-IL-13 mAb treatment, no significant 
effects were observed on the accumulation of Th2, Th1 or Th17 cells in BAL or LD, 
although there was a trend towards reduced Th2 cells in BAL (Figure 4.13 A-F). 
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Figure 4.10 Effects of IL-13 neutralisation on HDM induced pulmonary inflammation.  BAL and 
lungs (caudal lobe) were taken after 5 weeks of HDM exposure, 24 hours after the last HDM 
instillation.  Mice were dosed with 10mg/kg 582 (or vehicle) s.c., weekly, throughout the HDM 
exposure period.  Total leukocytes (A-B), eosinophils (C-D) and neutrophils (E-F) in BAL (A, C and 
E) and lung tissue digest (LD) (B, D and F) were identified and quantified by flow cytometry.  n = 10 
mice/group, bar represents median.  Data represents of one of two experiments.  * p<0.05, ** p<0.01 
and *** p<0.001 relative to vehicle group by Mann Whitney test. 
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Figure 4.11 Effects of IL-13 neutralisation on macrophage accumulation.  BAL and lungs (left 
lobe) were taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  Mice were 
dosed with 10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the HDM exposure period.  
Total macrophages (A-B), alveolar macrophages (AM) (C-D) and interstitial macrophages (IM) (E-F) 
in BAL (A, C and E) and lung tissue digest (LD) (B, D and F) were identified and quantified by flow 
cytometry.  n = 6 mice/group, bar represents median.  Data represents one of two experiments.  ** 
p<0.01 relative to 101.4 group by Mann Whitney test. 
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Figure 4.12 Effects of IL-13 neutralisation on HDM induced T and B cell accumulation.  BAL 
and lungs (caudal lobe) were taken after 5 weeks of HDM exposure, 24 hours after the last HDM 
instillation. Mice were dosed with 10mg/kg 582 (or vehicle) s.c., weekly, throughout the HDM 
exposure period.   CD4+ T cells (A-B), CD8+ T cells (C-D) and B cells (E-F) in BAL (A, C and E) and 
lung tissue digest (LD) (B, D and F) were identified and quantified by flow cytometry.  n = 10 
mice/group, bar represents median.  * p<0.05 relative to vehicle group by Mann Whitney test. 
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Figure 4.13 Effects of IL-13 neutralisation on T helper cell phenotype.  BAL and lungs (caudal 
lobe) were taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  Mice were 
dosed with 10mg/kg 582 (or vehicle) s.c., weekly, throughout the HDM exposure period.  Th2 cells (A-
B), Th1 cells (C-D) and Th17 cells (E-F) in BAL (A, C and E) and lung tissue digest (LD) (B, D and F) 
were identified and quantified by flow cytometry.  n = 10 mice/group, bar represents median.  Data 
represents one of two experiments. 
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4.3.5 Effects of IL-13 neutralisation on the cytokine milieu 
Cytokine and chemokine concentrations were measured in BAL and lung homogenate 
(LH) supernatants by multiplex and ELISA assays 4 hours post HDM exposure after 5 
weeks of concomitant HDM and anti-IL-13 mAb treatment.  IL-13 neutralisation 
reduced IL-4 concentration in BAL, but not LH, and had no effect on the level of IL-5 
in BAL or LH (Figure 4.14 A-D).  BAL IL-10 was reduced by anti-IL-13 mAb 
treatment, although this was not observed in LH (Figure 4.14 E-F).  Treatment with 
582 had no effect on the levels of IFNγ, IL-12 or IL-17 in BAL or LH after HDM 
exposure (Figure 4.15 A-F).  However IL-13 neutralisation profoundly inhibited 
HDM induced eotaxin in both BAL and LH and reduced BAL and LH KC 
concentrations (Figure 4.16 A-D).  Upon analysis of the epithelial derived cytokines, 
anti-IL-13 mAb treatment induced a modest reduction in LH IL-25 and TSLP 
concentrations.  No effects were seen on HDM induced IL-33 levels in LH (Figure 
4.17 A-C). 
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Figure 4.14 Effects of IL-13 neutralisation on IL-4, IL-5 and IL-10 production.  Lungs (cranial 
lobe) and BAL were taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  
Mice were dosed with 10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the HDM 
exposure period.  Cytokines were quantified in BAL and lung homogenate supernatant by MSD assay.  
n = 8 mice/group, bar represents median.  ** p<0.01 relative to 101.4 group by Mann Whitney test. 
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Figure 4.15 Effects of IL-13 neutralisation on IFNγ, IL-12 and IL-17 production.  Lungs (cranial 
lobe) and BAL were taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  
Mice were dosed with 10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the HDM 
exposure period.  Cytokines were quantified in BAL and lung homogenate supernatant by MSD assay 
(A-D) or ELISA (E-F).  n = 5-8 mice/group, bar represents median. 
Chapter 4 
 124
 
 
BAL Eotaxin
Sham 101.4 582
0
50
100
150
HDM
***
A
[E
ot
ax
in
]p
g/
m
l B
AL
LH Eotaxin
Sham 101.4 582
0
500
1000
1500
2000
HDM
***
B
[E
ot
ax
in
]p
g/
50
m
g 
lu
ng
BAL KC
Sham 101.4 582
0
200
400
600
800
1000
HDM
*
C
[IL
-K
C
]p
g/
m
l B
AL
LH KC
Sham 101.4 582
0
200
400
600
800
1000
HDM
*
D
[K
C]
pg
/5
0m
g 
lu
ng
 
 
Figure 4.16 Effects of IL-13 neutralisation on chemokines.  Lungs (cranial lobe) and BAL were 
taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  Mice were dosed with 
10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the HDM exposure period.  
Chemokines were quantified in BAL and lung homogenate supernatant by ELISA (A-B) or MSD assay 
(C-D).  n = 8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 relative to 101.4 group by 
Mann Whitney test 
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Figure 4.17 Effects of IL-13 neutralisation on epithelial derived cytokines.  Lungs (cranial lobe) 
were taken after 5 weeks of HDM exposure, 4 hours after the last HDM instillation.  Mice were dosed 
with 10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the HDM exposure period.  
Cytokines were quantified in lung homogenate supernatant by ELISA.  n = 7-8 mice/group, bar 
represents median.  * p<0.05 and ** p<0.01 relative to 101.4 group by Mann Whitney test 
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4.3.6 Effects of IL-13 neutralisation on antibody generation 
Serum levels of total IgE and HDM specific IgE, IgG1, IgG2a and IgG2b were 
determined by ELISA after 5 weeks of HDM exposure and prophylactic anti-IL-13 
mAb treatment.  IL-13 neutralisation significantly reduced total serum IgE (Figure 
4.18 A) however, no effects were observed on the generation of HDM specific IgE, 
IgG1, IgG2a and IgG2b in HDM exposed mice (Figure 4.18 B-E). 
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Figure 4.18 Effects of IL-13 neutralisation on antibody generation following HDM exposure.  
Blood was taken via cardiac puncture after 5 weeks of HDM exposure, 24 hours after the last HDM 
instillation.  Mice were dosed with 10mg/kg 582 or isotype control (101.4) s.c., weekly, throughout the 
HDM exposure period.  HDM specific antibodies were assessed in serum by ELISA.  n = 8 mice/group, 
bar represents median.  * p<0.05 by Mann Whitney test. 
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4.3.7 Effects of therapeutic IL-13 neutralisation 
Having characterised the effects of IL-13 neutralisation during the initiation of the 
allergic response it was important, and more clinically relevant, to determine the 
effects of neutralising IL-13 after the allergic response has been established.  To 
address this, mice were dosed with anti-IL-13 mAb therapeutically.  Mice were 
exposed to HDM for 5 weeks to provoke airway hyperreactivity, inflammation and 
remodelling prior to anti-IL-13 mAb treatment.  After 5 weeks mice were dosed with 
10mg/kg 582 s.c. weekly for 3 additional weeks, during continued HDM exposure.  
For assessment of the histological parameters an additional group of HDM exposed 
mice was terminated immediately prior to the first anti-IL-13 mAb dose (“pre-dose”).  
This was to assess the degree of goblet cell frequency and peribronchial collagen 
deposition prior to therapeutic intervention. 
Therapeutic IL-13 neutralisation partially reversed AHR to MCh.  Anti-IL-13 mAb 
treatment returned baseline lung function to that seen in sham sensitised mice 
however, the inhibition of AHR in response to MCh was incomplete (Figure 4.19).  
Analysis of BAL cell infiltrate revealed therapeutic administration of anti-IL-13 mAb 
fractionally reduced the total number of BAL leukocytes.  Significant reductions in 
the numbers of eosinophils, CD4+ T cells and specifically Th2 cells were also 
observed although there were no effects on the numbers of BAL neutrophils or CD8+ 
cells (Figure 4.20).  Therapeutic anti-IL-13 mAb treatment profoundly inhibited HDM 
induced goblet cell up-regulation, shown by both goblet cell score and muc5ac mRNA 
expression (Figure 4.21 A-B).  In addition, therapeutic anti-IL-13 mAb appeared to 
prevent collagen deposition during the dose period, but did not reduced existing 
peribronchial collagen.  Hence collagen depth at 8 weeks, following 3 weeks of 582 
treatment, was equivalent to that seen after 5 weeks of HDM exposure and 
significantly less than that observed after 8 weeks of HDM exposure (Figure 4.21 C). 
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Figure 4.19 Effects of therapeutic IL-13 neutralisation on AHR.  AHR to MCh was determined as 
changes in lung resistance (RL) (A, C) and dynamic compliance (Cdyn) (B, D) measured 24 hours post 
HDM, after 8 weeks of HDM exposure.  Mice were dosed with 10mg/kg 582 or isotype control (101.4) 
s.c., weekly, from week 6.  Data are shown as mean ± SEM, n = 7-8 mice/group.  * p<0.05 relative to 
HDM/101.4 group by Mann Whitney test. 
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Figure 4.20 Effects of therapeutic IL-13 neutralisation on pulmonary inflammation.  BAL was 
taken after 8 weeks of HDM exposure, 24 hours after the last HDM instillation.  Mice were dosed with 
10mg/kg 582 or isotype control (101.4) s.c., weekly, from week 6.  Total leukocytes (A), eosinophils 
(B), neutrophils (C), CD4+ T cells (D), CD8+ T cells (E) and Th2 cells (F) in BAL were identified and 
quantified by flow cytometry.  n = 8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 
relative to HDM/101.4 group by Mann Whitney test. 
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Figure 4.21 Effects of therapeutic IL-13 neutralisation on airway remodelling.  Lungs were taken 
after 5 (pre-dose) or 8 weeks of HDM exposure, 24 hours after the last HDM instillation.  Mice were 
dosed with 10mg/kg 582 (or vehicle) s.c., weekly, from week 6. (A) Goblet cell frequency was scored 
in AB/PAS stained sections.  (B) Muc5ac mRNA in lung tissue was quantified by real time PCR and 
normalised to sham.  (C) Peribronchial collagen depth was measured in Masson’s trichrome stained 
sections.  n = 9-10 mice/group, bar represents median.  * p<0.05 and *** p<0.001 relative to vehicle 
group by Mann Whitney test. 
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4.4 Discussion 
The objective of this chapter was to determine the effects of IL-13 neutralisation in 
HDM induced AAD.  Prior to in depth analysis of the effects of IL-13 neutralisation 
in this model a preliminary dose finding study was conducted.  Furthermore it was 
necessary to select a suitable IL-13 neutralising antibody.  Once an appropriate dose 
and antibody was chosen the effects of both prophylactic and therapeutic IL-13 
neutralisation were assessed. 
4.4.1 Anti-IL-13 mAb dose selection 
Prophylactic anti-IL-13 mAb treatment with mAb 582 reduced lung inflammation, 
specifically BAL eosinophils, although no dose-response relationship was observed 
over the dose range studied (0.3, 3 and 30mg/kg).  Dose proportionality was apparent 
on analysis of airway remodelling; 3mg/kg and 30mg/kg 582 elicited comparable 
inhibition of goblet cell frequency and muc5ac mRNA expression, whereas 0.3mg/kg 
only partially reduced goblet cell frequency and had no significant effects on muc5ac 
mRNA expression.  A similar dose-response relationship was noted in peribronchial 
collagen deposition although no significance reached in this study.  Berry et al. 
previously reported dose dependent effects of 582 (denoted mAb A) on muc5ac 
mRNA up-regulation in the lungs of mice sensitised and challenged with OVA (Berry 
et al., 2009).  In this study Berry et al. observed significant inhibition of muc5ac 
expression at 10, 1 and 0.1mg/kg 582 indicating mucin expression in this model may 
be more sensitive to IL-13 inhibition than in HDM induced AAD. 
In the current study maximal efficacy was observed at 3mg/kg 582, with no additional 
efficacy apparent at 30mg/kg, thus revealing the top of the dose-response curve to 
582.  However, in order to ensure the dose used for future studies was super-maximal, 
a dose of 10mg/kg was selected with which to proceed. 
4.4.2 Anti-IL-13 mAb selection 
Two anti-IL-13 mAbs binding distinct functional epitopes were available for use in in 
vivo neutralisation studies.  582 and 587 both bind IL-13 with high affinity (KD 11pM 
and 8pM, respectively) and prevent assembly of the type II IL-4 receptor, and hence 
signalling (characterised by (Berry et al., 2009).  MAb 582 prevents IL-13 binding IL-
13Rα1 and IL-13Rα2 whereas 587 permits these interactions but blocks the ensuing 
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association of the IL-13-IL-13Rα1 complex with IL-4Rα.  Due to these differences in 
binding specificity a study was conducted to directly compare 582 and 587 in HDM 
induced AAD.  Since 582 and 587 are affinity matched and previous studies have 
demonstrated equivalent potency both in vitro and in vivo, a single dose level of 
10mg/kg was used in this study to distinguish any discrepancies in activity (Berry et 
al., 2009). 
Analysis of HDM induced inflammatory BAL cell infiltrate, AHR and airway 
remodelling at 5 weeks after prophylactic, weekly treatment with 10mg/kg 582 or 587 
did not reveal any significant differences between the effects of 582 and 587.  Both 
mAbs significantly reduced BAL eosinophilia, completely prevented the development 
of AHR assessed by WBP, blocked goblet cell up-regulation determined by 
histological score and inhibited peribronchial collagen deposition.  Using the same 
mAbs Berry et al. demonstrated equivalent efficacy in basic models of IL-13 
stimulated eotaxin release and muc5ac mRNA up-regulation in OVA sensitised and 
challenged mice (Berry et al., 2009).  Taken together these data demonstrate complete 
or partial disruption of the type II IL-4R is sufficient for anti-IL-13 mAb efficacy.  In 
addition, since equivalent efficacy was observed whether IL-13Rα2 binding was 
blocked or permitted this indicates HDM induced AAD may be independent of IL-
13Rα2 signalling.  However, although IL-13 can bind IL-13Rα2 in the presence of 
587, it is not known whether the IL-13-587 complex can still induce signalling via IL-
13Rα2.  It is possible both 582 and 587 prevent IL-13Rα2 signalling and hence both 
inhibit IL-13 dependent fibrosis.  With respect to the role of sIL-13α2 as a decoy 
receptor it might be expected that preventing IL-13 binding sIL-13Rα2 would lead to 
reduced anti-IL-13 mAb efficacy.  This was not observed with 582 in this study most 
likely due to the use of super-maximal anti-IL-13 mAb doses.  However, even at very 
low doses of mAb Berry et al. did not observe any differences in efficacy between 
582 and 587, albeit in more simplistic, acute models of IL-13 driven pathology (Berry 
et al., 2009).  These data indicate IL-13Rα2 does not play a role in driving AAD 
pathology or as a negative regulator of IL-13 in this mouse model. 
Kasaian et al. evaluated the effects of two corresponding anti-human IL-13 mAbs, 
with receptor blocking mechanisms comparable to 582 and 587, in a cynomolgus 
monkey model of allergic lung inflammation driven by Ascaris suum (Kasaian et al., 
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2008).  The two antibodies were compared at a single dose, 10mg/kg, and elicited 
equivalent inhibition of BAL infiltrate, antigen specific IgE titres and histamine 
release from ex vivo stimulated basophils.  This supports the present observation that 
anti-IL-13 mAbs with distinct receptor blocking mechanisms do not confer any 
functional differences in efficacy.  However, the same mAbs did show some 
discrepancies in efficacy in a small clinical trial in mild atopic asthma (Gauvreau et 
al., 2011).  Blockade of the IL-13-IL-13Rα1 complex binding IL-4Rα significantly 
reduced both the early and late phase declines in lung function following allergen 
challenge whereas blockade of the initial interaction between IL-13 and IL-13Rα1 
(and IL-13 with IL-13Rα2) had no significant effects.  This may have been due to 
elevated levels of IL-13 detected after the latter but not former mAb therapy.  In a 
subsequent study the authors demonstrate IL-13Rα2 plays a role in IL-13 clearance, 
hence blockade of IL-13Rα2 lead to accumulation of IL-13 (Kasaian et al., 2011).  
Since IL-13 was not assessed in the present studies due to the potential for 582 and 
587 to interfere with IL-13 detection it is not know whether the same mechanism of 
IL-13Rα2 mediated IL-13 clearance occurs in mice.  The equivalent efficacy 
observed between 582 and 587 indicates IL-13 is not elevated when IL-13Rα2 
binding is prohibited and hence that this mechanism may not occur in mice.  
However, the effects of IL-13 accumulation may not have been seen in the present 
studies due to the use of super-maximal doses of anti-IL-13 mAb.  In addition, Cuff et 
al. reported that a mAb blocking IL-13 binding both IL-13Rα1 and IL-13Rα2 
conferred greater efficacy than an affinity matched anti-IL-13 mAb that permitted IL-
13Rα2 binding in a murine model of OVA induced lung inflammation (Cuff et al., 
2008).  It is likely that anti-IL-13 mAb efficacy is dictated by the specific epitope for 
each mAb and that these differences in epitopes give rise to variations in efficacy.  
Furthermore, the altered distribution of soluble and membrane IL-13Rα2 in humans 
compared to mice further complicates these potential mechanisms of action.  Of note, 
none of the studies discussed above assessed airway remodelling; a potential axis in 
which IL-13Rα2 may play a role and hence potentially a key differentiating feature 
between the two mAbs. 
In summary, no differences in efficacy were observed between 582 and 587 in HDM 
induced AAD in mice.  582 was selected for use in future studies investigating the 
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mechanisms of IL-13 inhibition in AAD due to it’s ability to block IL-13 binding both 
IL-13Rα1 and IL-13Rα2 and hence inhibit all potential components of IL-13 induced 
pathology. 
4.4.3 Effects of prophylactic IL-13 neutralisation in HDM induced AAD 
The effects of IL-13 neutralisation have previously been reported in mouse models of 
lung inflammation driven by OVA and fungal antigens and in sensitised sheep and 
NHP models.  However the role of IL-13 in HDM induced AAD in mice has not been 
reported, hence the current series of experiments was conducted to determine the 
effects of prophylactic IL-13 neutralisation in mice chronically exposed to HDM for 5 
weeks.  As established in previous studies, IL-13 was neutralised with 10mg/kg 582 
weekly.  See Table 4.1 for a summary of IL-13 dependent effects observed in the 
present series of experiments. 
4.4.3.1 AHR 
Prophylactic administration of anti-IL-13 mAb prevented the development of HDM 
induced AHR to MCh, assessed by direct measurement of RL and Cdyn.  This 
confirmed previous assessments of AHR determined by WBP after prophylactic 582 
treatment.  In addition, assessment of RL and Cdyn revealed anti-IL-13 mAb treatment 
prevented the HDM induced decline in basal lung function measured prior to MCh 
exposure.  A role for IL-13 in the development of AHR has previously been 
demonstrated in acute OVA induced models of lung inflammation using IL-13 
deficient mice, Il13ra1-/- mice, sIL-13Rα2-Fc fusion protein, polyclonal anti-IL-13 
and monoclonal anti-IL-13 antibodies (Walter et al., 2001;Leigh et al., 2004b;Grunig 
et al., 1998;Wills-Karp et al., 1998;Leigh et al., 2004a;Wang & McCusker, 
2005;Yang et al., 2004;Eum et al., 2005).  However, the use of alum in these models 
to induce a Th2 response may be biasing the system towards IL-13 dependency.  
Blease et al. assessed the role of IL-13 in the development of AHR in fungal induced 
AAD using a polyclonal anti-IL-13 antibody (Blease et al., 2001).  This model does 
not use alum although peripheral sensitisation with antigen in incomplete freunds 
adjuvant is still required to sensitise the mice.  Neutralisation of IL-13 in this model 
also abrogated AHR.  Furthermore, this study demonstrated that inhibition of AHR 
can be achieved by neutralisation of IL-13 during antigen challenge and that IL-13 
neutralisation during sensitisation is not required for ablation of AHR.  However, 
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there is also evidence that IL-13 neutralisation does not effect AHR when anti-IL-13 
treatment is commenced after chronic allergen challenge at a time-point when 
inflammation has resolved but airway remodelling persists (Leigh et al., 2004a).  
Importantly, this indicates aspects of AHR are independent of IL-13 and are instead 
attributable to the persistence of airway remodelling.  Taken together with the present 
study, these data prove the presence of IL-13 during allergen exposure in the lung is 
critical for the development of AHR, irrespective of the allergen or adjuvant used. 
The development of AHR is multi-factorial.  Inflammatory processes play a key role 
however, other factors such as airway wall remodelling (as illustrated by Leigh et al.) 
and neuronal control of airway tone also play a role in AHR.  In addition, airway wall 
oedema and epithelial desquamation can influence AHR.  Direct mediators of AHR 
include cytokines such as IL-13, IL-25 and IL-33 derived from T cells and epithelial 
cells, amongst others, and lipid mediators such as leukotrienes, prostaglandins and 
histamine released from mast cells and eosinophils.  The mechanisms by which IL-13 
drives AHR in HDM induced AAD are unknown; it may be via direct action of IL-13 
on ASM, via the activation and degranulation of mast cells and eosinophils, via 
remodelling of the airway wall or most likely a combination of these factors.  IL-13 
neutralisation prevented airway remodelling and inhibited various aspects of 
inflammation in the present study, which may contribute to the inhibition of AHR.  
However, IL-13 neutralisation does not alter the generation of antigen specific IgE 
and the effects of IL-13 neutralisation on the production of lipid mediators in HDM 
induced AAD is unknown.  Thus the precise mechanisms by which anti-IL-13 mAb 
treatment prevents AHR in this model are unknown. 
4.4.3.2 Inflammation 
In the present study anti-IL-13 mAb treatment inhibited the total number of 
leukocytes infiltrating the BAL and lung tissue.  This was primarily accounted for by 
the profound reduction in BAL and tissue eosinophilia induced by anti-IL-13 mAb. 
The role of IL-13 in allergen induced eosinophilia has been well established however 
relatively limited analysis of BAL and lung tissue inflammatory infiltrates has been 
conducted in previous studies reporting the effects of IL-13 neutralisation in vivo.  As 
observed in HDM exposed mice, total BAL cells were reduced after IL-13 
neutralisation with sIL-13Rα2-Fc in an acute model of OVA induced lung 
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inflammation (Leigh et al., 2004a).  Lung and BAL eosinophilia have also been 
demonstrated to be IL-13 dependent in acute OVA models by the employment of Il13-
/- mice, Il13ra1-/- mice, sIL-13Rα2-Fc and anti-IL-13 mAb (Leigh et al., 
2004b;Munitz et al., 2008;Grunig et al., 1998;Yang et al., 2004).  However, not all 
studies observed reduced eosinophilia with sIL-13Rα2-Fc or anti-IL-13 intervention 
(Wills-Karp et al., 1998;Leigh et al., 2004a;Eum et al., 2005).  This may be due to 
subtle differences in the dosing regimes employed, sensitisation and challenge 
protocols or, in some cases the strain of mice used.  Where reduced eosinophilia was 
apparent, lack of IL-13 or IL-13 neutralisation did not completely abrogate lung 
eosinophilia.  In the present study, BAL eosinophilia was almost completely 
dependent upon IL-13 mediated effector pathways.  However, a small degree of 
eosinophilia persisted in the tissue after IL-13 neutralisation indicating some IL-13 
independent factors contribute to the accumulation of eosinophils in the lung tissue. 
In the current study, anti-IL-13 mAb treatment prevented elevation of the eosinophil 
chemo-attractant eotaxin in the BAL and tissue of HDM exposed mice.  This 
corresponds with reduced eosinophilia following anti-IL-13 mAb treatment.  
Profound inhibition of allergen induced eotaxin and the consequent reduction in 
eosinophilia has previously been demonstrated in OVA sensitised and challenged 
Il13ra1-/- mice and anti-IL-13 mAb treated mice (Yang et al., 2004;Munitz et al., 
2008).  In addition, eotaxin mRNA expression was significantly reduced in Il13ra1-/- 
mice compared to wild type mice following SEA sensitisation and challenge 
(Ramalingam et al., 2008).  These data indicate that the primary mechanism driving 
eosinophilia in HDM exposed mice is via IL-13 dependent production of eotaxin.  
However, IL-13 and eotaxin independent pathways as identified by Munitz et al. may 
also be contributing to tissue eosinophilia (Munitz et al., 2008). 
The Th2 cytokine IL-5 can also induce eosinophilia and is up-regulated in both BAL 
and lungs following HDM exposure.  However, IL-5 production is not dependent 
upon IL-13 in this mouse model.  In OVA models IL-5 generation has also been 
demonstrated to be IL-13 independent using an anti-IL-13 mAb and Il13ra1-/- mice 
however, Yang et al. observed reduced LH IL-5 following anti-IL-13 mAb treatment 
(Yang et al., 2005;Eum et al., 2005;Munitz et al., 2008).  Furthermore, IL-5 mRNA 
was actually increased in lung tissue from Il13ra1-/- mice compared to wild type in an 
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SEA driven model of lung inflammation although protein concentrations are not 
reported (Ramalingam et al., 2008).  In human ASM there is evidence IL-13 
stimulates IL-5 production (Grunstein et al., 2002), thus the requisite of IL-13 for IL-
5 generation may be species dependent.  The IL-13 independent production of IL-5 in 
the present study may account for the low level of lung eosinophilia still present after 
anti-IL-13 mAb treatment. 
Partial inhibition of neutrophilia was noted in BAL and lung tissue of 582 treated 
HDM exposed mice, however this effect was not consistently observed across all 
experiments (Figures 4.3 C, 4.5 B and 4.10 E).  Accordingly, anti-IL-13 mAb 
treatment also partially reduced levels of the neutrophil chemoattractant KC in BAL 
and lung tissue.  In the literature, no significant reduction of BAL neutrophils has 
been demonstrated following IL-13 neutralisation despite Yang et al. reporting a 
reduction in KC in the lung tissue in an acute OVA model (Grunig et al., 1998;Yang 
et al., 2004).  Munitz et al. reported an increase in BAL neutrophils in OVA sensitised 
and challenged Il13ra1-/- mice (Munitz et al., 2008).  The present data suggest a 
component of HDM induced neutrophilia is dependent upon IL-13 induced KC 
however, KC production and neutrophilia is also driven by IL-13 independent events.  
One such pathway might be IL-17 stimulated KC production (Witowski et al., 2000); 
IL-17 is up-regulated in HDM exposed mice and not affected by IL-13 neutralisation.  
The balance between these IL-13 dependent and independent pathways in eliciting 
neutrophilia may account for the differences observed in OVA and HDM driven 
models of lung inflammation. 
Interestingly, IL-13 neutralisation in HDM exposed mice appeared to increase the 
number of macrophages in BAL and LD.  Classification of these macrophages into 
alveolar (AM) and interstitial (IM) macrophage phenotypes revealed the elevation in 
BAL macrophages to be attributable to an increase in AM, whereas both AM and IM 
sub-populations were increased in the tissue (Bedoret et al., 2009).  Administration of 
anti-IL-13 mAb to sham exposed mice had no effect on the number of lung 
macrophages (data not shown).  Ramalingham et al. also reported an increase in 
macrophages in the lungs of Il13ra1-/- mice in an SEA induced model of allergic lung 
inflammation, thus corroborating observations in the present HDM study 
(Ramalingam et al., 2008).  Taken together these data suggest the IL-13/IL-13Rα1 
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axis may play a role in regulating the number of macrophages in the lungs during 
AAD.  The functional consequences of increased accumulation of macrophages with 
respect to AAD pathogenesis is unknown and therefore warrants further investigation. 
IL-13 neutralisation had no significant effects on accumulation of CD4+ or CD8+ T 
cells in BAL and lung tissue of HDM exposed mice.  Detailed analysis of the effects 
of IL-13 neutralisation on T cells in the lung and BAL has not previously been 
reported, although no effects on the total numbers of BAL lymphocytes or 
mononuclear cells were demonstrated with sIL-13Rα2-Fc or anti-IL-13 mAb 
treatment in acute OVA models (Wills-Karp et al., 1998;Yang et al., 2004).  Upon 
further analysis of T cell phenotypes in the present study, a non-significant trend 
towards reduced BAL Th2 cells was observed, although not evident in the tissue.  
This reduction in BAL Th2 cells did reach significance in repeat studies (Tomlinson 
et al., 2010).  Analysis of the key Th2 differentiating cytokine IL-4 revealed IL-13 
neutralisation reduced BAL IL-4.  Inhibition of IL-4 secretion in the absence of IL-13 
has previously been observed ex vivo, in stimulated lymph node cells from SEA 
sensitised Il13-/- mice (McKenzie et al., 1998).  However in vivo, BAL IL-4 levels in 
mice sensitised and challenged with OVA were equivalent in Il13ra1-/- and wild type 
mice (Munitz et al., 2008).  Furthermore, IL-4 mRNA expression in an SEA model of 
lung inflammation in was actually increased in Il13ra1-/- compared to wild type mice 
(Ramalingam et al., 2008).  Hence, Munitz and Ramalingam propose the development 
of Th2 responses is IL-13Rα1 independent.  Data from the present study supports this 
hypothesis.   IL-13 neutralisation had no effect on the generation of HDM specific 
antibodies, specifically IgE and IgG1, suggesting a competent Th2 response is 
mounted in the absence of IL-13 stimulation.  Since Th2 cells (and naïve T cells) do 
not express IL-13Rα1, the contribution of IL-13 to Th2 responses must be indirect 
(Zurawski & de Vries, 1994;de Waal et al., 1995;Graber et al., 1998).  Hence, the 
modest effect on accumulation of BAL Th2 cells is likely to be downstream of the 
development of Th2 immunity, such as inhibition of Th2 cell trafficking to the lungs 
by reduced TARC expression or down-regulation of adhesion molecules.  TARC is a 
specific chemotactic factor for Th2 cells which selectively express the TARC receptor 
CCR4 (Bonecchi et al., 1998;Imai et al., 1999).  IL-13 neutralisation reduced BAL 
IL-4.  This may be due in part to the reduction in BAL Th2 cells however; IL-13 may 
also be modulating IL-4 expression in cells such as DC, macrophages, basophils and 
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innate lymphoid cells present in the lungs.  In summary, contrary to early reports from 
McKenzie et al. of Il13-/- mice, the present data demonstrate Th2 differentiation 
occurs independently of IL-13 (McKenzie et al., 1998).  Thus, the role of IL-13 in 
AAD is in modulating events downstream of Th2 cell development. 
IL-13 neutralisation in the current study had no significant effects on HDM induced 
accumulation of Th1 or Th17 cells in BAL or tissue.  Accordingly, no significant 
modulation of the Th1 cytokines IL-12 and IFNγ or the Th17 cytokine IL-17 was 
observed following anti-IL-13 mAb treatment.  IL-13 has previously been reported to 
negatively regulate Th17 cells in vitro; however no changes in the frequency of Th17 
cells, or IL-17 production were observed in the absence of IL-13 in the present study 
indicating this phenomenon may not be applicable in vivo (Newcomb et al., 2009).  
Thus, IL-13 neutralisation suppresses functions of Th2 immunity, without altering 
opposing Th1 or Th17 responses. 
Anti-IL-13 mAb treatment reduced the number of B cells in BAL although this effect 
was not seen in the tissue.  Unlike human B cells, mouse B cells do not express IL-13 
receptors and hence IL-13 has no direct effects on mouse B cells (Punnonen et al., 
1993;Gauchat et al., 1997;Graber et al., 1998).  Hence, as with Th2 cells, this 
reduction in BAL infiltrate is likely to be a reflection of IL-13 dependent modulation 
of factors controlling cell recruitment; however there are no previous reports of tissue 
infiltration of B cells following IL-13 depletion or neutralisation.  In accordance with 
the lack of IL-13 receptor expression on mouse B cells, isotype switching and the 
subsequent production of HDM specific antibodies in the present study were IL-13 
independent.  This has previously been demonstrated in mice sensitised and 
challenged with OVA in which IL-13 neutralisation had no affect on OVA specific 
IgE titres (Wills-Karp et al., 1998;Taube et al., 2002;Wang & McCusker, 2005).  
Contrary to this, Yang et al. reported anti-IL-13 mAb intervention reduced OVA 
specific IgE titres, but not OVA specific IgG1 and IgG2a titres, in an acute OVA 
model (Yang et al., 2004).  This latter study indicates IL-13 may play an indirect role 
in IgE production.  Of note, IL-13 neutralisation does reduce allergen specific IgE in 
NHPs (Kasaian et al., 2008) and would be predicted to affect IgE production in man 
due to the expression of IL-13Rα1 on human B cells (Punnonen et al., 1993;Zurawski 
& de Vries, 1994).  Interestingly, anti-IL-13 mAb treatment does reduce total serum 
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IgE in the current study.  This has previously been demonstrated in Il13-/- and Il13ra1-
/- mice, both naïve and sensitised, and implicates IL-13 in the homeostatic control of 
IgE levels (McKenzie et al., 1998;Munitz et al., 2008;Ramalingam et al., 2008).  In 
addition, transgenic over-expression of IL-13 in mice results in increased serum titres 
of total IgE (Emson et al., 1998).  It has been proposed that IL-13 controls the 
spontaneous production of natural IgE by a subpopulation of B2 cells (Munitz et al., 
2008;McCoy et al., 2006).  Thus, IL-13 does not play a role in the production of 
antigen specific antibodies in mice, possibly because this process is dependent on T 
cell help, the generation of which is IL-13 independent.  However, IL-13 is required 
for the modulation of total IgE titres. 
Cytokine analysis of BAL in the present study revealed IL-13 neutralisation reduced 
levels of the regulatory cytokine IL-10.  This appears contrary to the general reduction 
in inflammation observed with anti-IL-13 mAb treatment however, IL-13 has 
previously been reported to inhibit IL-10 production from LPS stimulated monocytes 
(de Waal et al., 1993).  Furthermore, HDM extract contains endotoxin thus providing 
a potential mechanism for the IL-13 dependent down-regulation of IL-10 in HDM 
induced AAD.  However, Il13ra1-/- mice sensitised and challenged with OVA exhibit 
elevated BAL IL-10 (Munitz et al., 2008).  These discrepancies may be due to the 
added effects of inhibiting IL-4 signalling in Il13ra1-/- mice, not affected during IL-13 
specific inhibition. 
HDM induced IL-25 and TSLP levels in the lung were also inhibited by anti-IL-13 
mAb treatment in the present study.  The effects of IL-13 neutralisation on IL-25 and 
TSLP have not previously been reported in models of AAD.  The primary function of 
these epithelial derived cytokines is to promote the initiation of Th2 immunity upon 
insult to the airway epithelium i.e. upon activation of pattern recognition receptors 
such as TLRs and protease-activated receptors (Paul & Zhu, 2010;Ziegler & Artis, 
2010).  However, TSLP mRNA expression has previously been reported to be up-
regulated in human bronchial epithelial cells following IL-13 stimulation in vitro 
(Kato et al., 2007), indicating a TSLP-IL-13 loop may play a role inTh2 amplification 
(Paul & Zhu, 2010).  Conversely, there is no evidence suggesting IL-25 can act 
downstream of IL-13, thus the effects of IL-13 neutralisation on IL-25 production 
may be indirect (Barlow & McKenzie, 2009;Fort et al., 2001). 
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4.4.3.3 Remodelling 
IL-13 is proposed to be a key mediator of airway remodelling in AAD and asthma.  Its 
role in the pathogenesis of airway remodelling is in part via direct action on epithelial 
cells, fibroblasts and ASM.  In addition, IL-13 may promote airway remodelling 
indirectly by stimulating the release of pro-fibrotic mediators such as TGFβ and 
growth factors e.g. PDGF (Malavia et al., 2008;Ingram et al., 2004).  In the present 
studies HDM induced structural changes within the airway wall were shown to be IL-
13 dependent.  Increased goblet cell frequency and muc5ac mRNA expression were 
completely abrogated by IL-13 neutralisation, despite the persistence of some 
inflammatory components such as neutrophilia.  The role of IL-13 in goblet cell up-
regulation has previously been established in OVA driven models of AAD.  Allergen 
induced goblet cell hyperplasia is absent in Il13-/- mice (Walter et al., 2001;Leigh et 
al., 2004b) and profoundly reduced in wild type mice treated with sIL-13Rα2-Fc or 
anti-IL-13 mAb (Grunig et al., 1998;Wills-Karp et al., 1998;Yang et al., 2004).  In an 
alternative model of AAD driven by fungal antigen Blease et al. also demonstrated 
goblet cell hyperplasia was sensitive to IL-13 inhibition, using a polyclonal anti-IL-13 
antibody (Blease et al., 2001).  Thus, IL-13 is essential for goblet cell 
metaplasia/hyperplasia and muc5ac mRNA up-regulation in AAD, apparently 
irrespective of allergen. 
In the current study peribronchial collagen deposition was prevented by prophylactic 
administration of anti-IL-13 mAb to HDM exposed mice.  Accordingly, OVA induced 
subepithelial fibrosis has been shown to be completely abrogated in Il13-/- mice and 
mice treated with anti-IL-13 mAb (Leigh et al., 2004b;Yang et al., 2004).  Similarly, 
subepithelial fibrosis is dependent upon IL-13 in AAD driven by exposure to fungal 
antigen (Blease et al., 2001).  These data demonstrate IL-13 is critical for the 
excessive deposition of collagen along the basement membrane during AAD.  
Furthermore, the prevention of airway remodeling in the present study may, in part, 
contribute to anti-IL-13 mAb induced inhibition of AHR. 
4.4.4 Effects of therapeutic IL-13 neutralisation in HDM induced AAD 
Having defined the effects of prophylactic IL-13 neutralisation in HDM induced AAD 
a therapeutic dosing protocol was employed to evaluate the effects of IL-13 
neutralisation in established AAD.  In these studies anti-IL-13 mAb treatment was not 
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commenced until significant airway hyperreactivity, inflammation and remodelling 
were present, thus, based on the time-course of pathophysiology characterised in 
chapter 3 dosing began after 5 weeks of HDM exposure.  After which administration 
of anti-IL-13 mAb continued for a further 3 weeks during concomitant HDM 
exposure.  As in previous studies, IL-13 was neutralised with 10mg/kg 582 s.c. 
weekly.  It is of greater clinical relevance to understand the role of IL-13 in 
maintaining established AAD and whether features of airway pathophysiology are 
reversible because prophylactic therapy of asthma is not feasible.  See Table 4.1 for a 
summary of therapeutic anti-IL-13 mAb effects compared to prophylactic anti-IL-13 
mAb treatment. 
4.4.4.1 AHR 
AHR was partially reversed by therapeutic IL-13 neutralisation in HDM exposed 
mice.  Specifically, anti-IL-13 mAb treatment reversed the HDM induced changes in 
basal lung function and attenuated changes in Cdyn, however inhibition of RL was 
incomplete with anti-IL-13 mAb treatment.  Thus, HDM induced changes in basal 
lung function and MCh induced decline in Cdyn are dependent on the continued 
presence of IL-13, while MCh induced increases in RL are in part IL-13 independent.  
This is contrary to the effects of prophylactic anti-IL-13 mAb treatment in which 
HDM induced changes in basal lung function, MCh induced Cdyn and RL are 
completely IL-13 dependent.  Hence, IL-13 is required for the development of AHR 
but not for the persistence of particular aspects of AHR.  These data demonstrate that 
HDM induced AHR is not driven solely by the direct actions of IL-13 on ASM.  
Furthermore, this may be indicative of the IL-13 independent AHR associated with 
airway remodelling observed by Leigh et al., particularly in light of the effects of 
therapeutic anti-IL-13 mAb on collagen deposition in the present study (Leigh et al., 
2004a); therapeutic IL-13 neutralisation inhibited collagen deposition, but did not 
affect the level of collagen deposited prior to treatment. 
Changes in basal lung function may be attributable to a combination of airway 
remodelling, mucus hyper-secretion, airway wall oedema (and therefore 
inflammation) and changes in airway tone.  Since therapeutic IL-13 neutralisation 
completely reversed the decline in basal lung function, the predominant determinants 
of basal lung function must also require the continued presence of IL-13.  The effects 
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of anti-IL-13 mAb on airway tone are unknown however goblet cell up-regulation 
was completely dependent on the presence of IL-13 whilst only partial inhibition of 
inflammation and collagen deposition was achieved with therapeutic anti-IL-13 mAb 
treatment.  Thus linking mucus over-production with HDM induced changes in basal 
lung function. 
The effects of therapeutic IL-13 neutralisation observed on MCh induced AHR were 
greater with respect to Cdyn than RL demonstrating anti-IL-13 mAb treatment has 
differential effects on the compliance and resistance aspects of MCh induced AHR.  
Increases in RL are predominantly determined by ASM contraction, i.e. 
bronchoconstriction, and accumulation of mucus in large, conducting airways whereas 
the decline in Cdyn is governed by changes in the small airways such as oedema in 
addition to ASM contraction.  Hence the present results suggest therapeutic 
neutralisation of IL-13 reverses changes in the small airways such as oedema.  In the 
conducting airways, therapeutic anti-IL-13 mAb treatment reversed goblet cell up-
regulation indicating the residual deficit in RL following IL-13 neutralisation may be 
attributable to incomplete inhibition of bronchoconstriction.  In addition, this 
irreversible component of AHR may be attributable to airway remodelling, as 
previously suggested. 
In the literature the extent to which IL-13 neutralisation can inhibit established AHR 
is variable and is likely to depend heavily on the antigen exposure protocol and the 
relative length of the anti-IL-13 treatment period.  In mice sensitised to OVA anti-IL-
13 mAb treatment during the last 17 days of a 31 day challenge period completely 
reversed AHR assessed by WBP however anti-IL-13 treatment for the last 14 days of 
a 42 day challenge period in a comparable model only partially reduced Penh at the 
top MCh concentration (Yang et al., 2005;Kumar et al., 2004).  Furthermore, IL-13 
neutralisation in OVA sensitised mice 4 weeks after cessation of chronic OVA 
challenge had no effect on AHR (Leigh et al., 2004a).  Similarly IL-13 neutralisation 
after chronic challenge with multiple, combined allergens did not reduce AHR 
(Goplen et al., 2009), although IL-13 neutralisation after antigen challenge in a fungal 
model of AAD did inhibit AHR (Blease et al., 2001).  Parallels may be drawn 
between therapeutic treatment in chronically sensitised mice and experimental models 
of asthma in larger mammals in which animals are naturally sensitised to allergen and 
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are likely to experience multiple challenges prior to therapeutic intervention.  Antigen 
induced AHR in sheep naturally sensitised to Ascaris suum is completely abrogated 
by pre-challenge anti-IL-13 treatment (Kasaian et al., 2007).  However, this efficacy 
is not supported by recent clinical data investigating the activity of IL-13 
neutralisation in patients with atopic asthma.  Neither anti-IL-13 mAb treatment, nor 
administration of a dual IL-4/IL-13 inhibitor pitrakinra, had any significant effects on 
AHR (Gauvreau et al., 2010;Wenzel et al., 2007).  These studies did demonstrate that 
IL-13 neutralisation improved lung function during the allergen induced late phase 
response or during both the early and late phase responses (Wenzel et al., 
2007;Gauvreau et al., 2010).  In addition, IL-13 neutralisation with lebrikizumab in 
patients with uncontrolled asthma has been demonstrated to improve basal lung 
function (Corren et al., 2011).  Thus, the effects of therapeutic IL-13 neutralisation on 
AHR observed in HDM exposed mice more accurately reflect data emerging from the 
clinic than data derived from prophylactic studies.  The improvement in basal lung 
function elicited by therapeutic administration of anti-IL-13 mAb in HDM exposed 
mice could be indicative of the diminished late phase response or improved lung 
function observed in anti-IL-13 mAb clinical trials. 
4.4.4.2 Inflammation 
As with prophylactic treatment, therapeutic anti-IL-13 mAb treatment significantly 
reduced the total number of BAL cells and eosinophils.  Therapeutic IL-13 
neutralisation also reduced the numbers of BAL CD4+ T cells and Th2 cells; an effect 
not consistently seen with prophylactic IL-13 neutralisation.  No significant effects on 
the numbers of BAL neutrophils or CD8+ T cells were observed.  A reduction in total 
BAL cells and reduced eosinophilia following therapeutic IL-13 neutralisation has 
previously been described in OVA induced AAD (Taube et al., 2002;Kumar et al., 
2004;Yang et al., 2005).  Although there are no reports of effects on specific T cell 
subsets, Yang et al. demonstrated therapeutic anti-IL-13 mAb treatment elicited a 
modest reduction in the number of BAL mononuclear cells whilst Taube et al. showed 
no significant effects on the number of BAL lymphocytes (Yang et al., 2005;Taube et 
al., 2002).  In agreement with the current study, no effects on the accumulation of 
BAL neutrophils were observed by Yang or Taube (Yang et al., 2005;Taube et al., 
2002).  Interestingly, IL-13 neutralisation in an NHP model of AAD also 
demonstrated reduced accumulation of total cells and eosinophils post-allergen 
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challenge (Bree et al., 2007), although these effects were not consistently significant 
(Kasaian et al., 2008).  Bree et al. also noted anti-IL-13 mAb treatment reduced BAL 
neutrophilia (Bree et al., 2007).  Significantly, IL-13 neutralisation with anti-IL-13 
mAb or pitrakinra in patients with atopic asthma showed no changes in the number of 
sputum eosinophils post allergen challenge compared to placebo, highlighting 
inconsistencies between animal models of asthma and clinical disease (Wenzel et al., 
2007;Gauvreau et al., 2010).  In summary, the present study demonstrates IL-13 is 
required for the perpetuation of certain aspects of airway inflammation in HDM 
induced AAD such as eosinophilia and accumulation of Th2 cells however, this may 
not hold true in man. 
4.4.4.3 Remodelling 
Therapeutic administration of anti-IL-13 mAb reversed HDM induced goblet cell 
hyperplasia and the corresponding up-regulation of muc5ac mRNA.  In accordance 
with the current study therapeutic IL-13 neutralisation consistently abrogated goblet 
cell up-regulation in OVA and Aspergillus induced AAD (Taube et al., 2002;Kumar 
et al., 2004;Yang et al., 2005;Blease et al., 2001).  IL-13 neutralisation after the 
allergen challenge period did not affect goblet cell frequency (Leigh et al., 2004a).  
These data indicate the maintenance of goblet cells during allergen exposure requires 
IL-13, whereas the frequency of goblet cells after cessation of allergen exposure is 
independent of IL-13.  In addition, the reduction in goblet cells and therefore mucin 
production in the current study may contribute to the improvement of basal lung 
function by prohibiting the formation of mucus plugs in the airways. 
In the present study therapeutic IL-13 neutralisation prevented peribronchial collagen 
deposition although treatment did not reverse existing subepithelial fibrosis.  
Comparable results have been obtained in OVA and Aspergillus induced AAD (Yang 
et al., 2005;Blease et al., 2001) and accordingly IL-13 neutralisation after allergen 
challenge does not reduce established collagen deposition (Leigh et al., 2004a).  Due 
to the invasive nature of assessing airway remodelling, no data is available on the 
effects of IL-13 neutralisation in NHP models or early clinical trials.  Thus, IL-13 is 
required for the deposition of collagen within the airway wall during allergen 
exposure, but once laid down the maintenance of subepithelial collagen is 
independent of IL-13.  This persistence of airway remodelling independently of IL-13 
Chapter 4 
 147
is proposed to account for IL-13 independent aspects of AHR, observed in the present 
study as a residual deficit in MCh induced changes in RL following anti-IL-13 mAb 
treatment (Leigh et al., 2004a). 
Therapeutic IL-13 neutralisation has been demonstrated to reduce HDM induced 
changes in lung function, eosinophilia, goblet cell frequency and collagen deposition 
in the present study.  By comparison, treatment with current asthma therapies in a 
similar mouse model of AAD has demonstrated HDM induced inflammation to be 
highly sensitive to therapeutic administration of oral or inhaled corticosteroids (Ulrich 
et al., 2008).  Oral prednisolone and i.n. fluticasone both dose-dependently inhibited 
the accumulation of eosinophils, neutrophils and lymphocytes in BAL.  Furthermore, 
prednisolone reduced mRNA expression of various pro-inflammatory mediators in the 
lung tissue.  However, corticosteroid treatment only partially inhibited HDM induced 
expression of Th2 cytokine mRNAs, including IL-13, and as a likely consequence 
inhibition of muc5ac mRNA only reached 64% at the top dose of corticosteroid used.  
Although the effects of corticosteroid therapy on HDM induced changes in lung 
function and airway remodelling have not been reported, these data suggest that IL-13 
and hence IL-13 induced airway pathology may be relatively resistant to 
corticosteroid therapy.  Indeed, airway disease induced by adenoviral expression of 
IL-13 has been demonstrated to be corticosteroid resistant (Therien et al., 2008).  If 
this also holds true for clinical asthma, novel IL-13 neutralising therapies could 
provide added efficacy in combination with corticosteroid therapy. 
In summary, after selection of an appropriate dose and anti-IL-13 antibody, the effects 
of both prophylactic and therapeutic IL-13 neutralisation in HDM induced AAD have 
been characterised.  Lung function, eosinophilia, goblet cell hyperplasia and 
subepithelial fibrosis have been identified as dependent upon IL-13 in this model.  In 
addition, preliminary data obtained using two different anti-IL-13 mAbs recognising 
distinct functional epitopes demonstrate that prevention of IL-13 signalling through 
partial or full disruption of the type II IL-4 receptor complex is sufficient for efficacy, 
irrespective of IL-13Rα2 binding. 
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 Prophylactic Therapeutic 
Baseline RL ↓↓↓ ↓↓ 
Baseline Cdyn ↓↓↓ ↓↓↓ 
AHR (RL) ↓↓↓ ↓ 
Lung function 
AHR (Cdyn) ↓↓↓ ↓↓ 
 BAL Tissue BAL Tissue 
Total cells ↓↓ ↓ ↓ ND 
Eosinophils ↓↓↓ ↓↓ ↓↓ ND 
Neutrophils ↓↓ ↓↓↓ - ND 
Total macrophages ↑ ↑ ND ND 
AM ↑ ↑ ND ND 
IM - ↑ ND ND 
CD4+ T cells - - ↓↓ ND 
CD8+ T cells - - - ND 
B cells ↓↓ - ND ND 
Th2 - - ↓ ND 
Th1 - - ND ND 
Inflammatory 
cells 
Th17 - - ND ND 
IL-4 ↓↓ - ND ND 
IL-5 - - ND ND 
IL-10 ↓↓↓ - ND ND 
IFNγ - - ND ND 
IL-12 - - ND ND 
IL-17 - - ND ND 
Eotaxin ↓↓↓ ↓↓↓ ND ND 
KC ↓↓ ↓ ND ND 
IL-25 ND ↓↓ ND ND 
IL-33 ND - ND ND 
Mediators 
TSLP ND ↓↓↓ ND ND 
Total IgE ↓ ND 
HDM specific IgE - ND 
HDM specific IgG1 - ND 
HDM specific IgG2a - ND 
Antibodies 
HDM specific IgG2b - ND 
Goblet cells ↓↓↓ ↓↓↓ 
Muc5ac mRNA ↓↓↓ ↓↓↓ Remodelling 
Peribronchial Collagen ↓↓↓ ↓↓↓ 
 
Table 4.1 Summary of IL-13 effects.  Table summarises the significant effects of prophylactic or 
therapeutic treatment with anti-IL-13 mAb in HDM induced AAD.  – No effect; ↓ <50% inhibition; ↓↓ 
>50% inhibition; ↓↓↓ >75% inhibition; ↑ elevation; ND not determined. 
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5. IL-13 RECEPTOR DISTRIBUTION 
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5.1 Introduction 
Multiple cells types have been reported to be responsive to IL-13, many of which are 
present in the lungs during AAD such as monocytes, macrophages, DC, eosinophils, 
mast cells, epithelial cells, fibroblasts, ASM and endothelial cells.  However, much of 
this data is derived from in vitro systems which do not reflect the complexity of the 
lung microenvironment or the cocktail of mediators that cells are likely to be exposed 
to in vivo and hence may not accurately represent pathways involved in the allergic 
response in vivo.  Furthermore, few studies have substantiated IL-13 responsiveness 
with analysis of IL-13 receptor expression on the cell surface.  In addition, data on the 
expression of IL-13 receptors in tissues is limited and has not yet been conducted in 
the context of AAD. 
The previous chapter established many pathophysiological features of HDM induced 
AAD were dependent upon IL-13, including airway eosinophilia, AHR, goblet cell 
hyperplasia and peribronchial collagen deposition.  To further elucidate the 
mechanisms involved in IL-13 driven pathology the present studies were conducted to 
investigate IL-13 receptor expression by cells within the lung tissue and circulation.  
Determination of the phenotype of IL-13 receptor expressing cells could then indicate 
IL-13 responsive cells that may be involved in driving AAD.  Furthermore, 
modulation of receptor expression during the course of HDM exposure, compared to 
sham, could be relevant to IL-13 dependent pathways involved in AAD.  Since both 
IL-13Rα1 and IL-13Rα2 are capable of signalling, it was important to investigate 
expression of both receptor subunits in HDM induced AAD.  Moreover, initial 
analysis of mRNA was followed up with determination of protein expression on the 
cell surface where possible, in order to verify that the receptor would be accessible to 
extracellular IL-13. 
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5.1.1 Aim 
3. To determine the distribution of IL-13 receptors in naïve and inflamed 
airways.  The key cell types expressing IL-13Rα1 and IL-13Rα2 will be 
identified. 
The aim of this chapter was to identify IL-13 receptor expressing cells within the 
lungs and circulation of HDM exposed mice.  And hence reveal the cell types 
implicated in IL-13 driven pathology to further elucidate the mechanisms involved in 
anti-IL-13 mAb inhibition of AAD. 
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5.2 Methods 
5.2.1 IL-13Rα2 ELISA 
IL-13Rα2 ELISA protocol was directly replicated from Tabata et al. (Tabata et al., 
2006).  Briefly, plates were coated with 1μg/ml goat anti-mouse IL-13Rα2 pAb 
(R&D Systems, AF539) overnight, washed twice, blocked for 1 hour with 1% BSA 
then washed a further two times.  Samples and standards (rmIL-13Rα2-Fc, R&D 
Systems, 539-1R) were loaded onto plates in duplicate and incubated for 2 hours and 
washed four times followed by incubation with biotinylated anti-mouse IL-13Rα2 
(R&D Systems, BAF539) at 0.5μg/ml for 2 hours.  After washing four times, 
streptavidin-HRP (R&D Systems, DY998) at 1 in 200 was loaded onto the plates, 
incubated for an hour then washed four times more.  Peroxidase activity was revealed 
by addition of TMB and the reaction subsequently stopped with H2SO4 and read at 
450-650nm. 
5.2.2 IL-13Rα1 staining for flow cytometry 
Goat anti-human IL-13Rα1 polyclonal with cross-reactivity to mouse (Santa Cruz 
Biotechnologies, sc-27861) was used to stain LD and BAL cells for analysis of 
receptor expression.  Cells were stained with 10μg/ml anti-IL-13Rα1 primary or 
control goat IgG (R & D Systems, AB-108-C) for 20min at +4ºC then washed prior to 
incubation with additional extracellular staining antibodies.  Donkey anti-goat IgG 
F(ab’)2-Cy5 or F(ab’)2-Dy-light 649 secondary (Jackson ImmunoResearch, 705-176-
147 or 705-496-147, respectively) was added to the cells at a dilution of 1 in 200, 
together with the relevant extracellular staining cocktail.  Cells were subsequently 
washed and treated according to the staining protocol in materials and methods. 
For visualisation of cells stained for flow cytometry stained samples were spun onto 
slides by cytocentrifugation according to 2.10.3.  After air-drying slides were 
mounted for imaging using ProLong Gold antifade reagent with DAPI (Invitrogen 
P36935). 
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5.3 Results 
5.3.1 IL-13 receptor mRNA expression following HDM exposure 
To determine whether the expression of IL-13 receptor subunits in the lungs was 
modulated during the development of HDM induced AAD the relative levels of IL-
13Rα1, IL-13Rα2 and IL-4Rα specific mRNA were quantified by real-time PCR.  No 
significant changes in IL-13Rα1 mRNA expression were observed after 1, 3 or 5 
weeks of HDM exposure, compared to sham (Figure 5.1 A).  IL-13Rα2 mRNA 
however, was significantly up-regulated by exposure to HDM.  Increased expression, 
relative to sham, was apparent after just one week of HDM exposure and further 
elevated by over 100-fold by weeks 3 and 5 (Figure 5.1 B).  Exposure to HDM 
induced a modest reduction in expression of IL-4Rα at week 1 compared to sham, 
followed by increased expression after weeks 3 and 5 weeks of HDM (Figure 5.1 C). 
5.3.2 IL-13Rα2 expression following HDM exposure. 
Soluble IL-13Rα2 (sIL-13Rα2) protein levels in BAL, lung homogenate (LH) and 
serum were determined over 5 weeks of HDM exposure to verify the increased 
expression of IL-13Rα2 mRNA described above.  Compared to sham, no changes in 
BAL sIL-13Rα2 concentrations were observed following 1, 3 or 5 weeks of HDM 
exposure (Figure 5.2 A).  Levels of sIL-13Rα2 protein in LH were increased above 
sham after 3 weeks of HDM exposure, and further elevated after 5 weeks (Figure 5.2 
B).  sIL-13Rα2 protein was also detected in the serum of HDM exposed mice, though 
only differed significantly from sham at week 3 (Figure 5.2 C). 
The greatest expression of both IL-13Rα2 mRNA and protein in the lung tissue was 
observed after 5 weeks of HDM exposure.  Therefore, lungs from this time point were 
used for IF staining to localise IL-13Rα2 within the tissue.  IL-13Rα2 was detected in 
the airway epithelia of sham exposed mice (Figure 5.3 A-B).  Following exposure to 
HDM the whole lung tissue stained positively for IL-13Rα2, with the airway epithelia 
remaining the brightest signal (Figure 5.3 D-E).  This HDM induced up-regulation of 
IL-13Rα2 expression in the lung tissue confirmed the elevation of IL-13Rα2 mRNA 
and protein in HDM exposed mice previously detected by real time PCR and ELISA, 
respectively.
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Figure 5.1 IL-13 receptor expression following exposure to HDM.  Lungs were taken after 1, 3 or 
5 weeks of HDM exposure, 4 hours after the last HDM instillation.  mRNA in lung tissue was 
quantified by real time PCR and normalised to sham; (A) IL-13Rα1, (B) IL-13Rα2 and (C) IL-4Rα 
mRNA.  n = 7-8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 by Mann Whitney test. 
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Figure 5.2 IL-13Rα2 concentrations following exposure to HDM.  BAL, Lungs and serum were 
taken after 1, 3 or 5 weeks of HDM exposure, 4 hours after the last HDM instillation (serum was taken 
24 hours after the last HDM instillation).  IL-13Rα2 concentrations were quantified by ELISA in BAL 
(A), LH (B) and serum (C).  n = 8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 by 
Mann Whitney test. 
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Figure 5.3 Localisation of IL-13Rα2 following exposure to HDM.  Lungs were taken after 5 
weeks of HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα2 staining 
and blue is DAPI.  Representative images of IL-13Rα2 staining in sham (A, C) and HDM lungs (B, D).  
(C) and (D) depict further magnified images of (A) and (B), respectively.  (E-F) Control staining in 
sham (E) and HDM lungs (F).  Scale bar represents 75μm, unless stated. 
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5.3.3 IL-13Rα1 expression in the lungs following HDM exposure. 
The expression and localisation of IL-13Rα1 was assessed by IF in the lungs of mice 
exposed to HDM or saline (sham) for 5 weeks.  IL-13Rα1+ cells were detected 
throughout the lung parenchyma of both sham and HDM exposed mice (Figure 5.4).  
Despite relatively high background staining in HDM mice, specific IL-13Rα1 
staining was bright and punctate.  IL-13Rα1+ cells appeared larger in HDM exposed 
mice than in sham mice. 
Due to the size and location of IL-13Rα1+ cells, sections were stained with MOMA2 
to determine whether IL-13Rα1+ cells were macrophages.  In addition, cytospin 
slides of BAL cells from sham and HDM exposed mice were stained with the same 
antibody combination to determine whether IL-13Rα1+ cells were present in BAL.  
Unfortunately, MOMA2 staining was not sufficiently bright in the lung sections, to 
establish whether the staining co-localised (Figure 5.5).  However, MOMA2 staining 
was detected in BAL cells.  IL-13Rα1+ cells were present in BAL, the majority of 
which were also positive for MOMA2 indicating IL-13Rα1+ BAL cells were 
macrophages (Figure 5.6).  Interestingly, an additional population of IL-13Rα1+ 
MOMA2- cells was identified in BAL from HDM exposed mice (Figure 5.6 D).  
These cells were small with a diffuse, membrane associated staining pattern, distinct 
from the punctate stain of larger cells. 
To verify whether the large IL-13Rα1+ cells in lung tissue and BAL were 
macrophages, sections and cytospins were stained with IL-13Rα1 and CD68.  IL-
13Rα1 staining in sham and HDM lungs was closely associated with CD68 
expression (Figure 5.7).  Of note, while the majority of IL-13Rα1 staining co-
localised to CD68+ cells, not all CD68+ cells were IL-13Rα1+.  This was particularly 
evident in lungs from HDM exposed mice in which macrophages residing throughout 
the parenchyma were CD68+ IL-13Rα1+ whereas macrophages in the peribronchial 
inflammatory cuffs were CD68+ IL-13Rα1-.  The majority of IL-13Rα1 staining in 
BAL cells from sham and HDM mice also co-localised to CD68 (Figure 5.8), 
although some of the IL-13Rα1 staining was masked by the intensity of CD68 
staining in HDM BAL cells. 
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Figure 5.4 Localisation of IL-13Rα1 following exposure to HDM.  Lungs were taken after 5 
weeks of HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα1 staining 
and blue is DAPI.  Representative images of IL-13Rα1 staining in sham (A, C) and HDM lungs (B, D).  
(C) and (D) depict further magnified images of (A) and (B), respectively.  (E-F) Control staining in 
sham (E) and HDM lungs (F).  Scale bar represents 75μm, unless stated. 
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Figure 5.5 Co-localisation of IL-13Rα1 with MOMA2 in Lungs.  Lungs were taken after 5 weeks 
of HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα1 staining, green 
MOMA2 and blue DAPI.  Representative images of IL-13Rα1 and MOMA2 staining in sham (A, C) 
and HDM lungs (B, D).  (C) and (D) depict further magnified images of (A) and (B), respectively.  (E-
F) Control staining in sham (E) and HDM lungs (F).  Scale bar represents 75μm, unless stated. 
A 
C 
25μm 
D
25μm 
B
E F
Chapter 5 
 160
 
Figure 5.6 Co-localisation of IL-13Rα1 with MOMA2 in BAL.  BAL was taken after 5 weeks of 
HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα1 staining, green 
MOMA2 and blue DAPI.  Representative images of IL-13Rα1 and MOMA2 staining in sham (A, C) 
and HDM BAL (B, D).  (C) and (D) depict further magnified images of (A) and (B), respectively.  (E-
F) Control staining in sham (E) and HDM BAL (F).  Scale bar represents 75μm, unless stated. 
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Figure 5.7 Co-localisation of IL-13Rα1 to CD68+ cells in lungs.  Lungs were taken after 5 weeks 
of HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα1 staining, green 
CD68 and blue DAPI.  Representative images of IL-13Rα1 and CD68 staining in sham (A, C) and 
HDM lungs (B, D).  (C) and (D) depict further magnified images of (A) and (B), respectively.  (E-F) 
Control staining in sham (E) and HDM lungs (F).  Scale bar represents 75μm, unless stated. 
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Figure 5.8 Co-localisation of IL-13Rα1 to CD68+ cells in BAL.  BAL was taken after 5 weeks of 
HDM exposure, 24 hours after the last HDM instillation.  Red indicates IL-13Rα1 staining, green 
CD68 and blue DAPI.  Representative images of IL-13Rα1 and CD68 staining in sham BAL (A, C) 
and HDM BAL (B, D).  (C) and (D) depict further magnified images of (A) and (B), respectively.  
Scale bar represents 75μm, unless stated. 
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5.3.4 Quantification of IL-13Rα1+ cells. 
To further investigate the phenotype and quantify IL-13Rα1+ cells it was necessary to 
develop a protocol to stain cells for IL-13Rα1 for analysis by flow cytometry.  A 
range of primary antibody concentrations were tested and IL-13Rα1 specific staining 
on BAL cells was detected in a concentration dependent manner (Figure 5.9).  
10μg/ml anti-IL-13Rα1 produced optimal staining and thus, was selected for use in 
subsequent studies assessing IL-13Rα1 expression by flow cytometry. 
IL-13Rα1+ cells in BAL from sham and HDM exposed mice were quantified by flow 
cytometry.  The total number of IL-13Rα1+ cells was elevated in BAL after 5 weeks 
of HDM exposure, compared to sham (Figure 5.10 A).  This was attributable in part, 
to an increase in the number of IL-13Rα1+ macrophages (Figure 5.10 B), but 
primarily due to a significant increase in the number of non-macrophage IL-13Rα1+ 
cells (Figure 5.10 C).  The identity of this latter population is explored later in this 
chapter. 
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Figure 5.9 Development of a flow cytometry stain for IL-13Rα1.  Naïve BAL cells were stained 
with 1-10μg/ml anti-IL-13Rα1 (A) or control Ig (B) followed by anti-goat-Cy5 secondary.  (C) 
Overlay of 10μg/ml anti-IL-13Rα1 and control Ig. 
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Figure 5.10 Quantification of IL-13Rα1+ BAL cells.  BAL was taken after 5 weeks of HDM 
exposure, 24 hours after the last HDM instillation.  The number of IL-13Rα1+ BAL cells was 
quantified by flow cytometry.  (A) IL-13Rα1+ BAL cells, (B) IL-13Rα1+ MOMA2+ BAL cells and 
(C) IL-13Rα1+ MOMA2- BAL cells.  n = 9-10 mice/group, bar represents median.  Data represents 
one of two experiments.  * p<0.05 and *** p<0.001 by Mann Whitney test. 
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5.3.5 IL-13Rα1+ macrophages 
Characterisation of IL-13Rα1+ macrophages in BAL from sham and HDM exposed 
mice revealed a reduction in the intensity of IL-13Rα1 staining following HDM 
exposure compared to sham (Figure 5.11 A-C).  This was associated with a fall in the 
proportion of IL-13Rα1+ cells within the macrophage population of HDM BAL 
(Figure 5.11 D); despite the actual number of IL-13Rα1+ macrophages in BAL 
increasing upon HDM exposure (Figure 5.11 E).  This may be due to a dilution effect 
of infiltrating IL-13Rα1- macrophages during lung inflammation; however loss of 
receptor from the cell surface may also be a contributing factor since IL-13Rα1 is still 
readily detected by IF after HDM exposure.  To gauge whether IL-13Rα1 may be 
internalised following HDM exposure BAL cells from sham and HDM exposed mice 
were stained for extracellular and intracellular IL-13Rα1 and analysed by flow 
cytometry.  Cells from the same preparation were also assessed visually by 
fluorescence microscopy.  The reduction in extracellular IL-13Rα1 staining intensity 
on macrophages from HDM mice was apparent by both flow cytometry and 
microscopy (Figure 5.12).  Intracellular staining revealed intense IL-13Rα1 staining 
in both sham and HDM macrophages however the distribution of IL-13Rα1 was 
distinct in sham and HDM macrophages.  Intracellular IL-13Rα1 in sham 
macrophages localised predominantly to the periphery of the cell, whereas IL-13Rα1 
in HDM macrophages was apparent throughout the cells in a punctate, vesicular 
pattern (Figure 5.13). 
To investigate the expression of IL-13Rα1 on macrophage subpopulations in the lung 
BAL and LD macrophages from sham and HDM exposed mice were subdivided into 
AM and IM populations based on F4/80 and CD11c expression.  Subsequently, 
extracellular receptor expression and its modulation after HDM exposure were 
assessed on each population.  The majority of BAL cells were AM in both sham and 
HDM exposed mice (Figure 5.14 A-B).  Hence, as previously observed in total BAL 
macrophages, IL-13Rα1 expression was present on BAL AM in sham exposed mice 
(Figure 5.14 C).  In addition, receptor expression on BAL AM was substantially 
reduced following HDM exposure (Figure 5.14 D).  Analysis of IL-13Rα1 expression 
on BAL IM was not conducted due to the small size of this population.  In LD IL-
13Rα1 expression was detected on AM in sham mice and, as in BAL, this was 
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significantly reduced in HDM mice (Figure 5.15 C-D).  LD IM from sham mice 
exhibited negligible IL-13Rα1 expression which appeared further diminished after 
exposure to HDM (Figure 5.15 E-F).  Quantitatively, the proportion of BAL AM 
expressing IL-13Rα1 was approximately 52% in sham mice, which fell to 6% in 
HDM mice (Figure 5.16 A).  Similarly, 22% of LD AM were IL-13Rα1+ in sham 
mice compared to 4% in HDM mice (Figure 5.16 B).  Approximately 17% of LD IM 
in sham exposed mice expressed IL-13Rα1 which was non-significantly reduced to 
6% after HDM exposure (Figure 5.16 C). 
Since the largest population of IL-13Rα1 expressing cells in the lung was BAL AM, 
the phenotype of BAL AM in sham and HDM exposed mice was analysed.  Sham 
BAL AM expressed minimal CD206 (mannose receptor) however expression was 
elevated by exposure to HDM (Figure 5.17 A and D).  The DC and AM marker 
CD205 (DEC-205) was expressed by both sham and HDM AM, with AM from HDM 
exposed mice having greater expression than sham (Figure 5.17 B and E).  Similarly, 
Dectin-1 (β-glucan receptor) was expressed by sham and HDM AM with higher 
expression on HDM AM compared to sham (Figure 5.17 C and F).  Intracellular 
cytokine staining of AM stimulated ex vivo was employed to further characterise the 
phenotype of BAL AM from sham and HDM exposed mice.  Minimal IL-13 was 
detected in HDM AM which was not present in sham AM (Figure 5.18 A, D).  Both 
sham and HDM AM expressed IL-10 and TGFβ, however little difference was 
observed between AM from sham and HDM exposed mice (Figure 5.18 B-C and E-
F). 
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Figure 5.11 IL-13Rα1 expression on BAL macrophages is reduced following HDM exposure.  
BAL was taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  The number 
of IL-13Rα1+ BAL cells was quantified by flow cytometry.  (A-B) Representative histograms and MFI 
of IL-13Rα1 expression on sham BAL cells (A) and HDM BAL cells (B).  (C) Mean fluorescence 
intensity (MFI) of IL-13Rα1 staining on BAL macrophages; (D) proportion of BAL macrophages 
staining positive for IL-13Rα1 and (E) number of IL-13Rα1+ BAL macrophages.  n = 9-10 
mice/group, bar represents median.  Data represents one of two experiments.  * p<0.05 and ** p<0.01 
by Mann Whitney test. 
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Figure 5.12 Extracellular IL-13Rα1 expression on BAL macrophages.  BAL was taken from sham 
or HDM exposed mice, 24 hours after the last HDM exposure.  (A-B) Representative histograms of 
extracellular IL-13Rα1 (red line) or control (blue line) staining on MOMA2+ BAL macrophages in 
sham (A) and HDM mice (B).  (C-D) Representative images of BAL cells stained for IL-13Rα1 (red), 
MOMA2 (green) and DAPI (blue) for analysis by flow cytometry.  n = 3 mice/group.  (E-F) BAL cells 
stained with control (red), MOMA2 (green) and DAPI (blue). 
0 100 1000 10000 1x105
<Cy5-A>: IL-13Ra1
0
20
40
60
80
100
%
 o
f M
ax
0 100 1000 10000 1x105
<Cy5-A>: IL-13Ra1
0
20
40
60
80
100
%
 o
f M
ax
A 
C 
E 
B
D
F
Sham HDM 
Chapter 5 
 170
 
Figure 5.13 Intracellular IL-13Rα1 expression in BAL macrophages.  BAL was taken from sham 
or HDM exposed mice, 24 hours after the last HDM exposure.  (A-B) Representative histograms of 
intracellular IL-13Rα1 (red line) or control (blue line) staining on MOMA2+ BAL macrophages in 
sham (A) and HDM mice (B).  (C-D) Representative images of BAL cells stained for intracellular IL-
13Rα1 (red), MOMA2 (green) and DAPI (blue) for analysis by flow cytometry.  n = 3 mice/group.  (E-
F) BAL cells stained with control (red), MOMA2 (green) and DAPI (blue). 
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Figure 5.14 IL-13Rα1 expression on BAL AM.  BAL was taken after 5 weeks of HDM exposure, 24 
hours after the last HDM instillation.  (A-B) Representative dot plots of BAL macrophages in sham 
exposed (A) and HDM exposed mice (B).  (C-D) Representative histograms of IL-13Rα1 staining 
(black line) compared to control stain (blue line) on BAL AM from sham exposed (C) and HDM 
exposed mice (D).  n = 6 mice/group, data represents one of two experiments. 
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Figure 5.15 IL-13Rα1 expression on LD AM and IM.  Lungs were taken after 5 weeks of HDM 
exposure, 24 hours after the last HDM instillation.  (A-B) Representative dot plots of LD macrophages 
in sham exposed (A) and HDM exposed mice (B).  (C-F) Representative histograms of IL-13Rα1 
staining (black line) compared to control stain (blue line) on LD AM from sham exposed mice (C); LD 
AM from HDM exposed mice (D); LD IM from sham exposed mice (E) and LD IM from HDM 
exposed mice (F).  n = 6 mice/group, data represents one of two experiments. 
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Figure 5.16 Proportion of IL-13Rα1+ AM and IM following HDM exposure.  BAL and lungs 
were taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  The proportions 
of IL-13Rα1+ cells were assessed by flow cytometry.  (A) The proportion of IL-13Rα1+ AM in BAL; 
(B) the proportion of IL-13Rα1+ AM in LD; and (C) the proportion of IL-13Rα1+ IM in LD.  n = 6 
mice/group, bar represents median, data represents one of two experiments.  ** p<0.01 by Mann 
Whitney test. 
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Figure 5.17 Phenotype of BAL AM.  Representative histograms of BAL AM from sham (A-C) or 
HDM exposed mice (D-F) depicting expression of CD206 (A, D), CD205 (B, E) and Dectin-1 (C, F) in 
red or isotypes controls in blue.  n = 5 mice/group, data represents one of two experiments. 
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Figure 5.18 Intracellular cytokine staining of BAL AM.  Representative histograms of BAL AM 
from sham (A-C) or HDM exposed mice (D-F) depicting expression of IL-13 (A, D), IL-10 (B, E) and 
TGFβ (C, F) in red or isotypes controls in blue.  n = 5 mice/group. 
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5.3.6 IL-13Rα1 expression on non-macrophages 
In addition to BAL and LD cells, IL-13Rα1 staining was also conducted in naïve 
blood to investigate whether any normal circulating cells have the potential to respond 
to IL-13.  IL-13Rα1 was detected on both MOMA2+ and MOMA2- cells (Figure 5.19 
A-B).  IL-13Rα1+ MOMA2+ cells were also Gr-1+ and CD11b+ indicating this was 
a subpopulation of monocytes (Figure 5.19 C-D).  IL-13Rα1+ MOMA2- cells 
however, were Gr-1- and CD11b- excluding granulocytic and monocytic phenotypes 
(Figure 5.19 E-F).  Further analysis demonstrated the majority of IL-13Rα1+ 
MOMA2- cells in naïve blood to be CD3+ CD4+ lymphocytes (Figure 5.20 A).  A 
small population, representing approximately 6% of CD4+ cells in naïve blood, were 
IL-13Rα1+ (Figure 5.20 B).  Negligible IL-13Rα1 staining was detected in CD8+ 
lymphocytes (Figure 5.20 C). 
Following induction of HDM induced AAD, IL-13Rα1+ CD4+ lymphocytes were 
also detected in BAL and LD (Figure 5.21 A and B, respectively).  Quantification of 
these cells revealed HDM exposure significantly increased the numbers of IL-13Rα1+ 
CD4+ cells in BAL and LD, compared to sham (Figure 5.21 C and D, respectively).  
No changes were observed in the total number of IL-13Rα1+ CD4+ cells in the blood 
of HDM exposed mice compared to sham (data not shown). 
A subsequent study was conducted to determine the phenotype of IL-13Rα1+ CD4+ 
cells in blood, BAL and LD from sham and HDM exposed mice.  In the blood a naïve 
phenotype (CD44lo) was the most common within the IL-13Rα1+ CD4+ population.  
However, IL-13Rα1+ CD44lo CD4+ cells represented only 3.3% of total CD44lo 
CD4+ cells in sham mice.  Following HDM exposure the frequency of IL-13Rα1+ 
CD44lo CD4+ cells increased to 5.5% of total CD44lo CD4+ cells.  Approximately 
27% of central memory cells (CD44hi CD62L+) and 35% of effector memory cells 
(CD44hi CD62L-) in the blood expressed IL-13Rα1; the size of these populations 
appeared unaltered following HDM exposure (Figure 5.22).  In BAL, the number of 
CD4+ T cells present in sham mice was negligible, however after exposure to HDM 
the majority of IL-13Rα1+ CD4+ cells were effector memory cells; representing 39% 
of total effector memory T cells.  Significant populations of IL-13Rα1+ cells were 
also detected within the naïve and central memory T cell populations following HDM 
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exposure.  29% of naïve CD4+ T cells and 80% of central memory T cells expressed 
IL-13Rα1 (Figure 5.23).  In LD, the numbers of IL-13Rα1+ naïve and memory T 
cells were elevated following HDM exposure.  The proportion of IL-13Rα1+ cells 
within the naïve T cell population in the lungs increased from 4% to 10% with 
exposure to HDM.  In addition, the proportion of IL-13Rα1+ cells within the central 
memory cell population increased from 57% to 67% with exposure to HDM.  The 
majority of IL-13Rα1+ CD4+ T cells in LD were effector memory cells.  IL-13Rα1+ 
effector memory cells represented 48% of the total effector memory cell population.  
The size of this population increase following exposure to HDM however the 
proportion of IL-13Rα1+ cells within the effector memory cell population remained 
relatively unaltered at 39% (Figure 5.24). 
Since the largest populations of IL-13Rα1+ CD4+ cells in BAL and LD were effector 
cells, the phenotypes of these populations were further investigated.  BAL and LD 
cells from HDM and sham mice were stained for IFNγ, T1ST2, IL-17, CD25 and 
FoxP3 expression, in conjunction with IL-13Rα1, CD4 and CD3, to define the 
phenotype of IL-13Rα1+ effector T cells.  IL-13Rα1 expression was detected on 
subsets of Th0, Th1, Th2, Th17 and regulatory T cells (Tregs) in BAL and LD from 
HDM exposed mice.  Furthermore, HDM exposure elevated the number of IL-
13Rα1+ Th0, Th1, Th2, Th17 and Tregs in BAL and LD.  In HDM BAL 17% of Th0 
cells; 28% of Th1 cells; 29% of Th2 cells; 22% of Th17 cell and 57% of Tregs 
expressed IL-13Rα1 (Figure 5.25).  In HDM LD 12% of Th0 cells; 19% of Th1 cells; 
28% of Th2 cells; 21% of Th17 cell and 46% of Tregs expressed IL-13Rα1 (Figure 
5.26). 
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Figure 5.19 Detection of IL-13Rα1+ cells in naïve blood.  Blood was taken from naïve mice.  (A-B) 
Representative dot plots of IL-13Rα1 staining (A) and control (B).  (C-D) Gr-1 (C) and CD11b (D) 
expression on IL-13Rα1+ MOMA2+ cells.  (E-F) Gr-1 (E) and CD11b (F) expression on IL-13Rα1+ 
MOMA2- cells.  n = 3 mice. 
 
0 100 1000 10000 1x105
0 
100 
1000 
10000 
1x10 5 
<FITC-A>: MoMa-2 
<C
y5
-A
>:
 IL
-1
3R
 
5.25 3.39 
0 100 1000 10000 1x105
0 
10 
20 
30 
40 
<PerCP-Cy5-5-A>: Gr-1 
0 100 1000 10000 1x10 5 
0
5
10
15
20
25
<PE-A>: CD11b 
C D
0 100 1000 10000 1x10 5 
0
100
1000
10000
1x105
<FITC-A>: MoMa-2 
<C
y5
-A
>:
 c
on
tro
l 
0.29 0.182
A B
0 100 1000 10000 1x105
0 
5 
10 
15 
20 
25 
<PerCP-Cy5-5-A>: Gr-1 
0 100 1000 10000 1x10 5 
0
5
10
15
20
<PE-A>: CD11b 
E F
IL-13Rα1 staining Control staining 
Blood 
MOMA2- MOMA2+ MOMA2- MOMA2+ 
IL-13Rα1+ MOMA2+
IL-13Rα1+ MOMA2-
Chapter 5 
 179
 
 
Figure 5.20 IL-13Rα1 expression on T cells in naïve blood.  Blood was taken from naïve mice.  (A) 
Representative dot plot of CD3 and CD4 expression on IL-13Rα1+ MOMA2- cells.  (B-C) IL-13Rα1 
staining (black line) or control (blue line) on naïve blood CD4+ (B) and CD8+ (C) T cells.  n = 3 mice. 
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Figure 5.21 IL-13Rα1 expression on CD4+ T cells in BAL and LD from HDM exposed mice.  
BAL and lungs were taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  
IL-13Rα1+ cells were quantified by flow cytometry.  (A-B) Representative histograms of IL-13Rα1 
expression (black line) or control staining (blue line) on CD4+ T cells from BAL (A) and LD (B).  (C-
D) The number of IL-13Rα1+ CD4+ T cells in BAL (C) and LD (D).  n = 4 mice/group, bar represents 
median, data represents one of two experiments.  * p<0.05 by Mann Whitney test. 
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Figure 5.22 Phenotype of IL-13Rα1+ CD4+ T cells in blood from sham and HDM exposed mice.  
Blood was taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  IL-13Rα1+ 
cells were quantified and phenotyped by flow cytometry.  (A-D) Representative dot plots of IL-
13Rα1+ (A, C) and IL-13Rα1- (B, D) CD4+ T cells from sham (A-B) and HDM (C-D) exposed mice.  
(E) Numbers of IL-13Rα1+ naïve, central memory and effector memory T cells in blood.  n = 6 
mice/group, mean ± SEM. 
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Figure 5.23 Phenotype of IL-13Rα1+ CD4+ T cells in BAL from sham and HDM exposed mice.  
BAL was taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  IL-13Rα1+ 
cells were quantified and phenotyped by flow cytometry.  (A-B) Representative dot plots of IL-
13Rα1+ (A) and IL-13Rα1- (B) CD4+ T cells from HDM exposed mice.  (C) Numbers of IL-13Rα1+ 
naïve, central memory and effector memory T cells in BAL.  n = 6 mice/group, mean ± SEM. 
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Figure 5.24 Phenotype of IL-13Rα1+ CD4+ T cells in LD from sham and HDM exposed mice.  
Lungs were taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  IL-
13Rα1+ cells were quantified and phenotyped by flow cytometry.  (A-D) Representative dot plots of 
IL-13Rα1+ (A, C) and IL-13Rα1- (B, D) CD4+ T cells from sham (A-B) and HDM (C-D) exposed 
mice.  (E) Numbers of IL-13Rα1+ naïve, central memory and effector memory T cells in LD.  n = 6 
mice/group, mean ± SEM. 
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Figure 5.25 Phenotype of IL-13Rα1+ T helper cells in BAL from HDM exposed mice.  BAL was 
taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  IL-13Rα1+ cells were 
quantified and phenotyped by flow cytometry.  (A-C) Representative dot plots of IL-13Rα1 expression 
on Th1 (A), Th2 (B) and Th17 (C) cells from HDM exposed mice.  The number of IL-13Rα1+ Th0, 
Th1, Th2, Th17 and Treg cells in LD (D) n = 6 mice/group, mean ± SEM. 
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Figure 5.26 Phenotype of IL-13Rα1+ T helper cells in LD from HDM exposed mice.  Lungs were 
taken after 5 weeks of HDM exposure, 24 hours after the last HDM instillation.  IL-13Rα1+ cells were 
quantified and phenotyped by flow cytometry.  (A-C) Representative dot plots of IL-13Rα1 expression 
on Th1 (A), Th2 (B) and Th17 (C) cells from HDM exposed mice.  The number of IL-13Rα1+ Th0, 
Th1, Th2, Th17 and Treg cells in LD (D) n = 6 mice/group, mean ± SEM. 
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5.4 Discussion 
Many cells types, both haematopoietic and stromal, have been reported to be 
responsive to IL-13.  The aim of this chapter was to identify IL-13 receptor expressing 
cells within the lungs and circulation of HDM exposed mice to determine the cell 
types implicated in IL-13 driven pathology.  Thus, further elucidating the mechanisms 
involved in anti-IL-13 mAb efficacy in AAD. 
IL-13 has two known binding proteins; IL-13Rα1 and IL-13Rα2.  The effects of IL-
13 are predominantly mediated via the type II IL-4 receptor, comprising of IL-13Rα1 
and IL-4Rα.  IL-13Rα2 has no known co-receptors and is proposed to function 
primarily as a soluble decoy receptor. However, membrane associated IL-13Rα2 can 
deliver a pro-fibrotic signal under certain circumstances (Fichtner-Feigl et al., 2006) 
and has been reported to impede signalling via the type II IL-4 receptor by 
sequestration of IL-4Rα (Andrews et al., 2006).  Expression of IL-13Rα1, IL-13Rα2 
and IL-4Rα mRNA in lung tissue during HDM exposure was assessed by real-time 
PCR.  Exposure to HDM over a 5 week period did not significantly modulate IL-
13Rα1 mRNA expression compared to sham, however analysis was only conduced 4 
hours post-HDM therefore any transient changes in IL-13Rα1 expression following 
HDM exposure may not have been captured.  Conversely, IL-13Rα2 mRNA 
expression was highly up-regulated following exposure to HDM.  Distinct from IL-
13Rα1, IL-4Rα mRNA expression was also modestly elevated after chronic exposure 
to HDM. 
5.4.1 IL-13Rα2 expression 
In mice IL-13Rα2 may be membrane bound or soluble.  Soluble IL-13Rα2 (sIL-
13Rα2) is generated from cleavage of membrane bound IL-13Rα2 or translation and 
secretion of a distinct IL-13Rα2 splice variant (Tabata et al., 2006;Daines et al., 
2007;Chen et al., 2009).  The expression of sIL-13Rα2 and membrane IL-13Rα2 
transcripts are differentially regulated (Tabata et al., 2006).  Furthermore, due to the 
putative roles of sIL-13Rα2 as a decoy receptor and membrane IL-13Rα2 as a pro-
fibrotic signalling receptor, these two forms of IL-13Rα2 may play opposing roles in 
AAD and IL-13 induced pathology. 
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Soluble IL-13Rα2 protein concentrations were assessed in BAL, LH supernatants and 
serum by ELISA and IL-13Rα2 was localised in the lungs by IF staining.  The up-
regulation of IL-13Rα2 mRNA in lung tissue upon HDM exposure was corroborated 
by an increase in sIL-13Rα2 in LH detected by ELISA.  Moreover, sIL-13Rα2 
expression appeared further elevated by increasing the period of HDM exposure.  
Despite this, BAL sIL-13Rα2 was not elevated above sham levels.  A modest increase 
in sIL-13Rα2 protein was also detected in the serum of mice exposed to HDM for 3 
weeks; however this was not evident at week 5.  There is some disparity in the 
magnitude of IL-13Rα2 mRNA and protein up-regulation in the lung tissue.  After 5 
weeks of HDM exposure IL-13Rα2 mRNA was over 150-fold greater than that in 
sham mice, whereas sIL-13Rα2 protein levels in HDM exposed mice were less than 
2-fold higher than sham.  This could indicate IL-13Rα2 translation is subject to a high 
degree of post-transcriptional control; that sIL-13Rα2 protein is short lived in allergic 
mice or that the majority of IL-13Rα2 protein is membrane associated and thus not 
present in the LH supernatants assayed.  Within the lung tissue, IL-13Rα2 IF staining 
was apparent in airway epithelial cells from both sham and HDM mice.  Following 
HDM exposure IL-13Rα2 was present throughout the lung tissue.  This signal could 
be due to expression of IL-13Rα2 by all lung cells or elevated secretion of sIL-13Rα2 
by specific cell types and its subsequent dispersal throughout the tissue.  IF staining 
for IL-13Rα2 did not allow discrimination between sIL-13Rα2 and membrane 
associated IL-13Rα2 hence the relative abundances of sIL-13Rα2 and membrane IL-
13Rα2 are unknown.  Therefore, it is not possible to determine whether the IL-
13Rα2+ cells identified by IF are capable of responding to IL-13.  Further 
investigation is required to determine whether the expression of IL-13Rα2 in airway 
epithelial cells in sham mice and IL-13Rα2 expression throughout the lung tissue 
following HDM exposure renders these cells IL-13 responsive.   
In agreement with the present study, IL-13Rα2 up-regulation following stimulation 
with allergen or Th2 cytokines has been previously reported in mice.  IL-13Rα2 
mRNA was up-regulated in the lungs of mice sensitised and challenged with OVA or 
SEA (Wilson et al., 2007;Yasunaga et al., 2003;Chiba et al., 2010).  The latter study 
also observed an increase in serum sIL-13Rα2 following allergen challenge.  IL-
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13Rα2 mRNA has been localised specifically to the airway epithelium and pulmonary 
macrophages in transgenic mice with lung targeted IL-13 or IL-4 over-expression.  In 
addition to IL-13 or IL-4 stimulation, IL-10 and IFNγ are also capable of up-
regulating IL-13Rα2 (Zheng et al., 2003).  Furthermore, Tabata et al. demonstrated ex 
vivo stimulation of lung cells with IL-4 or IL-13 induced expression of mRNA 
transcripts for both soluble and membrane forms of IL-13Rα2 (Tabata et al., 2006).  
Elevated concentrations of sIL-13Rα2 in BAL and serum have been demonstrated in 
mice sensitised and challenged with HDM compared to unsensitised mice (Tabata et 
al., 2006).  Upon quantitative RT-PCR analysis of the lung tissue from these mice, 
both IL-13Rα2 transcripts were up-regulated following HDM sensitisation and 
challenge.  Interestingly, addition of HDM to IL-13Rα2 over-expressing cells in vitro 
induces the release of sIL-13Rα2 in an allergen specific, protease dependent manner 
(Daines et al., 2007).  Accordingly, a single administration of HDM into the airways 
in vivo resulted in an elevation of sIL-13Rα2 in BAL.  However, repeated 
administration of protease active HDM into the airways could result in degradation of 
sIL-13Rα2 which may account for the discrepancies in sIL-13Rα2 BAL 
concentrations between these two latter, acute HDM studies and the present, chronic 
HDM study.  Taken together with the present data, these observations suggest both 
soluble and membrane bound forms of IL-13Rα2 are up-regulated in HDM induced 
AAD.  The sIL-13Rα2 protein detectable following HDM exposure in the present 
study is likely to result from both translation of the sIL-13Rα2 transcript and cleavage 
of membrane IL-13Rα2.  The resultant pool of sIL-13Rα2 is capable of neutralising 
IL-13 and thus limiting IL-13 driven pathology.  The levels of membrane bound IL-
13Rα2 protein in the current study remain unknown; hence the role of IL-13 induced 
IL-13Rα2 signalling in HDM induced AAD is undetermined. 
In contrast to mice, no alternatively spliced transcripts for sIL-13Rα2 have been 
discovered in human tissue.  Generation of human sIL-13Rα2 is solely dependent 
upon cleavage of membrane IL-13Rα2 (Chen et al., 2009).  Levels of sIL-13Rα2 in 
BAL and serum are undetectable in asthmatics and healthy controls (O'Toole et al., 
2008).  The presence and hence the role of IL-13Rα2 and regulation of IL-13 
signalling in humans are likely to be quite distinct from the systems involved in mice; 
thus, complicating the extrapolation of observations and mechanisms between the two 
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species.  Nevertheless, IL-13Rα2 expression by bronchial epithelial cells has 
previously been demonstrated in primary human cells and is up-regulated by IL-4 or 
IL-13 stimulation (Yasunaga et al., 2003;Tanabe et al., 2008).  Similarly, IL-13Rα2 
has been detected on the cell surface of primary human fibroblasts, and is up-
regulated by pre-treatment with IL-13 or IL-4 (Andrews et al., 2006).  However, 
Konstantinidis et al. reveal IL-13Rα2 expression by epithelial cells is greater than that 
of fibroblasts (Konstantinidis et al., 2008).  Reports of the localisation of IL-13Rα2 
within the cell are variable and may thus depend on culture conditions, in particular 
the degree of differentiation and stimulation.  In human epithelial cells IL-13Rα2 has 
been demonstrated on the cell surface; as predominantly intracellular; as a secreted 
soluble form and as nuclear and perinuclear staining (Andrews et al., 
2006;Konstantinidis et al., 2008;Tanabe et al., 2008;White et al., 2010).  Hence, the 
cellular localisation, signalling capabilities, modulation and function of IL-13Rα2 in 
man remain elusive.  However, a role for IL-13Rα2 has recently been demonstrated in 
clearance of IL-13 in man (Kasaian et al., 2011).  Thus, as sIL-13Rα2 modulates IL-
13 activity in mice by acting as a decoy receptor, membrane IL-13Rα2 regulates IL-
13 availability in humans by acting as an IL-13 scavenger. 
5.4.2 IL-13Rα1 expression 
Since IL-13Rα1 forms part of the principal IL-13 receptor signalling complex the vast 
majority of evidence pertaining to IL-13Rα1 expression on cell subsets is derived 
from functional responses to IL-13 rather than analysis of expression of IL-13Rα1 
protein.  Many cell types have been reported to respond to stimulation with IL-13, 
including monocytes, macrophages, fibroblasts, eosinophils, mast cells, basophils, 
dendritic cells, smooth muscle cells, endothelial cells and epithelial cells but the data 
available on IL-13Rα1 expression is limited.  In the present study, IF and flow 
cytometry analysis of BAL, LD and blood cells were conducted to identify IL-13Rα1 
expressing cells in sham and HDM exposed mice. 
IF staining revealed IL-13Rα1+ cells throughout the lung parenchyma in sham and 
HDM exposed mice.  The majority of these cells were identified as macrophages, 
although IL-13Rα1 was also detected on subsets of T cells and monocytes.  However, 
it is likely cells expressing low levels of IL-13Rα1 may have been masked by the 
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high level of background staining observed, particularly in lungs from HDM exposed 
mice.  Thus, while the current studies have focused on cells emitting the brightest IL-
13Rα1 signal, these are not likely to represent the only cell types expressing IL-
13Rα1 in the lung. 
5.4.2.1 IL-13Rα1 expression on macrophages. 
IL-13Rα1 expression in the lung parenchyma was co-localised to CD68 by IF staining 
and hence attributed to macrophages.  Further analysis by flow cytometry defined 
these macrophages as AM based on CD11c and F4/80 expression.  Interestingly, IF 
staining for IL-13Rα1 appeared brighter in lungs from HDM exposed mice than sham 
mice despite no significant changes in the levels of IL-13Rα1 mRNA in HDM lungs 
compared to sham lungs at the time-points assessed.  Analysis of IL-13Rα1 
expression by flow cytometry and microscopy revealed IL-13Rα1 was lost from the 
cell surface after exposure to HDM but present inside the cell indicating receptor 
internalisation may be occurring following allergen exposure.  Accordingly, IF 
staining for IL-13Rα1 in sham lungs was closely associated with the intracellular 
marker CD68 but did not co-localise precisely, whereas IL-13Rα1 staining in lungs 
from HDM exposed mice was observed within the CD68+ cytoplasmic regions of 
macrophages.  This suggests IL-13Rα1 may be predominantly expressed on 
macrophage processes in sham mice and subsequently internalised into vesicles 
following HDM exposure.  Quantification of BAL macrophages revealed a modest 
elevation in the number of IL-13Rα1+ macrophages following HDM exposure; 
however intensity of receptor staining was diminished.  Furthermore, the proportion 
of BAL macrophages expressing IL-13Rα1 fell from approximately 65% to 27% after 
exposure to HDM.  This is likely to be due to a combination of loss of surface 
receptor and the diluting effect of infiltrating IL-13Rα1- macrophages accumulating 
in the BAL of HDM mice. 
IL-13Rα1 was expressed on AM in the lung tissue and BAL, although the intensity of 
staining was greatest on BAL AM.  Negligible IL-13Rα1 expression was detected on 
IM in the lung tissue.  Again, surface expression of IL-13Rα1 on LD AM was lost 
upon exposure to HDM.  Analysis of whole BAL macrophages from HDM exposed 
mice described above revealed intracellular IL-13Rα1 staining by both flow 
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cytometry and fluorescence microscopy, thus indicating receptor internalisation is 
occurring on exposure to HDM.  The type II IL-4 receptor has previously been 
demonstrated to be internalised into endosomes following IL-4 or IL-13 stimulation of 
fibroblasts in vitro (Doucet et al., 1998).  HDM exposure is known to elevate both IL-
4 and IL-13 concentrations in the lung tissue; hence this mechanism may also be 
responsible for the loss of surface IL-13Rα1 on macrophages in vivo.  Alternatively, it 
is possible IL-13Rα1 staining is diminished because the detection antibody does not 
recognise IL-13Rα1 in the presence of IL-13.  However, the anti-IL-13Rα1 antibody 
employed for these studies was a polyclonal and thus should recognise multiple IL-
13Rα1 epitopes.  Whilst it is unlikely every epitope would be masked by IL-13 
binding, this could be confirmed by pre-incubating IL-13Rα1 expressing AM or 
whole lung sections with IL-13 prior to IL-13Rα1 staining. 
Taken together, these observations may illustrate a negative feedback mechanism in 
which IL-13Rα1 is internalised following IL-13 binding and thus potentially limiting 
IL-13 driven pathology.  Fate of IL-13Rα1 following internalisation is currently 
unknown, however further analysis of the type of endosomes containing IL-13Rα1 
would indicate whether the receptor is recycled back onto the cell membrane or 
degraded via lysosomes.  Furthermore, these data suggest IL-13Rα1 expression is 
controlled predominantly at the cell membrane rather than at the transcription level, 
since no significant modulation of IL-13Rα1 mRNA was observed during 
inflammation.  An increase in the intensity of receptor staining in permeabilised cells 
from HDM mice compared to sham mice, in the absence of mRNA up-regulation, 
indicates some control of IL-13Rα1 expression may also occur at the translation level. 
Further analysis of the phenotype of IL-13Rα1+ AM revealed expression of both 
macrophage and DC markers, consistent with the phenotype of AM.  HDM exposure 
elevated the expression of CD206, CD205 and Dectin-1 in AM, indicating activation.  
Specifically, up-regulation of Dectin-1 and the mannose receptor, CD206 are 
indicative of alternative activation (Menzies et al., 2010).  However, these molecules 
are early markers of alternative activation, and hence alternative activation should be 
verified by the additional analysis of late markers such as RELMα (FIZZ1) and YM-
1.  Furthermore, alternatively activated macrophages are reported to secrete IL-10, 
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TGFβ and Th2 cytokines such as IL-13 (Holtzman et al., 2009;Gordon, 2003), 
however no changes in the levels of intracellular IL-13, IL-10 or TGFβ were detected 
in AM following HDM exposure in the present study, although low levels of IL-10 
and TGFβ were detected in AM from sham and HDM exposed mice.  Thus, AM 
display signs of alternative activation following exposure to HDM.  This is in 
accordance with the induction of Th2 immunity and up-regulation of the alternatively 
activating cytokines IL-4 and IL-13 upon HDM exposure demonstrated in chapter 3. 
Macrophages are well documented to respond to IL-13 in a manner that induces 
alternative activation (Gordon & Martinez, 2010).  Alternative activation of 
macrophages is stimulated by IL-4 or IL-13 and results in a multitude of changes that 
promote humoral immunity, allergic and anti-parasite responses and tissue repair.  
These include up-regulation of mannose receptor, RELMα, YM-1 and MHC class II 
which results in increased endocytic activity.  Furthermore, arginase-1 is up-regulated 
leading to the differential use of L-arginine to produce, amongst other products, 
proline for collagen synthesis (Gordon, 2003).  Despite these established effects of IL-
13 on macrophages, limited analysis of IL-13Rα1 expression by these cells has been 
conducted.  Kim et al. described IL-13Rα1 mRNA and protein expression in lungs 
from mice with virally induced chronic lung inflammation (Kim et al., 2008).  And 
furthermore, identified the majority of IL-13Rα1 expression in this model was 
localised to CD68+ macrophages in the lung.  Expression of IL-13Rα1 mRNA and 
protein has also been demonstrated in human monocyte derived macrophages and 
mouse peritoneal macrophages (Junttila et al., 2008;Martinez-Nunez et al., 2011).  
AM exhibit a unique phenotype and verification of their response to IL-13 has not 
been directly studied.  The function of AM has been described as “ambidextrous”; 
being able to suppress or promote inflammatory responses to inhaled microbes and 
proteins in a manner appropriate to their potential pathogenicity (Peters-Golden, 
2004).  Thus, the role AM in asthma pathogenesis and their response to allergen 
challenge is complex and not well understood.  The present data illustrate naïve AM 
express receptors for IL-13 and are therefore likely to respond to IL-13, thereby 
implicating AM in IL-13 dependent AAD pathology.  Since IL-13Rα1 expression was 
significantly diminished on AM from allergic mice, the role of this IL-13/AM 
interaction in AAD pathogenesis is more likely to be in the initiation rather than 
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maintenance of AAD.  The role of AM in mice following exposure to exogenous IL-
13 or HDM is the subject of the forthcoming chapter. 
5.4.2.2 IL-13Rα1 expression on monocytes 
IL-13Rα1 was detected on the surface of a subset of monocytes in naïve blood; 
identified as MOMA2+ Gr-1+ CD11b+.  Akin to macrophages, it is well established 
that monocytes also respond to IL-13 stimulation, however the subsequent effects of 
IL-13 stimulation are multifaceted.  Pro-inflammatory actions of IL-13 on monocytes 
include up-regulation of various adhesion molecules, CD23, MHC class II, CD80 and 
CD86 (Zurawski & de Vries, 1994;de Vries, 1998).  Conversely, IL-13 down-
regulates the expression of pro-inflammatory mediators IL-1α, IL-1β, IL-6, IL-12, 
TNFα, IL-8, MIP-1α, MIP-1β and MCP-3; induces expression of 15-lipoxygenase 
and inhibits COX-2 induction in monocytes.  In addition, IL-13Rα1 mRNA 
expression in human monocytes has been demonstrated to be down-regulated upon in 
vitro differentiation into macrophages (Hart et al., 1999) and surface expression of IL-
13Rα1 on human monocytes down-regulated by incubation with IL-13 or IL-4 
(Graber et al., 1998).  This down-regulation of IL-13Rα1 expression upon 
maturation/activation is supported by the earlier observation in the present study that 
CD68+ macrophages infiltrating into the lungs of HDM exposed mice do not express 
IL-13Rα1 and is paralleled by the loss of surface IL-13Rα1 on AM after HDM 
exposure.  This indicates monocytes and macrophages, once activated, may lose the 
ability to respond to IL-13 stimulation.  Hence implying a limited role for the actions 
of IL-13 on activated monocytes and macrophages in the perpetuation of AAD in the 
lung tissue. 
5.4.2.3 IL-13Rα1 expression on T cells 
Unexpectedly, IL-13Rα1 was also found to be present on the surface of a small 
proportion of CD4+ T cells.  This population of IL-13Rα1+ CD4+ T cells was present 
in blood from naïve and HDM exposed mice and could also be detected infiltrating 
the BAL and lung tissue of HDM mice.  Attempts to identify the phenotype of this 
population revealed the majority of IL-13Rα1+ CD4+ cells in the blood were naïve T 
cells, however the IL-13Rα1+ CD4+ population was enriched for memory cells 
compared with the whole CD4+ T cell population.  Induction of HDM induced AAD 
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resulted in negligible changes in the respective sizes of these population.  Following 
HDM exposure the majority of IL-13Rα1+ CD4+ T cells in BAL and LD were 
effector cells.  Naïve and central memory cells in the lungs and BAL also expressed 
IL-13Rα1; in fact the majority of central memory cells were IL-13Rα1+.  Further 
analysis of IL-13Rα1+ CD4+ effector T cells in BAL and LD indicated IL-13Rα1 
expression was not specific to a particular T helper phenotype, but could be detected 
on subsets of Th1, Th2, Th17 and Tregs.  Thus, IL-13 may have direct actions on T 
cells present in the BAL and LD of allergic mice.  However, effects of IL-13Rα1 
ligation on specific T cell subsets and the involvement of these pathways in the 
pathogenesis of HDM induced AAD are largely unknown. 
Until recently it was believed CD4+ T cells did not express IL-13Rα1 at the cell 
surface, despite IL-13Rα1 mRNA and intracellular protein being present in human 
peripheral blood T cells (Gauchat et al., 1997;Graber et al., 1998).  Newcomb et al. 
have since demonstrated elevated IL-13Rα1 mRNA and protein specifically in murine 
Th17, but not Th0, Th1 or Th2 cells, polarised in vitro (Newcomb et al., 2009).  
Furthermore, Th17 cells responded to IL-13 stimulation by further up-regulating IL-
13Rα1 mRNA, reducing IL-17A and IL-21 production, down-regulating retinoic acid 
receptor-related orphan receptor-γt (ROR-γt) and up-regulating GATA-binding 
protein 3 (GATA3) expression.  This IL-13 dependent negative regulation was not 
observed in Th1 or Th2 polarised populations.  Equivalent data has been obtained in 
polarised human T cell populations in which surface expression of IL-13Rα1 was 
demonstrated in addition to elevated mRNA and a functional response to IL-13 
(Newcomb et al., 2011).  In addition, Newcomb et al. demonstrate the combination of 
TGF-β, IL-1β and IL-23 (but not IL-6) used for in vitro polarisation of Th17 cells is 
responsible for the up-regulation of IL-13Rα1.  This data appears contrary to 
observations in the present study in which IL-13Rα1 expression is observed in all T 
helper cell populations from mice with HDM induced AAD and is not unique to Th17 
cells.  However, Newcomb et al. rely heavily on in vitro polarisation of T cells, using 
very specific conditions, without analysing T cells polarised in vivo during an ongoing 
immune response.  It is possible the observed up-regulation of IL-13Rα1 is driven by 
TGF-β, IL-1β and IL-23 and is coincident with Th17 polarisation rather than specific 
to Th17 cells.  In support of this, chronic exposure to HDM up-regulates the 
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expression of TGF-β  and IL-1β (unpublished observation, data not shown) in the 
lungs, potentially providing a favourable environment for IL-13Rα1 up-regulation 
(Fattouh et al., 2008).  This hypothesis requires further investigation; of particular 
interest would be determination of IL-23 concentrations in the lungs following 
exposure to HDM and determination of the effects of TGFβ, IL-1β and IL-23 
stimulation on cells previously polarised to Th1 and Th2 phenotypes in vitro.  In 
addition, further analysis of in vivo polarised Th0, Th1, Th2 and Th17 cells and their 
responses to ex vivo IL-13 stimulation would be help elucidate the function of IL-
13Rα1 on T cells. 
In summary, IL-13Rα2 is constitutively expressed by airway epithelium in mice, and 
was up-regulated in HDM induced AAD, however, whether this IL-13Rα2 expression 
renders these cells responsive to IL-13 remains to be determined.  IL-13Rα1 is 
expressed by AM but lost from the cell surface following HDM exposure.  In 
addition, a proportion of blood monocytes and CD4+ T cells express IL-13Rα1, 
although the function of IL-13 signalling in these cell types requires further 
investigation.  The role of AM in IL-13 and HDM induced airway inflammation will 
be explored in the following chapter. 
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6. THE ROLE OF AM IN HDM INDUCED AAD 
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6.1 Introduction 
The previous chapter established AM as one of the key cell types in the lung 
expressing the primary IL-13 signalling receptor subunit IL-13Rα1.  Thus indicating 
AM may play a role in IL-13 dependent lung pathology.  Hence, the objective of this 
chapter was to investigate the role of AM in the pathogenesis of AAD.  To address 
this required the development of a protocol for specific AM depletion. 
Colony-stimulating factor-1 receptor (CSF-1R) blockade was used to deplete AM in 
preliminary studies.  CSF-1 is reported to be a survival factor for tissue macrophages 
hence blockade of this signal results in the loss of macrophages evident in 
Csf1op/Csf1op mice which lack functional CSF-1 and in mice dosed with a mAb to 
CSF-1R (Wiktor-Jedrzejczak et al., 1992;Roth et al., 1998;MacDonald et al., 2010) 
As an alternative approach to AM depletion clodronate (dichloromethylene-
bisphosphonate) filled liposomes were employed.  Clodronate induces apoptosis in 
phagocytes that engulf and digest the liposomes, hence intra-tracheal (i.t.) 
administration of clodronate liposomes depletes AM present in the airway spaces (van 
Rooijen & Sanders, 1994).  Liposomes cannot cross epithelial or endothelial barriers 
and hence do not deplete IM or other macrophage populations residing outside the 
lungs (Thepen et al., 1989).  Furthermore, DC are not depleted by liposomes, thus i.t. 
administration of clodronate liposomes elicits specific depletion of AM (Jakubzick et 
al., 2006). 
To investigate the role of AM in IL-13 dependent disease pathology initial studies 
were conducted in a simple model of lung inflammation induced by i.t. delivery of 
exogenous IL-13.  Administration of IL-13 directly into the airways induces 
accumulation of eosinophils and neutrophils in BAL, goblet cell up-regulation and 
AHR, moreover these effects are also evident in RAG1-/- mice implicating resident 
lung cells in the response to IL-13 (Wills-Karp et al., 1998;Grunig et al., 1998).  
Establishing this model in AM deficient mice and assessing the ensuing pathology 
would indicate whether AM are involved in the elicitation of IL-13 stimulated lung 
pathology. 
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Following on from assessing the role of AM in IL-13 stimulated lung pathology, 
HDM induced AAD was employed to explore the role of AM in IL-13 dependent lung 
pathology.  Although AM depletion in HDM induced AAD has not previously been 
reported, a small number of studies have investigated the effects of AM depletion in 
various other models of lung inflammation with conflicting outcomes.  AM depletion 
has been demonstrated to exacerbate, ameliorate or not affect lung inflammation and 
AHR (Thepen et al., 1989;Thepen et al., 1991;Thepen et al., 1992;Tang et al., 
2001a;Bang et al., 2011;Nagarkar et al., 2010;Yang et al., 2010;Careau & 
Bissonnette, 2004;Bedoret et al., 2009).  It is likely the inconsistency of these results 
arises from a multitude of differences in animal models, species, depletion approaches 
and time of AM depletion.  In the present studies AM depletion was conducted prior 
to HDM exposure and continued throughout the study to investigate the role of AM in 
the development of the allergic response.  In addition, AM depletion was conducted 
“therapeutically”, after the initiation of the allergic response, to determine the role of 
AM in the maintenance of AAD. 
6.1.1 Aim 
4. Use the appropriate cell types identified in chapter 5 to characterise the 
underlying mechanisms of IL-13 inhibition in vivo by specific cell depletion. 
The initial aims of this chapter were to establish protocols for specific AM depletion 
and IL-13 induced lung inflammation and to subsequently determine the effects of 
AM depletion on IL-13 induced lung pathology.  Furthermore, to investigate the 
effects of both prophylactic and therapeutic AM depletion on the development and 
maintenance of HDM induced AAD, respectively, in order to determine whether AM 
play a role in IL-13 dependent lung pathology. 
 
Chapter 6 
 199
6.2 Methods 
6.2.1 Macrophage depletion. 
6.2.1.1 Anti-CSF-1R treatment 
Blockade of the macrophage survival factor CSF-1 was accomplished by treatment 
with a high affinity anti-mouse CSF-1R mAb generated by UCB, CA019_00486 
(mAb 535).  Mice were dosed with 10mg/kg 535 s.c., 3 times per week for up to 14 
days; a dose previously demonstrated to be fully efficacious in murine disease models 
(unpublished data from UCB).  Control mice received 10mg/kg isotype control 
(101.4) s.c., 3 times per week for 14 days.  After 3, 7, 10 or 14 days of treatment mice 
were bled by cardiac puncture and killed for collection of BAL and lungs.  Cells were 
liberated from the lung tissue by digestion as detailed in materials and methods.  
Staining of monocytes and macrophages in blood, BAL and LD for analysis by flow 
cytometry was conducted according to materials and methods.  Identification of 
eosinophils was based solely on forward and side-scatter characteristics. 
6.2.1.2 Administration of clodronate liposomes 
Mice were dosed with 50μl of liposome encapsulated clodronate 
(ClodronateLiposomes.org, The Netherlands) i.t. once or twice per week, 
commencing two days prior to administration of IL-13 or HDM.  Control mice 
received PBS filled liposomes according to the same dosing schedule. 
6.2.2 IL-13 induced lung inflammation 
An IL-13 induced lung inflammation protocol was adapted from Wills-Karp and 
Grunig (Wills-Karp et al., 1998;Grunig et al., 1998).  Mice were dosed with 5μg IL-
13 i.t. for 3 consecutive days and killed 15 hours after the last administration for 
collection of BAL and lungs (Figure 6.1).  Control mice received i.t. vehicle (PBS + 
1% FCS).  Analysis of BAL and LD cellularity was conducted by flow cytometry as 
previously described in materials and methods.  Mice receiving liposomes were dosed 
once, two days prior to the first IL-13 administration. 
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Figure 6.1 Experimental protocol for IL-13 induced lung inflammation.  Mice were administered 
i.t. IL-13 on 3 consecutive days.  Control mice received i.t. saline alone.  Mice were dosed with i.t. 
liposomes 2 days prior to IL-13 administration.  Mice were culled 15 hours after the final IL-13 
administration for collection of BAL and lung samples. 
 
6.2.3 Clodronate liposome treatment of HDM exposed mice 
To determine the role of macrophages in AAD prophylactic or therapeutic 
administration of liposomes was conducted in mice exposed to HDM for 3 weeks.  
Mice dosed prophylactically received 50μl liposomes i.t., two days prior to the first 
HDM exposure and once weekly thereafter (Figure 6.2 A).  AHR to MCh was 
assessed by WBP on day 11, 24 hours post HDM.  Mice dosed therapeutically 
received 50μl liposomes i.t., twice weekly during the third week of HDM exposure 
(Figure 6.2 B).  AHR to MCh was assessed by WBP on day 16, 24 hours post HDM, 
prior to administration of liposomes.  Under both protocols mice were bled by cardiac 
puncture and killed 4 hours after the last HDM exposure for collection of BAL and 
lung samples. 
-2 2 Day 
5μg IL-13 i.t.
3 
BAL 
Lungs 
1 0 
50μl liposomes i.t.
Chapter 6 
 201
 
Figure 6.2 Experimental protocol for macrophage depletion during HDM induced lung 
inflammation.  Mice were exposed to HDM 4 times/week for 3 weeks.  Sham exposed mice received 
i.n. saline alone.  (A) Prophylactic protocol; mice were dosed with i.t. liposomes 2 days prior to the 
first HDM exposure and weekly thereafter.  AHR to MCh was assessed by WPB on day 11.  (B) 
Therapeutic protocol; mice were dosed with i.t. liposomes on day 12 and 16 of HDM exposure.  AHR 
to MCh was assessed by WBP on day 16.  In both protocols mice were bled via cardiac puncture and 
killed 4 hours after the final HDM exposure for collection of BAL and lung samples. 
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6.3 Results 
6.3.1 Anti-CSF-1 receptor induced macrophage depletion 
In an attempt to deplete alveolar macrophages, blockade of the macrophage survival 
factor CSF-1 was conducted by repeated administration of an anti-CSF-1 receptor 
mAb, 535.  535 treatment had no significant effects on the total number of BAL 
macrophages over the 14 day dosing period (Figure 6.3 A), however a partial 
reduction in the number of LD macrophages was observed from day 3 (Figure 6.3 B).  
This was accounted for by a modest decline in the number of LD AM, apparent from 
day 7, and a more robust reduction in LD IM evident after just one dose of 535 
(Figures 6.3 D and F, respectively).  No significant effects on the number of BAL AM 
were observed (Figure 6.3 C) however BAL IM were reduced from 3 days of receptor 
blockade (Figure 6.3 E).  The number of circulating monocytes in the blood was also 
significantly decreased after a single dose of 535 (Figure 6.4 A), however a significant 
increase in the number of circulating eosinophils was noted in the blood after 10 days 
of treatment which was further elevated by day 14 (Figure 6.4 B).  This elevation in 
eosinophils was also evident in LD (Figure 6.4 C) but not BAL (data not shown).  
Due to the incomplete depletion of AM and the greater number of circulating 
eosinophils observed with 535 treatment, alternative approaches for macrophage 
depletion were sought. 
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Figure 6.3 Effects of anti-CSF-1 receptor treatment on BAL macrophage frequency.  Mice were 
dosed with 10mg/kg 535 or isotype control (101.4) s.c., 3 times a week for 3, 7, 10 or 14 days.  BAL 
and lungs were taken 2 days after the last administration of 535 treatment.  Total macrophages (A-B), 
AM (C-D) and IM (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow 
cytometry.  n = 4 mice/group, bar represents median.  * p<0.05 relative to 101.4 group by Mann 
Whitney test. 
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Figure 6.4 Effects of anti-CSF-1 receptor treatment on blood monocytes and eosinophils.  Mice 
were dosed with 10mg/kg 535 or isotype control (101.4) s.c., 3 times a week for 3, 7, 10 or 14 days.  
Blood and lungs were taken 2 days after the last administration of 535 treatment.  Total blood 
monocytes (A) and eosinophils (B) and LD eosinophils (C) were identified and quantified by flow 
cytometry.  n = 4 mice/group, bar represents median.  * p<0.05 relative to 101.4 group by Mann 
Whitney test. 
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6.3.2 Clodronate liposome mediated macrophage depletion 
Clodronate encapsulated liposomes were employed to deplete AM.  Initial studies 
were conducted to determine the volume of i.t. liposomes required for adequate 
macrophage depletion.  Thereafter the time-course of macrophage depletion was 
established to inform dose frequency required for subsequent studies.  Administration 
of i.t. clodronate liposomes reduced the number of macrophages in BAL by 
approximately 83% 2 days after dosing, but did not affect the total number of LD 
macrophages (Figure 6.5 A-B).  AM were depleted in BAL (85%) and partially 
depleted in LD (65%; Figure 6.5 C-D), yet no effects were observed on IM in BAL or 
LD (Figure 6.5 E-F).  The standard protocol for macrophage depletion uses 100μl of 
liposomes i.t. however Home Office restrictions limited i.t. administration to 50μl 
(Thepen et al., 1989).  Therefore this initial study sought to determine the effects of 
one or two doses of 50μl of liposomes.  No differences in macrophage depletion at 
day 2 were observed between one dose of 50μl and two doses of 50μl one hour apart 
(Figure 6.5), demonstrating one dose of 50μl of clodronate liposomes i.t. was 
adequate to deplete AM in naïve mice.  Furthermore, two consecutive i.t. doses of 
clodronate liposomes was less well tolerated than one dose, resulting in 3 mice being 
culled prior to the end of the experiment.  In addition, two consecutive doses of PBS 
liposomes elicited a non-significant trend towards reduced total macrophages and AM 
in LD (Figure 6.5 B and D).  Subsequently, macrophage depletion was assessed for a 
week following one dose of i.t. liposomes.  A significant reduction in the number of 
total macrophages in BAL was apparent from day 1 and persisted until at least day 7 
(Figure 6.6 A).  This was mirrored by the numbers of BAL AM which were reduced 
by 75% at day 1, 83% at day 4 and 67% at day 7 (Figure 6.6 C).  In contrast, the 
numbers of BAL IM were elevated slightly from day 4 of liposome administration 
(Figure 6.6 E).  In LD i.t. liposomes had no effect on the total number of macrophages 
(Figure 6.6 B) however, AM were reduced at day 4 (65%) and 7 (63%; Figure 6.6 D).  
Akin to BAL, a small increase in the number of IM was observed in LD at day 4 
(Figure 6.6 F).  Since AM depletion in the lung tissue was not apparent until at least 
day 2, liposome dosing for prophylactic depletion of macrophages in vivo would 
commence 2 days prior to the start of the experiment in subsequent studies.  
Furthermore, there was some evidence of BAL AM repopulating by day 7 after 
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clodronate liposome administration therefore liposomes would be dosed weekly in 
future studies. 
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Figure 6.5 Effects of 1 or 2 doses of clodronate liposomes on BAL and LD macrophages.  Mice 
were dosed with 50μl clodronate liposomes or control (PBS liposomes) i.t., once or twice.  BAL and 
lungs were taken 2 days after liposome administration.  Total macrophages (A-B), AM (C-D) and IM 
(E-F) in BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow cytometry.  n = 3-6 
mice/group, bar represents median.  * p<0.05 by Kruskal-Wallis ANOVA with Dunn’s post test. 
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Figure 6.6 Time course of clodronate induced macrophage depletion.  Mice were dosed with 
50μl clodronate liposomes (Clod) or control (PBS) liposomes i.t., once.  BAL and lungs were taken 1, 
4 and 7 days after liposome administration.  Total macrophages (A-B), AM (C-D) and IM (E-F) in 
BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow cytometry.  n = 4-5 
mice/group, bar represents median.  * p<0.05 and ** p<0.01 by Mann Whitney test. 
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6.3.3 IL-13 induced lung inflammation 
A short term model of IL-13 induced lung inflammation was established to enable the 
subsequent investigation of the role of AM in the response to IL-13.  Administration 
of 5μg IL-13 i.t. on 3 consecutive days induced accumulation of eosinophils, T cells 
and specifically CD4+ T cells in the BAL 15 hours after the last IL-13 instillation 
(Figure 6.7 A, C and E).  This dosing regime did not induce any significant changes in 
tissue eosinophil or T cell numbers (Figure 6.7 B, D and F).  IL-13 administration had 
no effects on the total numbers of leukocytes in BAL and LD (Figure 6.8 A-B) or on 
the number of macrophages in BAL and LD (Figure 6.8 C-D).  A non-significant 
trend towards BAL neutrophilia was observed in IL-13 treated mice although there 
was no change in the number of LD neutrophils (Figure 6.8 E-F). 
Analysis of BAL cytokines and chemokines revealed i.t. IL-13 administration did not 
induce IL-4 or IL-5 release (Figure 6.9 A-B).  IL-13 induced a non-significant 
elevation in IL-10 concentration (Figure 6.9 C) and significant release of IL-12, 
eotaxin and KC (Figure 6.9 D-F).  In addition, administration of IL-13 increased 
tissue IL-33 but had no effect on IL-25 or TSLP concentrations in LH (Figure 6.10). 
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Figure 6.7 IL-13 induced accumulation of eosinophils and T cells.  Mice were dosed with 5μg IL-
13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  BAL and lungs were taken 15 hours 
after the last IL-13 administration.  Eosinophils (A-B), CD3+ T cells (C-D) and CD4+ T cells (E-F) in 
BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow cytometry.  n = 11-12 
mice/group, bar represents median.  Data represents two independent experiments.  ** p<0.01 by Mann 
Whitney test. 
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Figure 6.8 Effects of IL-13 on accumulation of total leukocytes, macrophages and neutrophils.  
Mice were dosed with 5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  BAL 
and lungs were taken 15 hours after the last IL-13 administration.  Total leukocytes (A-B), 
macrophages (C-D) and neutrophils (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and 
quantified by flow cytometry.  n = 11-12 mice/group, bar represents median.  Data represents two 
independent experiments.   
Chapter 6 
 212
 
IL-4
Veh IL-13
0.0
0.5
1.0
1.5
A
[IL
-4
]p
g/
m
l B
AL
IL-5
Veh IL-13
0.0
0.5
1.0
1.5
2.0
2.5
B
[IL
-5
]p
g/
m
l B
AL
IL-10
Veh IL-13
0
20
40
60
80
C
[IL
-1
0]
pg
/m
l B
AL
IL-12
Veh IL-13
0
50
100
150
200
*
D
[IL
-1
2]
pg
/m
l B
AL
Eotaxin
Veh IL-13
0
50
100
150
200
E
**
[E
ot
ax
in
]p
g/
m
l B
AL
KC
Veh IL-13
0
200
400
600
800
1000
*
F
[K
C
]p
g/
m
l B
AL
 
Figure 6.9 IL-13 induced mediator release.  Mice were dosed with 5μg IL-13 or vehicle (Veh; PBS 
+ 1% FCS) i.t., on 3 consecutive days.  BAL was taken 15 hours after the last IL-13 administration.  
BAL IL-4 (A), IL-5 (B), IL-10 (C), IL-12 (D), eotaxin (E) and KC (F) were quantified by MSD 
multiplex assay (A-D, F) or ELISA (E).  n = 6 mice/group, bar represents median.  * p<0.05 and ** 
p<0.01 by Mann Whitney test. 
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Figure 6.10 IL-13 induced release of epithelial cytokines.  Mice were dosed with 5μg IL-13 or 
vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  Lungs were taken 15 hours after the last IL-
13 administration for generation of LH supernatant.  LH IL-25 (A), IL-33 (B) and TSLP (C) were 
quantified by ELISA.  n = 6 mice/group, bar represents median.  ** p<0.01 by Mann Whitney test. 
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6.3.4 IL-13 induced lung inflammation in mice pre-treated with clodronate 
liposomes 
Pre-treatment with clodronate liposomes depleted the majority of BAL AM in both 
vehicle and IL-13 dosed mice and partially depleted LD AM (Figure 6.11 C-D).  As 
previously observed, a small increase in the number of BAL IM was evident in 
vehicle and IL-13 dosed mice treated with clodronate liposomes (Figure 6.11 E).  To 
assess the total inflammatory infiltrate in BAL without the loss of macrophages 
skewing the data in clodronate treated mice, the number of macrophages was 
subtracted from total leukocyte counts.  While IL-13 alone did not induce 
accumulation of leukocytes, IL-13 administration in clodronate pre-treated mice did 
induce significant accumulation of non-macrophage leukocytes in BAL (Figure 6.12 
A).  Furthermore, clodronate pre-treatment exacerbated IL-13 induced BAL 
eosinophilia (Figure 6.12 B).  Treatment with clodronate or IL-13 alone induced 
small, non-significant increases in BAL neutrophils, however the effect of IL-13 in 
clodronate treated mice induced a more than additive BAL neutrophilia (Figure 6.12 
C).  Similarly, IL-13 administration to clodronate treated mice provoked an 
accumulation of T cells, CD4+ cells and Th2 cells that was greater than the added 
effect of IL-13 or clodronate alone (Figure 6.12 D-F). 
IL-13 administration to clodronate pre-treated mice induced a trend towards elevated 
Th2 cytokines (IL-4 and IL-5) in BAL and a significant increase in the Th1 cytokines 
IFNγ and IL-12 (Figure 6.13 A-D).  No significant modulation of IL-13 induced BAL 
IL-10 was observed with clodronate pre-treatment (Figure 6.13 E).  Similarly, 
clodronate pre-treatment did not significantly affect IL-13 induced eotaxin and KC in 
BAL or IL-33 in LH (Figure 6.14). 
Administration of IL-13 into the airways increased the frequency of goblet cells and 
induced up-regulation of muc5ac mRNA in lung tissue.  Despite exacerbating airway 
inflammation, pre-treatment with clodronate liposomes had no significant effects on 
IL-13 induced goblet cell up-regulation, although a trend towards inhibition of 
muc5ac mRNA was observed (Figure 6.15). 
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Figure 6.11 Administration of clodronate liposomes reduced AM in IL-13 treated mice.  Mice 
were dosed with 5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  Mice were 
dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 2 days prior to IL-13 administration.  
BAL and lungs were taken 15 hours after the last IL-13 administration. Total macrophages (A-B), AM 
(C-D) and IM (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow 
cytometry.  n = 7-8 mice/group, bar represents median, data represents one of two experiments.  * 
p<0.05 and ** p<0.01 by Kruskal-Wallis test with Dunn’s post test. 
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Figure 6.12 Administration of clodronate liposomes increased BAL cellularity in IL-13 treated 
mice.  Mice were dosed with 5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  
Mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 2 days prior to IL-13 
administration.  BAL was taken 15 hours after the last IL-13 administration. Total leukocytes 
(excluding macrophages) (A), eosinophils (B), neutrophils (C), T cells (D), CD4+ T cells (E) and Th2 
cells (F) in BAL were identified and quantified by flow cytometry.  n = 6-8 mice/group, bar represents 
median, data represents one of two experiments.  * p<0.05 and ** p<0.01 by Kruskal-Wallis test with 
Dunn’s post test. 
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Figure 6.13 Effect of clodronate liposomes on IL-13 induced cytokines in BAL.  Mice were dosed 
with 5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  Mice were dosed with 
50μl clodronate (Clod) or PBS filled liposomes i.t. 2 days prior to IL-13 administration.  BAL was 
taken 15 hours after the last IL-13 administration.  Cytokines were quantified by MSD assay.  n = 7-8 
mice/group, bar represents median.  * p<0.05 and ** p<0.01 by Kruskal-Wallis test with Dunn’s post 
test. 
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Figure 6.14 Effect of clodronate liposomes on IL-13 induced mediators.  Mice were dosed with 
5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  Mice were dosed with 50μl 
clodronate (Clod) or PBS filled liposomes i.t. 2 days prior to IL-13 administration.  BAL and lungs 
were taken 15 hours after the last IL-13 administration.  BAL eotaxin was quantified by ELISA (A), 
BAL KC by MSD assay (B) and LH IL-33 by ELISA (C).  n = 7-8 mice/group, bar represents median. 
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Figure 6.15 Effect of clodronate liposomes on IL-13 induced goblet cell up-regulation.  Mice were 
dosed with 5μg IL-13 or vehicle (Veh; PBS + 1% FCS) i.t., on 3 consecutive days.  Mice were dosed 
with 50μl clodronate (Clod) or PBS filled liposomes i.t. 2 days prior to IL-13 administration.  Lungs 
were taken 15 hours after the last IL-13 administration.  (A) Goblet cell frequency was scored in 
AB/PAS stained sections and (B) muc5ac mRNA was quantified in lung tissue by RT-PCR and 
normalised to Vehicle/PBS liposomes group.  n = 7-8 mice/group, bar represents median. 
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6.3.5 Prophylactic administration of clodronate liposomes during HDM 
induced lung inflammation 
To determine the role of AM in the development of AAD mice were dosed with 
clodronate liposomes i.t., commencing two days prior to the first HDM exposure and 
weekly thereafter for 3 weeks during continued HDM exposure.  AHR was assessed 
by WBP after 2 weeks of HDM exposure.  Prophylactic treatment with clodronate 
liposomes profoundly increased AHR in HDM exposed mice compared to HDM 
exposed mice receiving PBS liposomes (Figure 6.16).  No changes in AHR were 
observed in sham exposed mice treated with clodronate liposomes compared to sham 
mice receiving PBS liposomes. 
Analysis of the cellular infiltrate in BAL and LD after 3 weeks of prophylactic 
treatment with clodronate liposomes in HDM exposed mice revealed clodronate 
treatment significantly exacerbated HDM induced lung inflammation.  As previously 
calculated, the number of macrophages was subtracted from the total number of 
leukocytes in BAL and LD to gauge the accumulation of inflammatory cells without 
macrophage depletion skewing the data.  The number of BAL and LD leukocytes in 
clodronate treated, HDM exposed mice was at least 2 fold greater than in HDM 
exposed mice receiving PBS liposomes (Figure 6.17 A-B).  Clodronate treatment 
increased HDM induced BAL and LD eosinophilia by 1.6 fold and 2.9 fold, 
respectively (Figure 6.17 C-D) and elevated HDM induced neutrophilia by 2.5 fold 
and 2.3 fold in BAL and LD, respectively (Figure 6.17 E-F).  Moreover, accumulation 
of T cells, CD4+ cells and Th2 cells in BAL and LD was significantly greater in 
HDM exposed mice receiving clodronate liposomes than in those receiving PBS 
liposomes (Figure 6.18).  However, quantification of BAL and LD macrophages 
revealed treatment with clodronate liposomes also elevated the total number of 
macrophages, AM and IM compared to PBS liposome treatment in HDM exposed 
mice (Figure 6.19).  This effect was specific to HDM exposure as depletion of 
macrophages was apparent in BAL and LD from sham exposed clodronate treated 
mice.  Scrutiny of the FACS data revealed AM present in HDM BAL (and LD; data 
not shown) from clodronate treated mice displayed a more variable phenotype with 
respect to the level of F4/80 and CD11c expression than AM from any of the other 
treatment groups (Figure 6.20 D compared to A-C).  Furthermore, the majority of AM 
from clodronate treated, HDM exposed mice expressed CD11b whereas this double 
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positive population (CD11b+ CD11c+) was relatively small in HDM exposed mice 
treated with PBS liposomes and in sham mice treated with either liposome preparation 
(Figure 6.21).  Quantification of CD11b+ AM demonstrated clodronate administration 
induced significant accumulation of CD11b+ AM in the BAL and LD of HDM 
exposed mice, but not sham mice (Figure 6.22 A-B).  In addition, quantification of 
CD11b- AM (resident AM) demonstrated this population was depleted in BAL 
following clodronate administration to HDM or saline exposed mice (Figure 6.22 C), 
however CD11b- AM were not diminished in the LD of clodronate treated, HDM 
exposed mice (Figure 6.22 D). 
Cytokine and chemokine concentrations in BAL and LH were assessed by MSD assay 
and ELISA.  No changes in the HDM induced Th2 cytokines IL-4, IL-5 and IL-13 
were detected following administration of clodronate liposomes (Figure 6.23).  
However, treatment with clodronate liposomes further increased HDM induced IFNγ 
and IL-10 in the BAL but not LH (Figure 6.24 A-D).  Administration of clodronate 
liposomes to sham exposed mice stimulated IL-12 production in BAL and LH which 
was further elevated in HDM exposed mice, in a greater than additive manner (Figure 
6.24 E-F). 
HDM induced eotaxin was increased in BAL and LH following clodronate treatment 
(Figure 6.25 A-B).  In addition, clodronate administration enhanced HDM induced 
production of KC in the lung tissue, however no significant effects were observed on 
the concentration of KC in BAL (Figure 6.25 C-D).  Interestingly, clodronate 
treatment inhibited HDM induced IL-25 and enhanced HDM induced IL-33 in LH, 
but had no effects on TSLP (Figure 6.26 A-C). 
Analysis of total serum IgE and HDM specific antibodies in terminal serum following 
clodronate administration to HDM exposed mice revealed an exacerbated antibody 
response.  Total serum IgE and HDM specific IgE, IgG1 and IgG2b were all 
significantly elevated following clodronate treatment of HDM exposed mice 
compared to HDM mice receiving control liposomes (Figure 6.27 A-C and E).  
Clodronate administration did not affect the generation of HDM specific IgG2a 
(Figure 6.27 D). 
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Histological analysis of lung sections stained with AB/PAS revealed clodronate 
liposome treatment of HDM exposed mice partially reduced goblet cell frequency, 
despite exacerbating cellular inflammation (Figure 6.28).  Clodronate treatment had 
no significant effects on HDM induced peribronchial collagen deposition (Figure 
6.29). 
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Figure 6.16 Administration of clodronate liposomes increased HDM induced AHR.  HDM 
exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  
AHR to MCh was determined as changes in Penh measured by WBP after the second week of HDM 
exposure, 24 hours post HDM.  Data are shown as mean ± SEM, n = 6-8 mice/group.  * p<0.05 and ** 
p<0.01 relative to PBS/HDM group by Mann Whitney test. 
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Figure 6.17 Administration of clodronate liposomes exacerbated HDM induced inflammation.  
HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 
prophylactically.  BAL and lungs were taken 4 hours after the last HDM exposure. Total leukocytes, 
excluding macrophages (A-B), eosinophils (C-D) and neutrophils (E-F) in BAL (A, C, E) and LD (B, 
D, F) were identified and quantified by flow cytometry.  n = 8 mice/group, bar represents median, data 
represents one of two experiments.  * p<0.05, ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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Figure 6.18 Administration of clodronate liposomes exacerbated T cell accumulation in HDM 
exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes 
i.t. prophylactically.  BAL and lungs were taken 4 hours after the last HDM exposure. T cells (A-B), 
CD4+ T cells (C-D) and Th2 cells (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and 
quantified by flow cytometry.  n = 8 mice/group, bar represents median, data represents one of two 
experiments.  *** p<0.001 by Mann Whitney test. 
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Figure 6.19 Administration of clodronate liposomes increased macrophage accumulation in 
HDM exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled 
liposomes i.t. prophylactically.  BAL and lungs were taken 4 hours after the last HDM exposure. Total 
macrophages (A-B), AM (C-D) and IM (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and 
quantified by flow cytometry.  n = 8 mice/group, bar represents median, data represents one of two 
experiments.  ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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Figure 6.20 AM and IM frequencies following administration of clodronate liposomes to HDM 
exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes 
i.t. prophylactically.  BAL was taken 4 hours after the last HDM exposure; macrophages were 
identified by flow cytometry.  Representative dot plots of BAL macrophages from sham exposed mice 
dosed with PBS (A) or clodronate liposomes (B) and HDM exposed mice dosed with PBS (C) or 
clodronate liposomes (D).  n = 8 mice/group, data represents one of two experiments. 
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Figure 6.21 CD11b expression on pulmonary macrophages following administration of 
clodronate liposomes to HDM exposed mice.  HDM exposed mice were dosed with 50μl clodronate 
(Clod) or PBS filled liposomes i.t. prophylactically.  BAL was taken 4 hours after the last HDM 
exposure; macrophages were identified by flow cytometry.  Representative dot plots of BAL 
macrophages from sham exposed mice dosed with PBS (A) or clodronate liposomes (B) and HDM 
exposed mice dosed with PBS (C) or clodronate liposomes (D).  n = 8 mice/group, data represents one 
of two experiments. 
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Figure 6.22 Clodronate liposomes increased accumulation of CD11b+ AM in HDM exposed 
mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 
prophylactically.  BAL and lungs were taken 4 hours after the last HDM exposure. CD11b+ AM (A-B) 
and CD11b- AM (C-D) in BAL (A, C) and LD (B, D) were identified and quantified by flow 
cytometry.  n = 8 mice/group, bar represents median, data represents one of two experiments.  *** 
p<0.001 by Mann Whitney test. 
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Figure 6.23 Effects of clodronate liposomes on HDM induced Th2 cytokines.  HDM exposed mice 
were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  BAL and lungs 
were taken 4 hours after the last HDM exposure. Cytokines were quantified in BAL and LH 
supernatants by MSD assay (A-D) or ELISA (E-F).  n = 8 mice/group, bar represents median. 
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Figure 6.24 Effects of clodronate liposomes on HDM induced IFNγ, IL-10 and IL-12 production.  
HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 
prophylactically.  BAL and lungs were taken 4 hours after the last HDM exposure. Cytokines were 
quantified in BAL and LH supernatants by MSD assay.  n = 8 mice/group, bar represents median.  * 
p<0.05, ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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Figure 6.25 Effects of clodronate liposomes on HDM induced chemokines.  HDM exposed mice 
were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  BAL and lungs 
were taken 4 hours after the last HDM exposure. Chemokines were quantified in BAL and LH 
supernatants by ELISA (A-B) or MSD assay (C-D).  n = 5-8 mice/group, bar represents median.  * 
p<0.05 and ** p<0.01 by Mann Whitney test. 
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Figure 6.26 Effects of clodronate liposomes on HDM induced epithelial derived cytokines.  HDM 
exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  
Lungs were taken 4 hours after the last HDM exposure. Cytokines were quantified in LH supernatant 
by ELISA.  n = 6-8 mice/group, bar represents median.  ** p<0.01 by Mann Whitney test. 
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Figure 6.27 Effects of clodronate liposomes on the generation of HDM specific antibodies.  HDM 
exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  
Blood was taken 4 hours after the last HDM exposure. HDM specific antibodies were assessed in 
serum by ELISA.  n = 8 mice/group, bar represents median.  * p<0.05 and *** p<0.001 by Mann 
Whitney test. 
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Figure 6.28 Effects of clodronate liposomes on HDM induced goblet cell hyperplasia.  HDM 
exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. prophylactically.  
Lungs were taken 4 hours after the last HDM exposure.  (A-D) Representative AB/PAS stained 
sections from sham exposed mice dosed with PBS (A) or clodronate liposomes (B) and HDM exposed 
mice dosed with PBS (C) or clodronate liposomes (D); original magnification x200.  (E) Goblet cell 
frequency was scored in AB/PAS stained sections.  n = 8 mice/group, bar represents median.  ** 
p<0.01 by Mann Whitney test. 
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Figure 6.29 Effects of clodronate liposomes on HDM induced peribronchial collagen deposition.  
HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 
prophylactically.  Lungs were taken 4 hours after the last HDM exposure.  (A-D) Representative 
Masson’s trichrome stained sections from sham exposed mice dosed with PBS (A) or clodronate 
liposomes (B) and HDM exposed mice dosed with PBS (C) or clodronate liposomes (D); original 
magnification x200.  (E) Peribronchial collagen depth was measured in Masson’s trichrome stained 
sections.  n = 8 mice/group, bar represents median. 
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C D
Chapter 6 
 237
6.3.6 Therapeutic administration of clodronate liposomes during HDM induced 
lung inflammation 
To determine the role of AM in the maintenance of AAD mice with established AAD 
were treated with clodronate liposomes for the third week of a 3 week HDM exposure 
period.  Due to the increased number of macrophages observed in HDM exposed mice 
receiving clodronate liposomes in the previous study, mice were dosed with 
liposomes twice, rather than once, weekly during the final week of HDM exposure.  
AHR was assessed by WBP during the third week of HDM exposure, on day 16.  
Therapeutic treatment with clodronate liposomes had no significant effect on HDM 
induced AHR at this time point (Figure 6.30). 
As previously demonstrated with prophylactic clodronate treatment, therapeutic 
administration of clodronate liposomes also exacerbated HDM induced lung 
inflammation.  Clodronate treatment increased the number of non-macrophage 
leukocytes in BAL and LD from HDM exposed mice by over 2 fold compared to 
treatment with PBS liposomes (Figure 6.31 A-B).  HDM induced eosinophilia in BAL 
and LD was further elevated following administration of clodronate liposomes by 2.2 
fold and 3.2 fold, respectively (Figure 6.31 C-D).  Similarly, HDM induced 
neutrophilia in BAL and LD was enhanced after clodronate treatment by 5.3 fold and 
1.8 fold, respectively (Figure 6.31 E-F).  In addition, therapeutic treatment with 
clodronate liposomes significantly increased HDM induced accumulation of T cells, 
CD4+ cells and Th2 cells in BAL and LD (Figure 6.32).  Analysis of BAL and LD 
macrophages revealed the total number of LD macrophages was augmented in HDM 
exposed clodronate treated mice compared to HDM exposed mice treated with control 
liposomes, however this was not evident in BAL (Figure 6.33 A-B).  Quantification of 
AM demonstrated administration of clodronate liposomes depleted BAL and LD AM 
in sham exposed mice.  A modest reduction in the number of BAL AM in HDM 
exposed clodronate treated mice was observed, however this was not apparent in LD 
(Figure 6.33 C-D).  Clodronate treatment of HDM exposed mice induced a significant 
accumulation of IM in BAL and LD (Figure 6.33 E-F).  Further analysis of AM 
demonstrated clodronate administration to HDM but not sham exposed mice induced 
significant accumulation of CD11b+ AM in BAL and LD (Figure 6.34 A-B).  In 
addition, quantification of CD11b- AM confirmed this population was depleted in 
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BAL and LD following clodronate administration to HDM or sham exposed mice 
(Figure 6.34 C-D). 
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Figure 6.30 Therapeutic administration of clodronate liposomes does not affect HDM induced 
AHR.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes i.t. 
therapeutically, during the final week of HDM exposure.  AHR to MCh was determined as changes in 
Penh measured by WBP on day 16 of HDM exposure, 24 hours post HDM.  Data are shown as mean ± 
SEM, n = 6-8 mice/group. 
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Figure 6.31 Therapeutic administration of clodronate liposomes exacerbated HDM induced 
inflammation.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes 
i.t. therapeutically, during the final week of HDM exposure.  BAL and lungs were taken 4 hours after 
the last HDM exposure. Total leukocytes, excluding macrophages (A-B), eosinophils (C-D) and 
neutrophils (E-F) in BAL (A, C, E) and LD (B, D, F) were identified and quantified by flow cytometry.  
n = 8 mice/group, bar represents median, data represents one of two experiments.  * p<0.05, ** p<0.01 
and *** p<0.001 by Mann Whitney test. 
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Figure 6.32 Therapeutic administration of clodronate liposomes exacerbated T cell accumulation 
in HDM exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled 
liposomes i.t. therapeutically, during the final week of HDM exposure.  BAL and lungs were taken 4 
hours after the last HDM exposure. T cells (A-B), CD4+ T cells (C-D) and Th2 cells (E-F) in BAL (A, 
C, E) and LD (B, D, F) were identified and quantified by flow cytometry.  n = 8 mice/group, bar 
represents median, data represents one of two experiments.  * p<0.05, ** p<0.01 and *** p<0.001 by 
Mann Whitney test. 
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Figure 6.33 Effects of therapeutic clodronate liposomes on macrophage accumulation in HDM 
exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes 
i.t. therapeutically, during the final week of HDM exposure.  BAL and lungs were taken 4 hours after 
the last HDM exposure. Total macrophages (A-B), AM (C-D) and IM (E-F) in BAL (A, C, E) and LD 
(B, D, F) were identified and quantified by flow cytometry.  n = 8 mice/group, bar represents median, 
data represents one of two experiments.  * p<0.05, ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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Figure 6.34 Therapeutic clodronate liposomes increased accumulation of CD11b+ AM in HDM 
exposed mice.  HDM exposed mice were dosed with 50μl clodronate (Clod) or PBS filled liposomes 
i.t. therapeutically, during the final week of HDM exposure.  BAL and lungs were taken 4 hours after 
the last HDM exposure. CD11b+ AM (A-B) and CD11b- AM (C-D) in BAL (A, C) and LD (B, D) 
were identified and quantified by flow cytometry.  n = 8 mice/group, bar represents median, data 
represents one of two experiments.  ** p<0.01 and *** p<0.001 by Mann Whitney test. 
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6.4 Discussion 
Data in the previous chapter demonstrated that alveolar macrophages were the 
predominant population of IL-13Rα1+ cells within the lung.  The aim of this chapter 
was to investigate the role of AM in the pathogenesis of lung inflammation induced 
by IL-13 and subsequently HDM by specific depletion of AM.  Hence the initial 
objective was to establish a protocol for depletion of AM. 
6.4.1 Anti-CSF-1R induced macrophage depletion 
CSF-1, via its receptor CSF-1R, regulates the survival, proliferation and 
differentiation of macrophages hence disruption of this interaction results in 
diminished numbers of tissue macrophages (Wiktor-Jedrzejczak et al., 1992;Cecchini 
et al., 1994;Dai et al., 2002).  Specifically, mice lacking functional CSF-1 
(Csf1op/Csf1op) exhibit significantly reduced numbers of macrophages in the lung 
tissue and BAL however, the number of AM is spontaneously corrected with age 
(Wiktor-Jedrzejczak et al., 1992;Roth et al., 1998;Shibata et al., 2001).  Disruption of 
the CSF-1 - CSF-1R interaction by administration of a mAb to CSF-1R has been 
reported to reduce the frequency of alveolar macrophages within the airway space, but 
not interstitial macrophages in the lung parenchyma (MacDonald et al., 2010); 
however this study characterised alveolar and interstitial macrophages based on 
situation rather than CD11c expression.  To determine whether administration of an 
anti-CSF-1R mAb could specifically deplete CD11c+ AM anti-CSF-1R mAb, 535, 
was dosed repeatedly for up to 14 days and the numbers of total macrophages, AM 
and IM assessed in BAL and LD at various intervals. 
Treatment with 535 had no significant effects on the numbers of BAL macrophages or 
AM over the 14 day period.  LD macrophages were reduced by approximately 50%; 
attributable to a 30% decline in AM and up to 85% reduction in IM.  In both BAL and 
LD IM appeared to be more susceptible to CSF-1R blockade than AM.  In addition, 
535 treatment significantly reduced the frequency of circulating monocytes.  
However, 535 administration also induced a profound increase in the number of 
eosinophils in blood and LD which was further increased with prolonged treatment.  
No eosinophils were detected in BAL hence it is unlikely 535 itself induced lung 
inflammation and it is probable that the elevation in LD eosinophils is a consequence 
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of increased circulating eosinophils.  Increased numbers of circulating granulocytes 
have previously been reported in Csf1op/Csf1op and Csf1r-/Csf1r- mice (Ryan 2001, 
Dai 2002).  Monocytes and granulocytes share a common progenitor cell (myeloblast) 
and thus preventing myeloblasts developing into monocytes by blocking CSF-1R may 
lead to increased granulopoiesis. 
Due to the incomplete and non-specific depletion of AM together with induction of 
blood eosinophilia, CSF-1R blockade was considered an inappropriate approach for 
AM depletion. 
6.4.2 Clodronate liposome mediated macrophage depletion 
Administration of clodronate liposomes is an established technique for depleting 
phagocytes (van Rooijen & Sanders, 1994).  Macrophages naturally phagocytose 
liposomes which are subsequently digested.  This releases clodronate into the cell 
where it induces apoptosis.  Liposomes cannot cross epithelial or endothelial barriers 
and consequently their site of action is restricted to the compartment into which they 
are administered.   Hence i.t. administration of clodronate liposomes depletes AM but 
not IM in the lung (Thepen et al., 1989).  Preliminary studies indicated a dose of 50μl 
liposomes i.t. was sufficient for robust depletion of AM in BAL and LD at day 2, and 
did not affect the frequency of IM.  A subsequent time-course demonstrated 
significant depletion of AM for at least 7 days after a single administration.  However, 
a small increase in the number of BAL IM was also observed 4 and 7 days after 
clodronate administration which was also evident in LD on day 4.  This apparent 
increase in the IM population may be due to a genuine rise in the number of IM, 
perhaps to compensate for the loss of AM, or the number of events acquired in the IM 
gate may be artificially increased by the inclusion of apoptotic AM that may have lost 
CD11c expression.  Nevertheless, the effects of clodronate administration on the IM 
population are marginal compared to the effects on the AM population.  Thus, a 
dosing regime of 50μl i.t. once weekly, commencing 2 days prior to induction of 
inflammation was established for use in subsequent studies. 
6.4.3 IL-13 induced lung inflammation 
To investigate the effects of AM depletion on the pathogenesis of IL-13 induced lung 
inflammation, a short term model of IL-13 induced inflammation was adapted from 
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Wills-Karp and Grunig (Wills-Karp et al., 1998;Grunig et al., 1998).  Three daily 
administrations of i.t. IL-13 induced eosinophilia and T cell accumulation in BAL, but 
not LD.  IL-13 did not affect the total number of BAL or LD leukocytes retrieved, nor 
the number of macrophages and neutrophils in BAL or LD.  In addition IL-12, IL-10 
(n.s.), eotaxin and KC were elevated in BAL and IL-33 was raised in LH.  BAL 
eosinophilia and the associated elevation in eotaxin is an established effect of IL-13 
administration (Grunig et al., 1998;Wills-Karp et al., 1998;Kibe et al., 2003).  
However Grunig et al. amongst others, also reported IL-13 induced neutrophilia in 
BAL which was not significant in the present study, despite elevated levels of BAL 
KC (Grunig et al., 1998).  IL-13 induced recruitment of BAL T cells has not 
previously been reported, although IL-13 has been demonstrated to provoke 
accumulation of lymphocytes in BAL following adenoviral delivery of IL-13 into the 
lungs or transgenic overproduction of IL-13 in airway epithelium (Therien et al., 
2008;Kuperman et al., 2002).  In addition, adenoviral delivery of IL-13 into the lungs 
revealed elevated BAL KC, IL-12, IL-10 and eotaxin induced by IL-13, corroborating 
the present findings (Therien et al., 2008).  However, IL-13 induced IL-33 has not 
previously been reported and suggests the relationship between these two cytokines 
may be more complicated than previously suggested in light of the known property of 
IL-33 to induce IL-13 production (Kondo et al., 2008;Kurowska-Stolarska et al., 
2009;Zhiguang et al., 2010;Chang et al., 2011).  Furthermore, it is interesting to note 
that administration of exogenous IL-13 stimulated IL-33 production yet neutralisation 
of IL-13 did not inhibit HDM induced IL-33 (Figure 4.17).  Thus demonstrating IL-13 
is not the only mediator capable of stimulating IL-33 production and that redundancy 
exists in HDM induced IL-33 generation. 
6.4.4 IL-13 induced lung inflammation in AM deficient mice 
To determine the role of AM in IL-13 induced pulmonary responses, AM were 
depleted by administration of clodronate liposomes two days prior to IL-13 treatment.  
Depletion of AM was assessed at the end of the study and significant depletion of AM 
from BAL and LD was apparent in both vehicle and IL-13 treated groups receiving 
clodronate liposomes.  As previously observed, administration of clodronate induced 
a marginal increase in BAL IM although this was not significant in IL-13 treated 
mice. 
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AM depletion exacerbated IL-13 induced inflammation in the lungs.  Accumulation of 
eosinophils, neutrophils and T cells, including CD4+ cells and Th2 cells in BAL 
following IL-13 treatment was significantly greater in mice pre-treated with 
clodronate liposomes compared to those pre-treated with control liposomes.  Pre-
treatment with clodronate liposomes in vehicle treated mice elicited an increase in 
BAL T cells, however this response was further elevated in IL-13 treated mice.  AM 
depletion had no significant effects on BAL IL-4, IL-5, IL-10, eotaxin or KC, or LH 
IL-33 in vehicle or IL-13 treated mice, yet BAL IFNγ and IL-12 concentrations were 
elevated in AM deficient IL-13 treated mice.  Furthermore, clodronate liposome pre-
treatment of vehicle dosed mice induced significant IL-12 production which may 
correspond to the accumulation of BAL T cells observed in the same mice.  In 
addition, muc5ac mRNA expression and goblet cell frequency in the lung tissue was 
assessed in this study.  As previously reported IL-13 induced muc5ac expression and 
increased goblet cell frequency (Kuperman et al., 2002;Kibe et al., 2003;Grunig et al., 
1998;Wills-Karp et al., 1998).  However, despite exacerbating inflammation AM 
depletion had no significant effects on IL-13 induced muc5ac up-regulation or goblet 
cell frequency. 
Taken together, these data demonstrate AM are not required for the pathogenesis of 
IL-13 induced lung inflammation.  Moreover, these data indicate AM may play a role 
in dampening the response to IL-13 in the lungs, hence the heightened inflammation 
in their absence.  However an alternative explanation for AM depletion exacerbating 
inflammation is that clodronate liposomes or the accumulation of apoptotic cells in 
the airways is having an adjuvant effect and enhancing the response to IL-13. 
6.4.5 Prophylactic clodronate treatment during HDM induced lung 
inflammation 
To investigate the role of AM in the development of AAD, AM were depleted by pre-
treatment with clodronate liposomes prior to HDM exposure.  Mice were 
subsequently exposed to HDM for 3 weeks to induce AAD concomitant with weekly 
administration of clodronate liposomes to maintain AM depletion.  Administration of 
clodronate liposomes induced a profound exacerbation of HDM induced AHR and 
inflammation.  Total leukocytes, eosinophils, neutrophils, and T cells, including 
CD4+ cells and Th2 cells, in BAL and LD were all significantly elevated in HDM 
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exposed mice treated with clodronate liposomes compared to HDM mice treated with 
control liposomes.  However, analysis of macrophage numbers at the end of the study 
indicated AM were not depleted by weekly clodronate treatment during HDM 
exposure, and were in fact increased compared to HDM mice receiving control 
liposomes.  The numbers of total macrophages, AM and IM in BAL and LD from 
HDM mice were augmented by clodronate treatment.  Conversely, this clodronate 
treatment regime was adequate for depletion of AM in sham exposed mice.  Further 
analysis of the AM population from clodronate treated, HDM exposed mice revealed 
greater heterogeneity with respect to F4/80 and CD11c expression and up-regulation 
of CD11b compared to AM from HDM mice treated with control liposomes or sham 
exposed mice.  Under normal circumstances AM are CD11b- although CD11b can be 
up-regulated upon activation (Guth et al., 2009;Padilla et al., 2005;Gonzalez-Juarrero 
et al., 2003).  In addition CD11b can be indicative of newly recruited macrophages 
(Gonzalez-Juarrero et al., 2003).  Quantification of CD11b+ AM showed this 
population was modestly increased in HDM compared to sham exposed mice and 
substantially amplified following clodronate treatment of HDM, but not sham mice.  
Furthermore, quantification of CD11b- AM revealed a significant reduction of this 
population in HDM BAL following clodronate liposome treatment.  Taken together 
these results indicate two possible scenarios:  Clodronate mediated depletion of AM is 
ineffective during inflammation, and the combination of HDM and clodronate 
liposomes merely alters the phenotype of AM perhaps by activation.  Alternatively, 
clodronate liposomes are depleting resident AM but the replenishment of this 
population occurs more rapidly in an inflamed environment and the newly recruited 
AM exhibit an altered phenotype with high CD11b expression.  In either case, 
exacerbation of inflammation is associated with loss of the CD11c+ CD11b- AM 
population and amplification of the CD11c+ CD11b+ AM population. 
Upon analysis of inflammatory mediators in the lungs, there were no changes in the 
HDM induced Th2 cytokines IL-4, IL-5 and IL-13 following clodronate treatment 
despite significantly greater numbers of Th2 cells present in the lungs of HDM 
exposed, clodronate treated mice compared to HDM mice treated with control 
liposomes.  However, concentrations of BAL IFNγ, BAL IL-10 and IL-12 in BAL and 
LH were elevated in HDM mice treated with clodronate liposomes compared to HDM 
mice receiving control liposomes. 
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The role of IFNγ in AAD is complex.  IFNγ is a Th1 cytokine capable of suppressing 
Th2 responses.  However, there is evidence suggesting IFNγ can drive AHR in AAD 
and augment expression of Th2 cytokines and eosinophilia in the lungs (Hessel et al., 
1997;Kumar et al., 2004;Kim et al., 2010;Koch et al., 2006;Kim et al., 2010).  In 
contrast, IFNγ can reduce AHR and inhibit IL-13 induced goblet cell hyperplasia and 
eosinophilia (Koch et al., 2006;Ford et al., 2001).  Under certain conditions IFNγ 
induces expression of IL-13Rα2 which may be the underlying mechanism for this 
IFNγ dependent inhibition of IL-13 induced pathology (Daines & Hershey, 2002).  
IFNγ is produced by T cells, amongst other inflammatory cells, and can induce 
lymphocyte accumulation at sites of inflammation.  Therefore the elevated levels of 
BAL IFNγ in the current study could be a cause or effect of the increased 
accumulation of T cells observed in the lungs of HDM exposed, clodronate treated 
mice.  In summary, elevated IFNγ provides a potential mechanism for the 
exacerbation of AHR and inflammation in the present study.  However, this requires 
further investigation perhaps by determining the source of IFNγ or the effects of 
neutralising IFNγ in HDM exposed, clodronate treated mice. 
IL-10 is an anti-inflammatory cytokine produced by many cell types including T cells, 
macrophages and DCs (Mosser & Zhang, 2008).  IL-10 in the airways limits 
pathology associated with viral, bacterial and allergen challenge (Lloyd & 
Hawrylowicz, 2009).  In models of AAD IL-10 can inhibit the production of Th2 
cytokines, BAL eosinophilia and AHR (van Scott et al., 2000;Fu et al., 2006;Kosaka 
et al., 2010).  However, IL-10 has also been reported to concurrently exacerbate AHR 
(van Scott et al., 2000).  IL-10 plays an important role in the maintenance of 
homeostasis and the resolution of inflammation.  In these capacities, both Tregs and 
macrophages represent key sources of IL-10.  IL-10 is produced by various 
macrophage populations including regulatory (M2b) macrophages induced by TLR 
stimulation in the presence of IgG immune complexes; M2c macrophages induced by 
IL-10; and AM themselves (Martinez et al., 2008;Mosser & Edwards, 2008).  
Furthermore, the generation of Tregs and M2c macrophages is dependent upon IL-10.  
However, the exacerbation of inflammation observed in AM depleted HDM exposed 
mice suggests a lack of regulation.  Thus, assessment of Tregs and macrophage 
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subpopulations generated in HDM exposed clodronate treated mice could help 
determine the implications of elevated IL-10 in these mice. 
IL-12 is predominantly produced by DC and macrophages and drives Th1 
differentiation, thus is capable of down-regulating Th2 responses.  Since IL-12 was 
up-regulated by clodronate treatment of sham and HDM mice in the present study it is 
likely to be a result of the accumulation of apoptotic bodies elicited by administration 
of clodronate liposomes.  However, the combined effects of HDM and clodronate 
resulted in a more than additive production of IL-12 in BAL and LH.  The role of IL-
12 in HDM induced AAD is unknown and there are conflicting reports on the role of 
IL-12 using exogenous IL-12, Il12rβ2-/- mice and anti-IL-12 mAbs in various models 
of AAD driven by sheep red blood cells, OVA/alum or Der p 1/alum.  IL-12 reduces 
Th2 cytokine production, inflammation, IgE and AHR partly by up-regulating IFNγ 
(Gavett et al., 1995;Lee et al., 2001;Kuribayashi et al., 2002;Fu et al., 2006).  
However, there is evidence from Il12rβ2-/- mice suggesting IL-12 is required for the 
development of allergen induced AHR and inflammation (Kim et al., 2010).  
Furthermore, studies employing anti-IL-12 mAbs elucidate that IL-12 neutralisation 
during allergic sensitisation exacerbates AAD pathogenesis whereas IL-12 
neutralisation in established AAD inhibits the production of Th2 cytokines, 
inflammation, antigen specific IgE and AHR in an IFNγ dependent manner (Meyts et 
al., 2006).  The converse of this latter finding implies excess IL-12 present in 
established AAD could exacerbate AHR and inflammation, via IFNγ.  As suggested 
previously this mechanism could be responsible for the enhanced AHR and 
inflammation observed in HDM exposed clodronate treated mice in the present study, 
although further studies would be required to verify this. 
In addition to the increased IFNγ, IL-10 and IL-12 in the present study; LH and BAL 
eotaxin, LH KC and IL-33 were also elevated in HDM exposed mice treated with 
clodronate liposomes compared to those treated with control liposomes.  In contrast, 
LH IL-25 was reduced following clodronate treatment of HDM mice.  Increased 
eotaxin is likely to account for the augmented accumulation of eosinophils in the BAL 
and lung tissue of HDM exposed clodronate treated mice.  Similarly, the increase in 
KC corresponds to increased neutrophilia in HDM exposed clodronate treated mice.  
IL-33 can both amplify and directly induce innate and allergic responses by multiple 
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mechanisms including activation and recruitment of Th2 cells and eosinophils and 
activation of innate lymphoid cells.  Hence, the increased concentration of IL-33 in 
LH from HDM mice following clodronate treatment may be contributing to the 
exacerbation of allergic inflammation in these mice.  IL-25 also promotes Th2 
immunity and activates innate lymphoid cells, however in contrast to IL-33; IL-25 is 
reduced in LH from HDM exposed mice treated with clodronate compared to control 
liposomes.  That treatment with clodronate liposomes should inhibit HDM induced 
IL-25 is unexpected but may indicate that AM are required for IL-25 production.  
Interestingly, there is evidence suggesting AM are required for IL-25 induced 
inflammation, but not for IL-25 production (Claudio et al., 2009). 
In the present study the generation of Th2 associated serum antibodies, IgE and IgG1, 
in response to HDM exposure was significantly increased after AM depletion with 
clodronate liposomes.  This was evident as elevated total IgE, HDM specific IgE and 
HDM specific IgG1.  HDM specific IgG2b was also increased, but to a lesser extent.  
Heightened humoral responses following delivery of clodronate liposomes into the 
airways have previously been observed in immunised rats (Thepen et al., 
1989;Thepen et al., 1992).  Together these data indicate AM depletion with 
clodronate liposomes exacerbates the systemic immune response to HDM, and 
specifically Th2 immunity. 
Surprisingly, despite exacerbated lung inflammation in HDM exposed mice treated 
with clodronate liposomes, and IL-13 production comparable to that in HDM exposed 
mice treated with control liposomes, clodronate liposome treatment reduced HDM 
induced goblet cell up-regulation.  This may be attributable to the increased 
production of Th1 cytokines such as IFNγ which has previously been demonstrated to 
inhibit IL-13 induced goblet cell hyperplasia (Ford et al., 2001).  In addition, the 
elevated levels of IL-10 and IL-12 and reduced IL-25 may influence goblet cell 
differentiation.  Alternatively, this data suggests AM may be required for HDM 
induced goblet cell up-regulation, however chemical depletion of AM after OVA 
challenge in pre-sensitised mice demonstrated AM are not required for the 
maintenance of goblet cells in AAD (Yang et al., 2010).  Administration of clodronate 
liposomes did not affect HDM induced peribronchial collagen deposition in the 
present study, indicating AM are not involved in this aspect of the remodelling 
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process, in this model.  However, it is possible that the accumulating macrophages in 
the lung tissue following HDM exposure may contribute to collagen deposition. 
In summary, these data demonstrate AM are not required for the pathogenesis of 
HDM induced AAD, and furthermore indicate AM may actually suppress the 
development of AAD in response to HDM exposure.  Thus an exacerbated response 
to HDM ensues in the absence of AM.  However, there are alternative explanations 
for this phenomenon which are discussed in section 6.4.7. 
6.4.6 Therapeutic clodronate treatment during HDM induced lung 
inflammation 
Having established the effects of prophylactic administration of clodronate liposomes 
on HDM induced AAD, the following study was conducted to investigate the effects 
of therapeutic administration of clodronate liposomes on established HDM induced 
AAD.  Mice were dosed with i.t. liposomes twice during the final week of HDM 
exposure.  Clodronate treatment had no significant effects on AHR however; lung 
inflammation was exacerbated in HDM exposed mice dosed with clodronate 
compared to control liposomes.  As with prophylactic administration, but to a lesser 
extent, therapeutic administration of clodronate liposomes increased the accumulation 
of BAL and LD leukocytes, eosinophils, neutrophils and T cells, including CD4+ 
cells and Th2 cells in HDM exposed mice treated with clodronate compared to HDM 
exposed mice treated with control liposomes.  The apparent discord between AHR 
and inflammation suggests the exacerbation of inflammation in the present study is 
not great enough to significantly affect AHR.  Alternatively, AHR exacerbation may 
be independent of inflammation under these circumstances and driven by an 
alternative mechanism present during prophylactic clodronate dosing but absent in 
this therapeutic study.  Determining the effects of dosing clodronate liposomes 
therapeutically, but for a longer period would indicate whether exacerbated AHR 
could be achieved or whether this phenomenon is due to the absence of AM 
specifically during the initiation of AAD. 
Analysis of macrophage numbers at the end of the study demonstrated significant 
depletion of AM in BAL although the total numbers of macrophages in LD and IM in 
BAL and LD from HDM exposed mice were enhanced by treatment with clodronate 
liposomes.  The increased frequency of liposome dosing in the current study elicited a 
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significant reduction in total BAL AM which was not achieved with once weekly 
prophylactic dosing in the previous study.  As with prophylactic treatment, therapeutic 
treatment with clodronate increased the number of CD11b+ AM and reduced the 
number of CD11b- AM in HDM exposed mice compared to those dosed with control 
liposomes.  This demonstrates clodronate liposomes are still capable of macrophage 
depletion in inflamed lungs.  Hence when revisiting the possible explanations for the 
presence of AM in the previous study the latter scenario appears more plausible; in 
which weekly administration of clodronate liposomes depletes AM, but the 
replenishment of these cells is more rapid during inflammation and the recruited 
macrophages express CD11b.  Thus, exacerbation of inflammation is associated with 
a reduction in the CD11c+ CD11b- AM population and an increase in the CD11c+ 
CD11b+ AM population.  In the absence of inflammation, the AM population has 
been reported to be replenished by both local proliferation and migration of monocyte 
derived, tissue resident macrophages into the alveolar space, however this study only 
assessed CD11c+ CD11b- AM (Landsman & Jung, 2007).  The expression of CD11b 
on recent AM and the balance between these two processes of replenishment is likely 
to be complicated by the presence of ongoing inflammation.  To investigate whether 
the accumulation of CD11c+ CD11b+ AM arises from recruitment of monocytes and 
to explore the role of these cells during exacerbated inflammation, the present studies 
could be repeated in mice in which monocyte recruitment is impeded by blocking 
trafficking into the tissue or depleting monocytes themselves. 
6.4.7 The role of AM in lung inflammation 
Depletion of AM by administration of clodronate liposomes in models of lung 
inflammation driven by exogenous IL-13 or HDM invariably exacerbated 
inflammation and was associated with increased Th1 cytokines.  Previous studies 
have reported comparable increases in immune responses in the lung following AM 
depletion by clodronate liposomes (Thepen et al., 1989;Thepen et al., 1992;Tang et 
al., 2001a;Bang et al., 2011).  This heightened inflammation may be attributable to a 
number of potential mechanisms (Figure 6.30), each of which shall be discussed; 
1. Clodronate liposomes may be acting as an adjuvant to enhance the response to 
IL-13/HDM. 
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2. The accumulation of apoptotic cells in the airways induced by administration 
of clodronate liposomes could have an adjuvant effect and elevate the response 
to IL-13/HDM. 
3. Infiltrating macrophages recruited to replenish the depleted AM population are 
pro-inflammatory. 
4. AM limit and subsequently resolve tissue inflammation by killing and 
phagocytosing pathogenic cells.  In the absence of this clearance mechanism 
pathogenic cells are allowed to accumulate. 
5. AM are immunosuppressive. 
 
 
Figure 6.35 Potential mechanisms by which administration of clodronate liposomes may 
exacerbate airway inflammation. 
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6.4.7.1 Adjuvanticity of liposomes 
The administration of liposomes alone can alter immune function.  Phagocytosis of 
liposomes has been reported to suppress further phagocytic activity and migration in 
engorged macrophages and even stimulate immunity, however this is minimised by 
the use of zwitterionic liposomes to deliver clodronate (de Haan A. et al., 1996).  
Furthermore, any effects of the liposomes themselves are controlled for in the present 
studies by use of PBS filled liposomes.  Hence this mechanism is unlikely to be 
contributing to the exacerbated responses to IL-13 and HDM observed in mice treated 
with clodronate liposomes. 
6.4.7.2 Adjuvanticity of apoptotic cells 
Administration of clodronate liposomes induces apoptosis of macrophages however 
clearance of the resulting apoptotic cells may be insufficient due to the deficiency of 
macrophages themselves.  Thus, whilst apoptosis is a silent death, the persistence of 
apoptotic cells leads to secondary necrosis (Medan et al., 2002;Grainger et al., 2004).  
This release of DAMPs would in turn amplify any ongoing immune response.  In the 
present studies AM depletion induced by clodronate liposome treatment is not 
complete and the total number of macrophages in BAL and LD is actually greater in 
HDM mice treated with clodronate.  Hence, the clearance of apoptotic cells may be 
adequate.  Furthermore, phagocytosis of apoptotic cells can induce macrophages to 
release anti-inflammatory mediators, such as TGFβ, and down regulate pro-
inflammatory mediators (Fadok et al., 1998).  Assessment of secondary necrosis in 
BAL or lungs could indicate whether clearance of apoptotic cells is sufficient in the 
present study and hence whether secondary necrosis is contributing to the enhanced 
inflammation observed in clodronate treated mice.  In addition, assessing the 
functional phenotype of pulmonary macrophages from clodronate treated HDM mice 
ex vivo could indicate whether ingestion of apoptotic cells is inducing an anti-
inflammatory profile.  Specifically, the activity of these cells could be determined by 
analysis of their phagocytic activity in vitro and assessment of cytokine production 
upon phagocytosis of beads or apoptotic bodies and following other activating stimuli 
such as LPS. 
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6.4.7.3 Pro-inflammatory macrophages replenish the AM population 
Following depletion of AM with clodronate liposomes in HDM exposed mice this 
population is replaced by CD11b+ AM, indicative of activated and/or newly recruited 
macrophages.  This effect is specific to HDM exposed mice as it is not apparent in 
AM depleted sham mice.  Accumulation of CD11b+ CD11c+ macrophages has 
previously been associated with OVA induced AAD, furthermore adoptive transfer of 
these macrophages enhanced allergen induced inflammation, Th2 cytokine production 
and AHR (Moon et al., 2007).  It is not clear whether accumulation of CD11b+ AM 
in the present study is a consequence or cause of the exacerbated inflammation 
observed in HDM exposed clodronate treated mice.  Further analysis of the phenotype 
of CD11b+ AM would indicate whether these cells are indeed pathogenic and by what 
mechanisms they may be contributing to allergic inflammation. 
Also of note, is the substantial increase in BAL and LD IM in HDM exposed 
clodronate treated mice, not apparent in HDM exposed mice treated with control 
liposomes or sham exposed mice.  IM are reported to inhibit allergic sensitisation by 
producing high levels of IL-10 and preventing DC maturation and migration (Bedoret 
et al., 2009).  In concurrence with this, the expansion of this population correlates 
with elevated IL-10 concentrations in the same mice.  Thus, IM are unlikely to be 
contributing to the exacerbation of inflammation. 
In the present study, clodronate liposome treatment of HDM exposed mice 
significantly increased the number of CD11b+ AM and IM in the lungs although the 
source of these macrophages is unknown.  A recent study has demonstrated that the 
accumulation of macrophages in the tissue during Th2 inflammation is due to IL-4 
dependent proliferation of local tissue macrophages whereas the accumulation of 
macrophages during a Th1 response occurs through the recruitment of monocytes 
(Jenkins et al., 2011).  Since the presence of both Th2 and Th1 cytokines has been 
demonstrated in the tissue of clodronate treated HDM mice in the current study it is 
likely that both of these processes are occurring.  However, investigation into the 
relative contributions of proliferation and recruitment to both the AM and IM 
populations would aid our understanding of these macrophage populations and their 
origins. 
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6.4.7.4 Lack of macrophage mediated clearance of inflammatory cells 
Macrophages play a key role in the limitation and resolution of inflammation by 
inducing apoptosis and subsequently phagocytosing granulocytes at sites of 
inflammation (Ying et al., 1997;Kodama et al., 1998).  Upon AM depletion and hence 
loss of this clearance mechanism increased accumulation of granulocytes might be 
expected.  However, in the present studies granulocyte chemoattractants were 
elevated indicating increased recruitment and not simply diminished clearance of 
granulocytes contributed to the enlargement of these populations.  Furthermore, this 
clearance mechanism is relatively specific for granulocytes and hence does not 
explain the accompanying elevation in the number of lymphocytes observed in the 
current studies. 
6.4.7.5 AM are immunosuppressive 
The exacerbation in AAD in the absence of AM suggests one of the functions of AM 
is to dampen down the inflammatory response.  Heightened inflammation resulted 
from both prophylactic and therapeutic administration of clodronate liposomes 
indicating AM may be continually limiting ongoing inflammation, and that this 
activity is not specific to the initiation of an allergic response.  The inhibitory 
functions of AM in rodent models of lung inflammation have previously been 
reported.  AM depleted mice and rats exhibit exacerbated immune responses to hapten 
and OVA, demonstrated by augmented humoral immunity, allergic inflammation, Th2 
cytokine production and AHR (Thepen et al., 1991;Thepen et al., 1992;Thepen et al., 
1989;Tang et al., 2001a;Bang et al., 2011).  Several mechanisms by which AM are 
capable of suppressing components of AAD pathophysiology have been identified.  
AM can inhibit DC function both in vitro and in vivo (Holt et al., 1993;Jakubzick et 
al., 2006).  Via these effects on DCs or directly, AM restrict the reactivity of T cells 
resident in the lungs (Strickland et al., 1993;Thepen et al., 1992).  Accordingly, the 
immunocompetence of these T cells is restored in the absence of AM (Strickland et 
al., 1993).  This corroborates the increased accumulation of T cells observed in the 
present study.  Furthermore, analysis of pulmonary DC frequency and phenotype 
following AM depletion in HDM exposed mice could indicate whether this increased 
T cell accumulation is driven by enhanced DC activation. 
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AM have also been reported to suppress AHR under certain circumstances.  Adoptive 
transfer of AM from allergy-resistant or naïve rats prevents AHR in AM deficient 
allergic rats, without affecting the accumulation of BAL cells (Careau & Bissonnette, 
2004;Careau et al., 2006;Careau et al., 2010).  Pouliot et al. suggested AM possess an 
intrinsic ability to inhibit AHR that is suppressed by the microenvironment of the 
allergic lung (Pouliot et al., 2008).  This was illustrated by the inhibition of AHR in 
allergic rats after receiving AM harvested from allergic rats and “re-programmed” ex 
vivo by exposure to classically activating stimulus.  Thus, AM can transfer resistance 
to AHR however, this is dependent on the phenotype of AM, which is in turn dictated 
by the lung microenvironment.  Accordingly, AM can also exacerbate AHR if they 
have been alternatively activated.  Alternatively activated AM from mice sensitised 
and challenged with OVA maintain their phenotype upon viral challenge and hence 
exacerbate AAD via the inappropriate production of Th2 cytokines leading to 
enhanced eosinophilia and AHR (Nagarkar et al., 2010).  Consequently, AM 
depletion after allergen challenge and prior to viral infection in this model reduced 
eosinophilia and AHR.  Similarly, depletion of AM post-allergen challenge prevented 
the development of prolonged AHR in mice sensitised and challenged with OVA; 
although this protocol did not affect short-term AHR or pulmonary inflammation 
(Yang et al., 2010).  Moreover, allergen challenge stimulates expression of pro-
inflammatory cytokines from AM and consequently stimulates Th2 cytokine 
production from T cells (Herbert et al., 2010).  This dichotomy of AM functions and 
hence variable effects of AM depletion illustrates the significance of the activation 
state of the AM and hence lung microenvironment prior to cell depletion.  
Collectively, these data suggest naïve macrophages and classically activated 
macrophages (CAM) suppress AAD and therefore their depletion would exacerbate 
AAD whereas alternatively activated macrophages (AAM) contribute to AAD and 
therefore their depletion would dampen AAD.  Since macrophage depletion in the 
present studies resulted in exacerbated AAD this implies the AM may be classically 
activated in HDM exposed mice.  However, analysis of AM phenotype following 
HDM exposure in the preceding chapter indicated alternative activation, in 
accordance with the predominance of Th2 immunity and the consequent up-regulation 
of the alternatively activating cytokines IL-4 and IL-13, despite exposure to 
significant levels of the classical activation stimulus LPS present in HDM extract.  
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AAM (or M2) do not represent a single, homogeneous population of macrophages 
but, due to their implicit plasticity, reflect a range of activation states induced by some 
common stimuli.  Thus M2 macrophages can be further subdivided into M2a, M2b 
and M2c phenotypes based primarily upon polarising stimuli (Martinez et al., 2008).  
Mosser and Edwards go further still and suggest all macrophages exist in a broad 
spectrum of activation states elicited by a multitude of environmental stimuli (Mosser 
& Edwards, 2008).  Briefly, M2a macrophages arise following exposure to IL-4 or IL-
13 and thus represent AAM involved in Th2 immunity.  M2b macrophages are 
induced by stimulation with immune complexes in the presence of LPS or IL-1β and 
subsequently secrete high levels of IL-10 as well as pro-inflammatory mediators such 
as TNFα, IL-1β and IL-6.  M2c macrophages differentiate in response to IL-10, 
TGFβ or glucocorticoid exposure and possess anti-inflammatory activities.  During 
HDM induced AAD AM are likely to be exposed to a cocktail of IL-4, IL-13, LPS, 
IL-1β, immune complexes, IL-10 and TGFβ, thus it is possible M2a, M2b and M2c 
phenotypes are all generated (Mosser & Edwards, 2008;Martinez et al., 2008).  
Moreover, the discrepancies observed following AM depletion in the present study 
compared to findings in other models of lung inflammation may be a reflection of the 
predominance of macrophage subtypes induced by HDM compared to OVA or hapten 
exposure. 
IL-10 is up-regulated following HDM exposure which may indicate the presence of 
M2b and/or M2c macrophages in the current studies.  Both M2b and M2c 
macrophages have the potential to regulate immune responses.  Therefore depletion of 
these cells in AAD may exacerbate disease.  Further definition of the phenotype of 
AM in HDM induced AAD would aid determination of the function of these cells in 
vivo and hence whether this is a plausible mechanism for the exacerbation of AAD 
observed following AM depletion.  In addition, the employment of alternative 
strategies for AM depletion or adoptive transfer of polarised AM could verify whether 
AM are suppressing allergic inflammation. 
The role of AM in the pathogenesis of asthma is still largely unknown.  In healthy 
individuals the primary role of AM is in maintaining or restoring homeostasis 
however, there is evidence that AM are inappropriately or insufficiently activated in 
asthmatic patients (Moreira & Hogaboam, 2011).  Analogous to AM in HDM induced 
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AAD, AM in asthmatics are also likely to be exposed to a range of stimuli, including 
LPS, immune complexes and cytokines, which potentially differentiate AM into 
multiple phenotypes.  Plausibly, classical activation of AM could exacerbate 
inflammation by aiding the recruitment and activation of inflammatory cells, while 
alternatively activated AM could contribute specifically to Th2 inflammation and the 
fibrotic process.  Thus, either phenotype might contribute to asthma pathogenesis.  
Several studies have endeavoured to distinguish the phenotype of AM from asthmatic 
patients compared to healthy controls.  Analysis of cell markers shows no differences 
in the proportions of CD68, CD14, CD11b, CD83, CD64, CD80, CD86 or FIZZ1 
expressing AM from mild asthmatics compared to healthy controls, indicating no 
changes in the activation status of AM and no change in the frequency of alternatively 
activated AM (St-Laurent et al., 2009).  However, many of these markers have been 
demonstrated to be up-regulated following allergen challenge; CD14, CD11b, CD80, 
CD86 (Lensmar et al., 2006;Viksman et al., 2002;Tang et al., 2001b;Balbo et al., 
2001).  St-Laurent et al. did demonstrate an increased proportion of RFD7+ cells in 
BAL from asthmatic patients, indicative of mature, phagocytic, tissue macrophages 
(St-Laurent et al., 2009).  Cytokine expression, assessed by mRNA, demonstrated 
asthmatic AM expressed higher levels of IL-6, IL-10 and TGFβ but lower IL-8 and 
TNFα than healthy controls, with no differences observed in IL-1, IL-4, IL-12, IL-13 
and IFNγ expression (Prieto et al., 2000;Pouliot et al., 2005).  Using the macrophage 
classification system described above this phenotype most closely resembles the pro-
Th2, M2b cells which produce IL-6, IL-1β, TNFα, high levels of IL-10 and low levels 
of IL-12 (Martinez et al., 2008).  Furthermore, elevated secretion of IL-6, IL-1β, 
TNFα and IL-10 protein from AM, and low IL-12 production, has previously been 
demonstrated in AM from asthmatic compared to healthy controls (Tang et al., 
1999;Gosset et al., 1991;Colavita et al., 2000).  Interestingly, impaired IL-12 
production from AM from asthmatic individuals has been demonstrated to be due to 
lower levels of CD40 expression, both at rest and following activation (Tang et al., 
2001b).  In healthy controls, this release of IL-12 inhibits IL-5 production from T 
cells whereas the diminished release of IL-12 from asthmatic AM permits IL-5 
production.  Thus, the M2b-like phenotype of AM observed in asthmatic patients 
could be contributing to the pathogenesis of disease via the direct production of pro-
inflammatory and pro-fibrotic cytokines and the indirect production of Th2 cytokines.  
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However, the high levels of IL-10 produced by AM from asthmatic individuals could 
be regulating airway pathology.  Thus, the net effects of AM activity and hence the 
role of AM in disease pathogenesis is difficult to predict. 
Collectively, these data suggest the phenotype of AM in mouse AAD and human 
asthma may be similar, and therefore that depletion of AM, or inhibition of AM 
activity, in asthma could exacerbate disease as observed in mouse AAD.  This 
hypothesis requires much further investigation into the understanding of the role of 
AM in asthma.  However, elucidation of the mechanisms involved in AM suppression 
of AAD could provide insights and opportunities for the future treatment of asthma. 
In summary, prophylactic or therapeutic treatment with clodronate liposomes induced 
exacerbation of AAD induced by IL-13 or HDM.  Exacerbation of AAD was 
associated with increased expression of Th1 cytokines and loss of CD11b- CD11c+ 
AM.  These data indicate the role of AM in AAD may be suppression of AAD, 
however further investigation is required to verify this function. 
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7. CONCLUDING DISCUSSION 
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7.1 Summary of findings 
The working hypothesis for this thesis was that IL-13 is required for the initiation, 
development and maintenance of pulmonary inflammation, airway remodelling and 
AHR in mice chronically exposed to inhaled HDM allergen.  In order to address this, 
a previously described murine model of HDM induced AAD with similarities to 
asthma was established (Johnson et al., 2004).  This model was characterised by a 
predominant Th2 response, allergen specific antibody generation, AHR, goblet cell 
up-regulation and airway remodelling.  Furthermore, IL-13 was demonstrated to be 
up-regulated in allergen exposed mice.  Hence, IL-13 neutralising antibodies were 
employed to determine the role IL-13 in this model of AAD.  Prophylactic anti-IL-13 
mAb treatment established IL-13 as indispensable for the development of airway 
eosinophilia, AHR, goblet cell up-regulation and subepithelial fibrosis.  However, IL-
13 was not required for the initiation of the allergen specific Th2 response.  
Therapeutic IL-13 neutralisation demonstrated IL-13 was essential for the 
maintenance of goblet cells and continued peribronchial collagen deposition during 
allergen exposure.  In addition these studies demonstrated IL-13 also played a role in 
the maintenance of airway inflammation and AHR.  Thus, the hypothesis can be 
accepted. 
To further explore the mechanisms of action of IL-13 in HDM induced AAD the 
expression and distribution of IL-13 receptors were investigated.  Airway epithelial 
cells were found to constitutively express IL-13Rα2; the expression of which was up-
regulated upon exposure to allergen.  However, the role of this receptor in AAD 
remains unknown.  IL-13Rα1 was detected on AM and subsets of monocytes and T 
cells.   Following allergen exposure IL-13Rα1 expression was not modulated at the 
gene level however; this receptor subunit was internalised from the surface of AM.  
As the principal IL-13Rα1 expressing cell type, the role of AM in IL-13 induced 
airway pathology and AAD was investigated by specific depletion of AM.  Contrary 
to abrogating IL-13 dependent pathology, AM depletion exacerbated IL-13 and HDM 
induced airway pathophysiology.  Thus, IL-13 dependent airway pathology was not 
driven by AM and the role of the IL-13—AM axis in AAD remains to be determined.  
Furthermore, these studies provided evidence that the predominant function of AM 
during AAD was anti-inflammatory. 
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7.2 Impact of project 
The present studies have described for the first time the effects of IL-13 neutralisation 
in HDM induced AAD; a chronic murine model driven by the repeated administration 
of an environmentally relevant aeroallergen to the airways, in the absence of prior 
sensitisation with chemical adjuvants.  The data substantiate IL-13 as a key mediator 
not only in the development of AAD but also in the maintenance of disease.  Thus 
indicating that novel therapeutics inhibiting IL-13 activities in man may be beneficial 
in the treatment of established asthma, and furthermore have the potential to modify 
disease. 
In addition, several novel findings were made which require future verification.  
Neutrophils were identified as a potential source of IL-13 during airway 
inflammation.  Neutrophils from healthy humans cannot produce IL-13 however, the 
production of IL-13 from lung neutrophils derived from asthmatic patients would be a 
more appropriate analysis (Reglier et al., 1998).  This potential source of IL-13 could 
be significant in patients with pulmonary neutrophilia such as severe asthmatics or 
patients experiencing an exacerbation. 
A significant proportion of CD4+ T cells were shown to express IL-13Rα1, however 
this expression was not restricted to Th17 cells as previously reported (Newcomb et 
al., 2009).  The data imply many T cell populations have the potential to respond to 
IL-13 which carries implications for numerous Th2 driven pathologies in which IL-13 
is up-regulated, including asthma.  However, IL-13Rα1 expression must first be 
demonstrated on human CD4+ T cells.  Furthermore, elucidation of the down-stream 
effects of IL-13Rα1 ligation in various T cell populations would be of value in 
determining the significance of IL-13Rα1 expression on T cells. 
Administration of IL-13 into the airways induced IL-33 production.  This has not 
previously been reported and carries significant implications, not least because IL-33 
can stimulate IL-13 production (Kondo et al., 2008).  This potentially creates a 
positive feedback loop in which both cytokines are capable of promoting Th2 
associated immunopathology (Lloyd, 2010;Kurowska-Stolarska et al., 2009).  
Investigation into the existence of this mechanism in man and its relevance in the 
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amplification and perpetuation of airway inflammation could provide valuable 
insights for developing future asthma therapies. 
The present studies also report, for the first time, the effects of AM depletion on IL-13 
and HDM induced AAD.  The exacerbated response corroborates AM are potentially 
immunosuppressive, although confirmation of this capacity in alternative 
experimental systems is required (Thepen et al., 1994).  These findings have raised a 
multitude of unanswered questions that shall be addressed in future work.  However, 
if AM are capable of immune suppression disclosing and exploiting the mechanisms 
involved could have vast therapeutic implications, not just for asthma, but potentially 
all inflammatory lung diseases. 
7.3 Future work 
7.3.1 Source of IL-13 during AAD 
The present series of studies failed to identify sources of IL-13 in the lung tissue 
during AAD due to difficulties detecting IL-13 by IF.  To overcome this Il13-eGFP 
(enhanced green fluorescent protein) transgenic mice could be employed (Neill et al., 
2010).  Induction of AAD followed by imaging of the lung tissue would allow the 
localisation and identification of the principal IL-13 producing cells during the 
development and maintenance of AAD.  This information would help to identify 
processes up-stream of IL-13 that may be significant in the pathogenesis of the 
disease.  In particular, the presence of IL-13 producing innate lymphoid cells in the 
lungs of mice has recently been described (Chang et al., 2011).  These cells have been 
demonstrated to be potent inducers of AHR however their role in AAD and 
furthermore their existence in man is yet to be elucidated. 
7.3.2 Macrophage population expansion following anti-IL-13 mAb treatment 
during HDM exposure 
Anti-IL-13 mAb treatment significantly increased the number of BAL AM and lung 
AM and IM in HDM exposed mice compared to HDM exposed mice receiving 
isotype control.  This effect was not seen in sham exposed mice treated with anti-IL-
13 mAb.  Thus indicating IL-13 may negatively regulate the size of pulmonary 
macrophage populations during AAD.  The mechanisms involved and the 
implications of expanding these macrophage populations are unknown.  However, 
given that both AM and IM are proposed to regulate pulmonary inflammation, it is 
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tempting to speculate that expansion of these populations may contribute to the 
therapeutic effects of anti-IL-13 mAb treatment in the present studies (Bedoret et al., 
2009;Thepen et al., 1994).  Assessment of the phenotype of AM and IM following IL-
13 neutralisation in HDM exposed mice could indicate whether these macrophages 
are pathogenic or promote resolution of AAD.  In addition, the functions of AM and 
IM isolated from anti-IL-13 mAb treated, HDM exposed mice could be assessed in 
vitro and furthermore in vivo by adoptive transfer of these populations into the lungs 
of mice with AAD to determine whether they are capable of modulating the 
pathogenesis of AAD.  Elucidation of this pathway could provide a novel mechanism 
of action for anti-IL-13 therapeutics.  Of particular interest would be to determine 
whether IL-13 neutralisation in ongoing clinical trials in asthma patients also leads to 
expansion of IM and AM populations. 
7.3.3 Role of IL-13Rα2 in AAD 
Studies in this thesis demonstrated IL-13Rα2 was up-regulated during HDM induced 
AAD.  IL-13Rα2 was detected as a soluble molecule in the lung tissue and serum and 
in the lungs by IF; however the techniques used failed to establish whether tissue IL-
13Rα2 was present as a membrane bound receptor in addition to its soluble form. 
This is key to determining whether IL-13Rα2 functions solely as a decoy receptor in 
HDM induced AAD or whether this receptor possesses additional functionality.  
Specifically, it is not yet known whether IL-13Rα2 can mediate IL-13 clearance in 
mice as has been reported in man or whether IL-13Rα2 is involved in allergen 
induced peribronchial collagen deposition, as it is in bleomycin induced lung fibrosis 
(Kasaian et al., 2011;Fichtner-Feigl et al., 2006).  Assessment of IL-13Rα2 by flow 
cytometry analysis of macrophages and epithelial cells isolated from HDM exposed 
mice could indicate whether this receptor is membrane associated.  Further in vitro 
IL-13Rα2 dependent functional assays and knockdown assays could subsequently 
determine the signalling capabilities of IL-13Rα2. 
Evaluation of the effects of mAbs 582 and 587, that block or permit IL-13Rα2 
binding, respectively, could also provide an indication of the function of IL-13Rα2 in 
AAD.  However, it is not known whether IL-13 can stimulate IL-13Rα2 signalling or 
promote internalisation in the presence of 587 mAb.  The capacity of IL-13Rα2 to 
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signal in the presence of 587 could be determined in vitro by assessment of TGFβ up-
regulation in macrophages stimulated with IL-13 and TNFα (Fichtner-Feigl et al., 
2006).  In addition, IL-13-IL-13Rα2 internalisation in the presence of 587 could be 
analysed using techniques similar to those of Kasaian et al. which would require the 
identification or engineering of a cell line expressing murine IL-13Rα2 (Kasaian et 
al., 2011).  Internalisation could subsequently be determined by depletion of IL-13 in 
culture media or IF of murine IL-13–FLAG.  If these studies demonstrate 587 permits 
the regular function of membrane associated IL-13Rα2, in vivo studies in which 587 
exhibited equivalent efficacy to 582 would indicate membrane IL-13Rα2 is unlikely 
to play a role in the pathogenesis of HDM induced AAD.  It is important to establish 
the role of IL-13Rα2 in the pathogenesis of AAD and subsequently how this 
translates to man.  As has been demonstrated by Kasaian et al., the function of IL-
13Rα2 has a significant bearing on the efficacy of anti-IL-13 mAbs and consequently 
will influence the design and selection of novel IL-13 neutralising entities for the 
treatment of asthma (Kasaian et al., 2011). 
7.3.4 IL-13Rα1 internalisation 
A series of experiments assessing the expression of IL-13Rα1 on AM in this project 
indicated this receptor was internalised following HDM exposure, however this 
requires confirmation.  Furthermore, identification of the stimuli inducing receptor 
internalisation and the fate of the receptor after internalisation would provide valuable 
information regarding this pathway and hence IL-13 responsiveness.  IL-13Rα1 
internalisation has previously been demonstrated in vitro in fibroblasts, thus 
assessment of IL-13Rα1 internalisation in AM in vitro would confirm these initial 
observations (Doucet et al., 1998b).  Furthermore, an in vitro system would allow 
analysis of both human and murine AM.  This could be achieved by temporal analysis 
of HDM, IL-13 or IL-4 stimulated macrophages stained by IF and would establish 
whether internalisation is driven by receptor ligation.  These mechanisms could be 
further verified in vivo by analysis of receptor staining in AM from mice administered 
IL-13 or IL-4 into the airways and from mice treated with anti-IL-13 mAb during 
exposure to HDM.  Furthermore, the localisation of IL-13Rα1 within early, late or 
recycling endosomes following internalisation would indicate whether the receptor is 
degraded or recycled; this could be accomplished by counterstaining the cells for 
Chapter 7 
 268
endosome markers such as Rab proteins.  In addition, determining whether this 
mechanism of IL-13Rα1 internalisation occurs in all IL-13Rα1 expressing cells 
following stimulation may have implications for IL-13 dependent pathology in AAD. 
7.3.5 AM mediated immune suppression 
The present series of experiments have demonstrated that AM depletion during AAD 
exacerbates disease, indicating one of the primary functions of AM is to dampen 
disease.  Due to a number of caveats associated with the technique used for AM 
depletion (discussed in 6.4.7) these findings require confirmation in alternative 
experimental systems.  In an ideal experimental system, specific AM depletion would 
be achieved avoiding the use of liposomes and the potential for accumulation of 
apoptotic bodies which may influence the immune response themselves.  
Furthermore, the absence of AM would be maintained for the duration of the study, 
without replenishment by tissue macrophages or circulating monocytes.  It is difficult 
to envisage how current approaches to cell depletion, including GM technology, could 
be employed to fulfil these criteria.  Therefore, in the absence of appropriate depletion 
techniques to study the function of AM, adoptive transfer of AM could be used to 
investigate their functions.  If indeed, AM are capable of suppressing AAD, transfer 
of AM into the airways of mice with AAD may be able to ameliorate disease.  
Furthermore, adoptive transfer of AM permits more in-depth investigation into the 
mechanisms involved.  Transfer of AM from sham versus HDM exposed donor mice 
would indicate whether AM require activation or polarisation into a specific 
phenotype to dampen AAD.  If this is the case; which phenotype of AM confers 
immunosuppression? Can this phenotype by recapitulated by in vitro stimulation with 
particular mediators or a combination thereof? Moreover could this phenotype be 
induced, and enhanced, in vivo by administration of a specific cocktail of mediators?  
The mechanisms of AM immunosuppression and dependencies could be explored by 
transfer of AM from donors deficient in specific mediators such as IL-10 or TGFβ.  
Further investigation could explore whether this type of immunoregulation is specific 
to AM, or whether all macrophages have the potential to dampen inflammation by the 
same mechanisms.  Is AM mediated immunoregulation specific to the lung 
microenvironment or can inflammation in other organs be controlled?  Is it specific to 
Th2 responses or can AM suppress Th1 and Th17 responses? 
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In summary, many questions remain regarding the putative immunosuppressive 
activity of AM.  Future work should focus on confirming the capacity of AM to 
suppress AAD and to further understand the underlying mechanisms.  Elucidation of 
the pathways involved could reveal multiple targets for therapeutic intervention and 
thus provide future therapies for asthma and possibly other diseases characterised by 
excessive inflammation. 
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